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Traumatic brain injury (TBI) represents a significant cause of death and disability in 
industrialized countries.  Of particular importance to patients is the chronic effect that TBI has on 
cognitive function. Therapeutic strategies have been difficult to evaluate because of the 
complexity of injuries and variety of patient presentations within a TBI population. Experimental 
therapies based upon cortical and hippocampal neuroprotection have not translated clinically. 
However, pharmacotherapies targeting dopamine (DA) have consistently shown benefits in 
attention, behavioral outcome, executive function, and memory. Striatal damage causes deficits 
in executive function, learning, and memory. Dopamine and cAMP regulated phosphoprotein 32 
(DARPP-32), expressed within striatal medium spiny neurons, is known to regulate several 
substrates of cognition. We found that controlled cortical impact injury in rats produces a chronic 
decrease in DARPP-32 threonine-34 phosphorylation and increase in protein phosphatase-1 
activity. There is no effect of injury on threonine-75 phosphorylation or DARPP-32 protein. 
Amantadine has known benefits on post-TBI cognitive deficits and when given daily for two 
weeks reversed the DARPP-32 and protein phosphatase-1 changes. Amantadine also 
decreased the phosphorylation of threonine-75 consistent with activity as a partial N-methyl-D-
aspartic acid receptor antagonist and partial dopamine agonist. FK-506, also known as 
tacrolimus, is a calcineurin inhibitor that has been shown to decrease cell death in the 
hippocampus following a fluid percussion experimental TBI. Calcineurin is also an important 
regulator of DARPP-32 phosphorylation in the striatum. We evaluated the effect of FK-506 on 
the hippocampus and DARPP-32 in the striatum to better detail its effects after a TBI. An acute 
administration of FK-506 following controlled cortical impact reversed the effects of TBI on 
DARPP-32 phosphorylation seen chronically. We then evaluated the effect of a combined drug 
therapy on cognitive deficits post TBI. An acute treatment with FK-506 post TBI followed by 
chronic Amantadine therapy demonstrated an improvement in both motor behavior and Morris 
water maze deficits seen following TBI. Neither drug produced benefit when given alone. These 
data demonstrate that DARPP-32 represents a promising new therapeutic target for TBI 
induced cognitive deficits. 
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1.  INTRODUCTION 
 
 
Traumatic brain injury (TBI) represents a significant cause of death and disability in 
industrialized countries.  Of particular importance to patients is the chronic effect that TBI has on 
cognitive function. Therapeutic strategies have been difficult to evaluate because of the 
complexity of injuries and variety of patient presentations within a TBI population. However, 
pharmacotherapies targeting dopamine (DA) have consistently shown benefits in attention, 
behavioral outcome, executive function, and memory. Still it remains unclear what aspect of TBI 
pathology is targeted by DA therapies and what time-course of treatment is most beneficial for 
patient outcomes.  Fortunately, ongoing research in animal models has begun to elucidate the 
pathophysiology of DA alterations after TBI.  
 
1.1 TRAUMATIC BRAIN INJURY 
 
TBI is the leading cause of death and disability in individuals less than 45 years of age in 
industrialized countries (Bruns and Hauser, 2003). Each year an estimated 1.4 million 
Americans experience a TBI and 80,000 to 90,000 suffer long-term substantial loss of function 
(Rutland-Brown et al., 2006). Clinical studies have shown that 10-15% of individuals with mild 
TBI have persistent cognitive and behavioral complaints. Outcomes from moderate TBI are 
much less favorable with some estimates suggesting that 50% of these individuals endure long-
term injury-related disabilities (Kraus et al., 2005). This places an enormous economic burden 
on the U.S. healthcare system with an estimated cost of $9-10 billion in acute care and 
rehabilitation annually. This cost is in addition to lost earnings, social services, and the cost to 
family members who must care for TBI survivors. TBI also represents a global healthcare crisis 
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with an estimated 2% of the world’s population suffering from chronic symptoms of brain 
trauma, equating to more than 120 million individuals (NIH, 1998; Ragnarsson, 2002). For these 
reasons it has been a long sought goal of TBI researchers to understand the mechanisms of 
chronic disability after TBI to help develop treatment strategies that may assist patients with 
cognitive recovery. 
 
However, researching chronic disability following TBI has posed a unique challenge to both 
clinical and experimental researchers. TBI is a highly variable and extremely complex 
phenomenon. Following the acute primary injury, which often consists of a focal contusion and 
more diffuse structural damage, there are a series of subsequent secondary responses, which 
include, but are not limited to, excitotoxicity, ischemia, oxidative stress, and ongoing structural 
and chemical alterations (Kochanek, 1993; DeKosky et al., 1998; Park et al., 2008). 
Traditionally, research in recovery of function after TBI has focused on preventing or 
manipulating early events in order to prevent chronic dysfunction. Drugs inhibiting apoptosis, 
blocking glutamate-induced excitotoxicity, or attenuating oxidative stress were designed to 
reduce cell loss with the premise that neuronal sparing would enhance recovery (Faden et al, 
1989; Jennings et al., 2008). Unfortunately, the neuroprotective effects observed in the TBI 
laboratories have not translated successfully to the clinic (Gualtieri, 1988; Tolias and Bullock, 
2004). In contrast, therapeutics used during the rehabilitative phase have shown more promise 
in addressing long term disability, although they don’t necessarily demonstrate the same level of 
neuroprotection as drugs designed to inhibit apoptosis or block excitotoxicity (Gualtieri, 1988; 
Rees et al., 2007).   
 
The failure of translating experimental preventative strategies to clinical efficacy has raised the 
question about what events in TBI are crucial for long-term outcome. The development of 
clinically relevant small animal models has greatly assisted the understanding of both acute and 
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chronic TBI-induced alterations in brain chemistry. The two most widely used models of TBI are 
fluid percussion (FP; Dixon et al., 1987) and controlled cortical impact (CCI; Lighthall, 1988; 
Lighthall et al., 1989; Dixon et al., 1991; Kline et al., 2001; Kline and Dixon, 2001). Both models 
produce clinically relevant brain pathology as well as behavioral and cognitive dysfunction in 
rats and mice (Dixon et al., 1987, 1991; Hamm et al., 1992, 1996a,b; Fox et al., 1998, 1999; 
Kline et al., 2002; Wagner et al., 2002, 2004; Kline et al., 2007a,b; Cheng et al., 2007, 2008; 
Hoffman et al., 2008a,b).  Animal studies (Bramlett and Dietrich, 2002; Lifshitz et al., 2007) and 
human positron emission tomography (PET) imaging (Langfitt et al., 1986; Fontaine et al., 1999; 
Donnemiller et al., 2000) have shown that in addition to overt damage (e.g., cortical lesions and 
hippocampal cell loss), there exist areas of chronic dysfunction previously unappreciated, 
particularly in the striatum and thalamus, which are regions known to have important roles in 
cognitive, motor, and emotional processing (Vertes, 2006). 
 
1.1.1 Introduction to dopamine in TBI 
 
DA represents a unique signaling system within the central nervous system (CNS) due to its 
role as both a neurotransmitter and neuromodulator. Furthermore, DA receptors are abundantly 
expressed in brain areas known to be damaged after TBI, such as the frontal cortex and 
striatum, which are important for cognitive function (Seeman et al., 1978; Baron et al., 1985; 
McDonald et al., 2002; Chudasama and Robbins, 2006). The hippocampus, which is also critical 
for cognitive function does not have a high level of DA receptor expression, but is dependent on 
DA activity to modulate function (Lemon and Manahan-Vaughan, 2006; O’Carroll et al., 2006; 
Granado et al., 2008).     
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1.2.  DOPAMINERGIC FUNCTIONAL ANATOMY: A TBI PERSPECTIVE 
 
1.2.1 Persistent cognitive disability 
 
Cognitive disorders experienced by TBI patients can present immediately after the initial injury 
or evolve during the subsequent months to years.  Regardless of presentation, many patients 
live with sustained alterations in cognition and behavior for the rest of their lives (Millis et al., 
2001). Non-pharmacological options for TBI patients experiencing cognitive and behavioral 
dysfunction are limited, with cognitive training paradigms often being the only consistent 
treatment provided.  However, cognitive training effectiveness has not been fully validated, and 
program implementation can be variable (Turner-Stokes et al., 2005).   
 
Persistent cognitive deficits can be categorized into one of three general domains: attention and 
processing speed, memory, and executive function (Gronwall, 1976; Levin and Grossman, 
1978; Gronwall and Wrightson, 1981; Stuss et al., 1985; Binder, 1986, 1987; McMillan and 
Glucksman, 1987; Levin et al., 1988a,b; Gentilini et al., 1989; Stuss et al., 1989; Leininger et al., 
1990; Binder, 1997; Binder et al., 1997; McMillan, 1997). Of these, memory difficulties are the 
most commonly reported and most difficult for patients and caregivers (Binder, 1987). In 
addition to cognitive difficulties, TBI survivors often experience behavioral difficulties 
characterized by enhanced emotional lability and alterations in affect (Fugate et al., 1997). 
Importantly, a prior TBI has been shown to be a risk factor for developing psychiatric and 
psychotic disorders (Koponen et al., 2002). Due to its often diffuse nature and the variety of 
cognitive disturbances experienced post-TBI, it has been difficult to localize a single disruption 
in neural function that could explain such an array of events. Indeed, persistent deficits 
experienced by TBI patients are probably due to a wide spectrum of different neural system 
dysfunctions. However, that does not preclude the possibility of utilizing a targeted therapeutic 
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strategy to enhance cognitive recovery after TBI.   DA is a particularly important system to study 
in this context because it is known to have an important role in physiological events relevant to 
cognition and in numerous systems also affected by TBI, including the hippocampus, striatum, 
and frontal cortex. 
 
1.2.2 Dopamine and TBI: The effect on cognition 
 
Figure 1 is a depiction of the rat CNS demonstrating an overlay of injury processes that occur 
with a TBI and their direct relationship to DAergic pathways important to cognition. As 
illustrated, TBI can have widespread effects on brain anatomy and function within DAergic 
regions.  What is not depicted in Figure 1 is the indirect effect of TBI on DA signaling, including 
disruptions in glutamatergic cortico-striatal projections and striatal gamma-Aminobutyric acid 
(GABA)ergic outputs.        
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Figure 1: Depiction of TBI induced damage to DA systems in rat brain demonstrating 
widespread disruption in DA structures. Areas involved in both ascending and descending 
DAergic signaling pathways are damaged following a TBI. Not pictured is the extensive damage 
caused to other neurotransmitter systems and brain structures not directly involved in DAergic 
signaling pathways. 
 
Ascending DAergic pathways in the CNS can be divided into two predominant systems: 1) the 
nigrostriatal pathway [substantia nigra (SN) innervating striatum], and 2) the mesocorticolimbic 
pathway [ventral tegmental area (VTA) projecting to the prefrontal cortex (PFC), hippocampus, 
amygdala, and nucleus accumbens (NAcc)] (Alexander and Crutcher, 1990; Graybiel, 1990).  
Projections from the mesocorticolimbic pathway are believed to be involved in modulating 
memory consolidation (Ploeger et al., 1991; Cools et al., 1993; Ploeger et al., 1994; Setlow and 
McGaugh, 1998; Coccurello et al., 2000), motivation (Mitchell and Gratton, 1994; Salamone, 
1994; Baldo and Kelley, 2007), and drug reinforcement and addiction (Carelli, 2002; Schultz, 
2004; Salamone et al., 2005; Berridge, 2006; Di Chiara and Bassareo, 2007; Ikemoto, 2007; 
Sutton and Beninger, 1999). Change in the release of DA in the mesocorticolimbic system is 
also associated with neuropsychiatric disorders, arousal, stress, and addiction (Tidey and 
Miczek, 1996; Viggiano et al., 2003; Sonuga-Barke, 2005).  The nigrostriatal system is 
predominantly associated with voluntary movement (Hornykiewicz, 1966; Seeman and Niznik, 
1990; Jackson and Westlind-Danielsson, 1994), but it has also been shown to be important for 
behavioral events including reward processing (Wickens et al., 2007) and acquisition of spatial 
learning and memory (Mura and Feldon, 2003). Research investigating Parkinson’s disease 
(PD) has also shown that dysfunctional nigrostriatal signaling has implications for other 
cognitive functions including memory, executive function, and attention (Tamaru, 1997; Ridley et 
al., 2006).   
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The striatum, which includes the NAcc and caudate putamen, exists as part of an anatomic 
network that subserves functions associated with the dorsolateral PFC (DLPFC), but also 
receives inputs from numerous other brain areas including the hippocampus and limbic cortex.  
The DLPFC has dense projections to the head of the caudate and there exist reciprocal 
pathways back to the DLPFC through the thalamus (Middleton and Strick, 2000).  Due to this 
complex relationship with surrounding cortical and subcortical structures through DAergic 
projections, the striatum is in a prime location for mediating human cognition. Studies have 
demonstrated that both the striatum and DLPFC are important for executive function and 
working memory (WM) (Crosson, 2003).   
 
In Huntington’s disease (HD), projections from the caudate to the frontal lobes are disrupted and 
result in significant motor, attentional, and executive dysfunction (Brandt et al., 1988; Zakzanis 
and Kaplan, 1999). Experiments producing lesions in the striatum suggest that the caudate, in 
particular, plays a specific role in cognition. Damage to the caudate produces deficits that 
resemble damage to corresponding projection targets of the PFC (Divac et al., 1967). In 
nonhuman primates, metabolic activity within the striatum has also been linked to specific 
changes in WM task performance (Levy et al., 1997).  In a recent review by Grahn et al (2008) 
the authors examine the role of the basal ganglia relevant to learning and memory concluding 
that the goal-directed behaviors subserved by basal ganglia function are crucial to all forms of 
normal behavior. 
 
Human neuroimaging studies also support the role of the striatum in cognition. PET studies 
using 18F-dopa in individuals with PD show a correlation between DA depletion and 
neuropsychological performance (Broussolle et al., 1990; Marie et al., 1999; Bruck et al., 2001; 
Duchesne et al., 2002).  PET imaging studies in HD using C11-Raclopride indicate that striatal 
DA receptor subtype 2 (D2) binding is decreased and is sensitive to cognitive performance on a 
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variety of tasks including executive function, attention, and WM (Backman et al., 1997; 
Lawrence et al., 1998).  While striatal dysfunction is associated with cognitive sequelae of HD 
and PD, DAergic system dysfunction within the PFC has been strongly tied to attentional and 
cognitive symptoms associated with schizophrenia and attention deficit hyperactivity disorder 
(ADHD; Heilman et al., 1991; Tassin, 1992; Knable et al., 1997; Tanaka, 2006).   
 
These clinical studies strongly suggest that the striatum and PFC are functionally important for a 
variety of cognitive behaviors, and that the alterations in DA signaling appear to be the 
underlying cause of cognitive dysfunction in a variety of disease states.  In TBI, it is known that 
both the striatum and PFC are vulnerable to damage. The known effects of TBI on the striatum 
include axonal degeneration (Ding et al., 2001), neuronal cell loss (Dunn-Meynell and Levin, 
1997), and ischemia (Dietrich et al., 1994). Effects on the PFC include decreased glucose 
metabolism (Fontaine et al., 1999), changes in frontal lobe blood flow during memory tasks 
(Ricker et al., 2001), and hypoactivation with memory tasks (Sanchez-Carrion et al., 2008).  
Furthermore, experimental models of TBI have shown fairly robust effects on hippocampal 
neurons as demonstrated by significant loss in the CA2 and CA3 regions (Dixon et al., 1987; 
Hicks et al., 1993; Smith et al., 1994).  While the hippocampus is not generally thought of in 
reference to DA signaling, it does have glutamatergic projections to the striatum that are 
important to the activity of GABAergic medium spiny neurons. Striatal medium spiny neurons 
also receive DAergic input from the VTA and SN (Meredith et al., 1990; Pennartz and Kitai, 
1991). Furthermore, DA receptors in the hippocampus receive projections from the SN and 
have been shown to facilitate the maintenance of long term potentiation (LTP), which is 
hypothesized to be the physiologic basis for memory formation and consolidation (Li et al., 
2003; Lemon and Manahan-Vaughan, 2006). 
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1.2.3 Attention, processing speed, working memory, and executive function after TBI 
 
Following TBI, patients often demonstrate confusion as well as an inability to concentrate. They 
are also distracted, have difficulties performing more than one task at a time, and require 
increased time to perform tasks (Gentilini, 1989; Draper and Ponsford, 2008). While these tasks 
are often broad in nature, they share a commonality in the form of attention processing. TBI 
patients consistently show impairments on measures of processing speed, including the Symbol 
Digit Modalities Task and Digit Symbol Coding.  Attentional processing is believed to be a 
widely distributed cognitive function that involves both cortical and subcortical pathways 
including striatal and thalamic inputs and reticular activation.  However, it is generally accepted 
that DA function plays a significant role in the ability to focus attention (Cohen and Servan-
Schreiber, 1992; Wise et al., 1996; Brennan and Arnsten, 2008). In ADHD, DAergic drug 
treatments have been shown to be effective in treating attentional disorders (Solanto, 1998).  
This does not rule out other possible neural dysfunctions as being the underlying cause of 
attentional difficulties after TBI, but it does provide compelling reasons to examine DAergic 
function in TBI. 
 
Attention processing can be difficult to localize given that there are multiple modalities of 
attentional function, including auditory, tactile, and visual attention (Arciniegas et al., 2000; 
Spence and Gallace, 2007; Adair and Barrett, 2008). Furthermore attention can refer to a wide 
variety of different cognitive processes that are both voluntary and involuntary and involve 
several brain systems including the parietal cortices, basal ganglia, PFC, and anterior cingulate 
cortex (Raz, 2004). In contrast, the anatomy of memory function is comparatively better 
understood with specific memory processing events (e.g., retrieval, consolidation) ascribed to 
specific brain regions (Izguierdo and Medina, 1997; Izguierdo et al., 1997). In particular, 
damage to the hippocampus has historically been associated with reproducible deficits in spatial 
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and temporal memory processing (Buckley, 2005). In experimental TBI it is known that the 
hippocampus is exquisitely sensitive to both acute apoptotic events and excitotoxicity (Kotapka 
et al., 1991; Hicks et al., 1993; Dietrich, 1994; Smith et al., 1994). Regionalization of memory 
function and the reduction of hippocampal memory processing to spatial and temporal memory 
are simplistic views of memory processing in the CNS, but have helped guide research in the 
mechanisms of cognitive dysfunction following diffuse injuries such as TBI.  However, at least 
one study (Lyeth et al., 1990) showed spatial memory impairments without clear neuronal loss 
in the hippocampus. Furthermore,  strategies to reduce neuronal cell loss in the hippocampus 
using N-methyl-D-aspartic acid (NMDA) receptor antagonists and inhibitors of apoptosis have 
not always demonstrated behavioral improvements that correlate well with the level of neuronal 
sparing (Tolias and Bullock, 2004).  These findings have challenged the practice of attributing 
cognitive dysfunction to discrete damage in specific brain regions after TBI and raised a new set 
of challenges for TBI research to look beyond anatomic damage and into functional studies. 
 
Numerous studies have shown that after TBI there is a dysfunction in hippocampal LTP 
(Reeves et al., 1995; Sanders et al., 2000).  The reasons for this impairment are not entirely 
clear.  Falo et al (2006, 2008) have suggested that the impairments may be due to changes in 
synaptic composition and dysfunction in normal molecular processes that influence synaptic 
plasticity in the hippocampus, including dysfunction in scaffolding proteins.  What has not been 
examined is the role that DA may have in this process. It is known that blockade of D1/D5 
receptors in the hippocampus eliminates late LTP and can even affect early LTP, suggesting 
that synaptic plasticity in the hippocampus depends upon a synergistic interaction between 
glutamate and DA (Frey et al., 1991; Granado et al., 2008). This raises the question about what 
other structures and what other events, besides hippocampal neuronal loss, could also be 
relevant to memory function after TBI. 
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The PFC and corticostriatal DA signaling system have, in addition to the hippocampus, been 
shown to be important for memory formation. The aspect of memory generally assigned to the 
PFC has been that of WM.  WM commonly refers to those cognitive processes that provide the 
capacity to maintain and manipulate a limited amount of information over a brief period of time 
(Baddeley et al., 1986; Baddeley, 1992).  WM incorporates aspects of divided attention, which is 
vulnerable to disruption after TBI (Stuss et al., 1985; Levin, 1990; Ponsford and Kinsella, 1992; 
McDowell et al., 1997).  For example, a study of patients one year following treatment for severe 
TBI consistently found that these individuals were significantly impaired on the Paced Auditory 
Serial Addition Test, a demanding task that recruits WM (Levin et al., 1990). WM deficits can be 
particularly disabling given the critical role of WM in overall intellectual functioning (Smith et al., 
1996). WM processes are, arguably, an encoding process for long-term memory (Johnson, 
1992). WM is also important for a wide variety of cognitive skills, such as problem solving, 
planning, and active listening (Jonides,1995). Individuals with significant WM deficits have great 
difficulty recording features from a changing environment and keeping them in mind in order to 
guide behavior (Smith et al., 1996). As such, WM is a primary and critical component of all 
aspects of cognition, and impairment in this cognitive domain can be particularly disruptive for 
everyday functioning 
 
TBI also causes an impairment in executive control or executive functioning, a critical aspect of 
cognition (Hanks et al., 1999; McDonald et al., 2002). Although individuals and clinicians often 
report or emphasize “memory” as being a primary functional concern, executive control 
dysfunction might actually be the most disabling aspect of cognitive compromise after brain 
injury (Mateer, 1999; Millis et al., 2001). It is known that impairments in executive control can 
compromise other aspects of cognition, such as memory for verbal information (Tremont et al., 
2000) and visual information (Ricker et al., 1994; Lange et al., 2000; Ricker et al., 2001).   
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1.2.4 Emotional lability and behavioral alterations after TBI 
 
Although not as well studied as cognitive deficits after TBI, it is widely recognized that TBI 
patients experience alterations in emotional control and general behavior (Oddy et al., 1985; 
Arciniegas et al., 2000).  Dyer et al (2006) reported that of three groups, TBI, spinal cord injury, 
and non-injured, the TBI group was more likely to be rated worse in areas of impulsivity and 
verbal aggressiveness.  Patients with TBI are also known to have increased rates of depression 
(Seel et al., 2003; Jorge et al., 2004; Moldover et al., 2004). The mesocorticolimbic DA signaling 
pathway has been implicated in emotional and behavioral disturbances (Mega and Cummings, 
1994).  In fact, in schizophrenia, many of the observed affective mood disorders are proposed to 
be due to changes in DA signaling within the mesocorticolimbic signaling pathway (Abi-
Dargham and Moore, 2003).   
 
1.2.5 The contribution of animal models in understanding persistent cognitive dysfunction after 
TBI 
 
FP and CCI rodent models of TBI have been used extensively to produce deficits reminiscent of 
those seen clinically. Both models produce spatial learning and WM deficits in adult rats (Lyeth 
et al., 1990; Smith et al., 1991; Hamm et al., 1992, 1993; Hicks et al., 1993; Colicos et al., 1996; 
Dixon et al., 1996; Hamm, et al., 1996; Dixon et al.,1997; Scheff et al., 1997; Kline et al., 2000, 
2002; Wagner et al., 2002; Kline et al., 2004, 2007a,b, 2008) and mice (Smith et al., 1994; Fox 
et al., 1998; Whalen et al., 1999) as tested in the Morris water maze (MWM). One concern when 
utilizing the MWM paradigm of memory testing is that this task represents a particularly stressful 
environment to animals. Furthermore, the MWM task is both a learning and memory task, and it 
is possible that dysfunction in MWM performance is, in part, due to defects in learning and 
coping strategies associated with damage in thalamic structures (Markowitsch, 1982; Aggleton 
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and Brown, 1999; Van der Werf et al., 2003). Importantly experimental TBI has also been 
shown to cause dysfunction in less stressful paradigms including open field exploration and 
radial arm maze tasks (Lyeth et al., 1990; Soblosky et al., 1996; Lindner et al., 1998; Enomoto 
et al., 2005; Wagner et al., 2007b). While open field exploration tasks typically assess mobility 
and anxiety, changes in the exploration of novel environments is considered an important 
indicator of learning and memory function in rats if other factors (anxiety, olfactory sensitivity, 
etc.) are properly controlled for (File, 2001; Christoffersen et al., 2008).  Interestingly deficits 
post-TBI have also been observed in passive-avoidance tasks, which are typically considered to 
be a hippocampal independent measure of learning (Hogg et al., 1998; Milman et al., 2005). 
Due to its versatility and consistent results the MWM task remains a useful measure of memory 
dysfunction following experimental TBI. However, it is important to consider its limitations and 
the contribution of other cognitive processes to MWM deficits. 
 
Analysis of the affected brain regions in animal models coupled with clinical studies have helped 
identify the brain areas thought to be responsible for cognitive processes commonly affected by 
TBI. The PFC, hippocampus, striatum, and limbic structures have all been shown to be sensitive 
to damage after TBI (Dixon et al., 1987; Lighthall, 1988; Lighthall et al., 1989).  The degree of 
damage to these structures depends in large part on the localization and severity of TBI.  Mild 
TBI models may only show diffuse white matter damage, cortical cell loss, and some 
hippocampal cell loss (Hicks et al., 1993; Sanders et al., 2001), while more moderate to severe 
injuries show greater degrees of both cortical and subcortical neuronal death and damage to 
structures beyond the contusion site including ischemic alterations in subcortical structures 
(Dietrich et al., 1994; Hellmich et al., 2005). There are also differences in structural damage 
depending upon the location of the insult (Lighthall et al., 1989, Thompson et al., 2005).     
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Animal studies of spatial learning and WM, coupled with clinical research examining executive 
function, attention, and behavior have consistently demonstrated prolonged cognitive 
dysfunction after TBI. Due to its importance to WM, executive function, behavior and emotion, 
and psychosis, DA represents a promising avenue of research in TBI therapy. TBI also shares 
some similarities to PD and other DA disorders. Similar to PD, TBI patients can experience 
memory impairment, bradykinetic motor dysfunctions, and decreases in cognitive processing 
speed. TBI patients also exhibit attention difficulties similar to ADHD, such as easy distractibility. 
Unlike pure disorders in DA function, TBI has its own unique set of concerns including 
inflammation, white matter damage, disruption of other neurotransmitter systems, and a unique 
series of temporal events in DA effects that are unlike other insults.  For these reasons, 
understanding the DAergic signaling system and its relation to brain function is an important 
step in the proper utilization of DA targeted treatment strategies.  
 
1.3. DOPAMINE AT THE CELLULAR LEVEL: GATEKEEPER OF COGNITION 
 
In the brain, DAergic neurons arise from the VTA and SN and project to the striatum, cortex, 
limbic system, and hypothalamus (Graybiel, 1990). DA influences on a number of physiologic 
functions including hormone secretion, movement control, motivation, emotion, and cognitive 
processing (Jackson and Westlind-Daniesson, 1994; Floresco and Magyar, 2006).   
 
The unique effects of DA at each of its terminal sites are mediated by membrane receptors 
belonging to the large seven transmembrane domain (7TM) G-protein coupled receptors.  
Activation of DA receptors leads to alterations in intracellular second messengers either through 
formation or inhibition.  Cloning experiments have identified five different DA receptors that are 
divided into two groups based upon their structural and pharmacological properties; D1-like and 
D2-like receptors (Bunzow et al., 1988; Dal Toso et al., 1989; Dearry et al, 1990; Zhou et al., 
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1990).  Each of these receptor families have unique differences in regional CNS expression and 
unique intracellular signaling pathways that will be discussed briefly in the context of cognition. 
For a more complete review of the complex biochemical signaling pathways related to each 
receptor and the information gained from knockout mouse studies (D1-D5) see Gonon et al. 
(2000) and Tan et al. (2003). 
 
In addition to different subsets of receptor populations throughout regions of the brain, DA 
effects are regulated through a complex control of DA release, re-uptake, and metabolism.  
Changes in a number of DA constituents, including the DA transporter (DAT) and tyrosine 
hydroxylase (TH), can effectively alter DA extracellular concentrations and its physiologic effect 
without directly affecting binding or receptor response.   
 
1.3.1 DA release, metabolism, and the DA transporter 
 
DA is synthesized first by the hydroxylation of the amino acid L-tyrosine to 3,4-dihydroxy-L-
phenylalanine via the enzyme TH and is then decarboxylated by L-amino acid decarboxylase to 
DA.  DA can be inactivated either by reuptake via the DAT and subsequent enzymatic 
breakdown by catechol-O-methyl transferase and monoamine oxidase or repackaged into 
vesicles for reuse. 
 
The DAT is particularly important to presynaptic DA regulation, and differences in DAT 
expression due to genetic polymorphisms have been implicated in a number of diseases 
including bipolar disorder and ADHD (Greenwood et al., 2001; Thapar et al., 2005).  
Furthermore, DAT inhibition is the mechanism of action for a number of pharmaceuticals 
designed to enhance DA neurotransmission as well as drugs of abuse, such as cocaine (Hitri et 
al., 1994; Madras et al., 1994). 
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The DAT is a Na+/Cl -dependent plasma membrane neurotransmitter transporter containing 
twelve transmembrane domains with both the amino and the carboxyl termini located on the 
intracellular side of the membrane (Hersch et al., 1997).  DAT terminates the action of vesicular 
DA release at the synapse via re-uptake of extracellular DA (Torres et al., 2003) and acts as a 
reverse transporter of DA under basal conditions (Borland and Michael, 2004). Regional 
distribution of DAT has been found in areas of the brain with established DAergic circuitry 
including mesostriatal, mesolimbic, and mesocortical pathways (Ciliax et al., 1999). The rate at 
which DAT removes DA from the synapse has a profound affect on the amount of DAergic 
activity seen by the cell. This is best evidenced by the severe cognitive deficits, motor 
abnormalities, and hyperactivity seen in DAT knockout mice (Perona et al., 2008). DAT activity 
and expression has also been shown to change during normal aging (Bannon et al., 1992) and 
differs between males and females (Piccini, 2003). 
 
There are many ways in which the DAT may be chronically regulated, including gene 
transcription, post-translational modifications, oligomerization, and trafficking (Doolen and 
Zahniser, 2001). Second messenger systems, in particular protein kinase C (PKC) activation, 
affect transporter activity (Huff et al, 1997).  Activation of PKC via substrate and inhibitor binding 
appears to regulate DAT by altering its cellular distribution; specifically by altering levels of 
membrane bound DAT (Daniels and Amara, 1999). In addition, DA itself can regulate DAT via 
its interaction with the transporter or pre-synaptic autoreceptors (Williams and Galli, 2006). The 
DAT is also the target of several “DAT-blockers” including amphetamines and methylphenidate 
(MPD). These chemicals inhibit the action of DAT and, to a lesser extent, the other monoamine 
transporters. In contrast, amphetamines trigger a signal cascade thought to involve PKC or 
mitogen-activated protein kinase (MAPK) that leads to the internalization of DAT molecules, 
which are normally expressed on the neuron’s surface (Kahlig et al., 2004). 
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1.3.2 D1-like 
 
The D1-like receptor family includes D1 and D5 receptors. For the purpose of this review, we 
will focus on the D1 receptor because the D5 receptor is less well studied in TBI. The 
distribution of the D1 receptor differs dependent upon the brain region that is being examined. 
Within the frontal cortex, D1 receptors are localized on post-synaptic dendrites of both 
pyramidal and non-pyramidal neurons. Similar structural localization of D1 receptors can be 
seen in the hippocampus and limbic cortex (Dearry et al., 1990; Monsma et al., 1990; Zhou et 
al., 1990).  However, within the striatum, D1 receptors have been localized to non-synaptic 
dendritic spines suggesting that DA activity within the striatum is unique compared to cortical 
structures (Hersch et al., 1995; Caille et al., 1996).   
 
D1 receptor activation is classically associated with the stimulation of adenylate cyclase (AC) 
and subsequent activation of cAMP.  However, it has also been demonstrated that D1 receptors 
are able to activate phosphoinositide hydrolysis (Undie et al., 1994) and inhibit arachidonic acid 
release (Schinelli et al., 1994).  These varied receptor signaling mechanisms demonstrate the 
wide range of effects that D1 agonism or antagonism can have in the CNS.  Activation of 
phosphoinositide hydrolysis is known to affect intracellular trafficking, cell growth, differentiation, 
and survival (Undie et al., 1994, 2000; Ming et al., 2006; Liu et al., 2008).  Arachidonic acid 
release is important for inflammatory signaling and neuronal functioning such as LTP and 
synaptic plasticity (Tassoni et al., 2008). While both of these D1 receptor actions are important 
to DAergic function and have the potential to mediate insults to DA containing neurons affected 
by TBI, it is D1 receptor mediated control over intracellular cyclic adenosine monophosphate 
(cAMP) signaling that represents perhaps the most pertinent aspect of D1 signaling to cognition.  
Manipulation of cAMP levels can affect cAMP response element binding (CREB) through both 
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MAPK dependent and MAPK independent pathways (Greengard, 1976; Schulman, 1995; 
Waltereit and Weller, 2003). In medium spiny neurons within the striatum, there is an 
intracellular signaling molecule, DA and cAMP-regulated phosphoprotein mKDa 32 (DARPP-
32), which is known to mediate a number of important cellular signaling events and is intimately 
involved in cAMP signaling (Ouimet et al., 1984; Walaas and Greengard, 1984; Hemmings and 
Greengard, 1986; Greengard et al., 1999).   
 
D1 knockout mice demonstrate spatial learning deficits (El-Ghundi et al., 1999), and D1a (a 
subtype of the D1 receptor) knockout mice show broad impairments in the initiation of learning 
cue related tasks (Smith et al., 1998).  However, the idea of receptors being impaired versus not 
impaired may be a simplistic viewpoint of DA interaction at the D1 receptor.  A review by 
Williams and Castner (2006) describes the mathematical relationship of tight DAergic control 
and its relation to dysfunction.  They point out that D1 receptor mediation of PFC function is 
often dependent upon both concentration and the temporal sequence of DA release.  A series of 
papers examining DA signaling and calcium regulation describe a paradigm in which there 
exists a difference in the kinetics of CREB phosphorylation that is dependent upon the length of 
incubation with a D1 agonist (Liu and Graybiel, 1996, 1998a,b). Ruskin and Marshall (1997) 
have shown that D1 receptor mediated induction of Fos in striatal neurons is dependent on D2 
activation. Goldman-Rakic (1995) has described at least three possible cellular mechanisms for 
DAergic control of WM in the PFC; 1) direct synaptic control over pyramidal neuron activity, 2) 
nonsynaptic interaction with DA receptors located on distal spines of PFC pyramidal neurons, or 
3) indirect modulation through GABAergic interneurons. Frey et al. (1991) have demonstrated 
that blockade of D1 receptors in the hippocampus impairs hippocampal late LTP maintenance, 
which may be another reason DA dysfunction impairs memory. This alteration in hippocampal 
LTP associated with D1 receptor changes is believed to contribute to spatial memory 
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deficiencies observed in D1 receptor knockout mice (Matthies et al., 1997; Granado et al., 
2008). 
 
Recent studies in PD (Cooper et al., 1991; Postle et al., 1997) have shown that WM dysfunction 
is often one of the first cognitive symptoms experienced by patients. This WM deficit is believed 
to be D1 receptor-mediated because D1 agonist treatment has been shown to alleviate 
impairments in young and aged non-human primates (Arnsten et al., 1994; Cai and Arnsten, 
1997; Castner and Goldman-Rakic, 2004), as well as in other conditions characterized by 
prefrontal DA loss, such as chronic stress (Mizoguchi et al., 2000), chronic neuroleptic treatment 
(Castner et al., 2000), and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treatment-
induced delayed response performance (Schneider et al., 1994a,b).  How hippocampal DA loss 
is associated with these processes is unclear, but in non-PD paradigms, the administration of 
D1 agonists has been shown to facilitate hippocampal LTP (Otmakhova and Lisman, 1996).  
 
1.3.3 D2-like 
 
The D2-like receptor family comprises D2, D3, and D4 receptors. For the purpose of this review, 
the focus will be on D2 receptors because D3 and D4 receptors are less well studied in TBI.  D2 
receptors are different from D1 in that they are associated both with terminal receptor activation 
and with presynaptic autoreceptor function and demonstrate a much greater expression in the 
striatum compared to other brain regions. However, like D1, D2 receptor expression in the 
striatum and frontal cortex are of particular interest in cognitive research. Interestingly, within the 
striatum, the pre and post-synaptic localization of the D2 receptors maintain a much closer 
proximity to actual synapses as opposed to the more diffuse location of D1 receptors on spines. 
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D2 receptor activation is more complex than D1 activation for a number of reasons. For 
example, D2 receptors can act through inhibitory G-proteins that lead to an inhibition of AC and 
cAMP (Cote et al., 1983; Onali et al., 1985; Weiss, 1985) or independently of cAMP pathways 
(Memo et al., 1986). D2 receptors have also been shown to inhibit phosphoinositide hydrolysis 
and subsequent Ca2+ mobilization (Vallar and Meldolesi, 1989; Picetti et al., 1997).  An 
interesting caveat of D2 receptor activation is that in vitro studies utilizing co-
immunoprecipitation methods and in-vivo studies utilizing fluorescent and bioluminescent 
energy transfer (FRET and BRET) analyses have shown that many D2 receptor systems exist in 
heterodimerized pairs (Canals et al., 2003; Fuxe et al., 2005).  D2 receptors have been shown 
to form heterodimers with adenosine A2a receptors and metabotropic glutamate-5 (Mglut-5) 
receptors (Diaz-Cabiole et al., 2002; Fuxe et al., 2003; Hillion et al., 2002; Fuxe et al., 2005; 
Ferré et al., 2008). A2a and Mglut-5 heterodimers are of particular interest for TBI research due 
to their role in striatal LTP and long term depression (LTD) and subsequent plasticity of striatal 
connections (Ferré et al., 2002; Fuxe et al., 2003). The identification of heterodimer systems 
within the striatum indicate that D1 and D2 have control over CREB signaling within striatal 
neurons.  Further, they modulate LTP and LTD dependent glutamatergic and adenosine 
transmitter systems (Calabresi et al., 2000, 2007; Centonze et al., 1999, 2003).   
 
In PD, the contribution of neurotransmitters beyond DA is important to therapeutic manipulation 
as utilization of these other receptor systems provides an alternative way to manipulate DAergic 
signaling (Kase et al., 2000). D2-A2a interactions proposed by Fuxe et al. (2005) allow for 
precise alterations in intracellular signaling pathways that have been associated with cognitive 
function and striatal output. Mglut-5 receptors have also been implicated as important for control 
of DA signaling at the D2 receptor in a similar fashion to the A2a receptor. These heterodimer 
subtypes are highly concentrated on DAergic terminals within the striatum.   
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1.3.4 DARPP-32 
 
DA signaling cascades in the striatum are involved in numerous physiologic functions including 
synaptic plasticity, movement regulation, and even the modulation of other neurotransmitter 
systems (e.g., acetylcholine, calcium, glutamate, and GABA). DARPP-32 is a cytoplasmic 
phosphoprotein found in 95% of the medium spiny neurons in the striatum (Figure 2), and it 
plays a central role in nearly all DA mediated events (Greengard et al., 1999; Calabresi et al., 
2000; Svenningsson et al., 2005; Valjent et al., 2005). Two distinct phosphorylation sites, 
threonine-34 (T34) and threonine-75 (T75), make DARPP-32 a bifunctional signal transduction 
molecule that controls the activities of both protein phosphatase-1 (PP1) and protein kinase A 
(PKA) (Halpain et al., 1990; Nishi et al., 2002). The activity of both PP1 and PKA tightly 
regulates protein transcription related to numerous important cellular functions including 
neurotrophic factor production, regulation of synaptic plasticity, and cell homeostasis.       
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Figure 2: Schematic of DARPP-32 adapted from Nairn et al., 2004. DARPP-32 represents an 
important regulator of cell signaling within the medium spiny neurons of the striatum. Changes 
in phosphorylation state due to DA alterations effectively alter CREB activity and PKA activity, 
both of which are integral to cell homeostasis function 
 
DA induced phosphorylation of ionotropic glutamate and GABA receptors are attenuated in 
DARPP-32 knockout mice, suggesting that DARPP-32 plays an important role in regulating 
excitatory neurotransmission (Yan et al., 1999; Flores-Hernandez et al., 2000, 2002). Ethanol 
reinforcement, which is known to act through regulation of NMDA receptors, is also reduced in 
DARPP-32 knockout models (Risinger et al. 2001; Maldve et al., 2002). Studies assessing the 
behavioral effects of other drugs of abuse, including cocaine and morphine, have shown that 
23 
 
DARPP-32 knockout mice demonstrate lower levels of psychomotor activation following drug 
administration compared to wild-type mice (Borgkvist et al., 2007).  Further evidence using 
knockout mice indicates that DARPP-32 is necessary for the induction of striatal LTD and LTP, 
both important processes in models of memory acquisition and consolidation (Calabresi et al., 
2007). Furthermore, after hypoxia-ischemia injury, DARPP-32 phosphorylation states were 
shown to be important to membrane potential, glutamate receptor activity, and oxidative stress 
(Yang et al., 2007). 
 
DA acts through D1 receptor mediated increases in PKA to promote DARPP-32 phosphorylation 
at its Thr34 site, which leads to an inhibition of PP-1. Additionally, DA, glutamate, and 
adenosine act on protein phosphatase 2B (PP2B), also known as calcineurin, and protein 
phosphatase 2A (PP2A) to decrease phosphorylation at Thr34 and increase phosphorylation at 
Thr75. A reduction in phosphorylation at Thr34 subsequently removes the inhibitory effect of 
DARPP-32 on PP-1 (Greengard et al., 1999; Nairn et al., 2004; Svenningsson et al., 2004).  The 
regulation of PP-1 and PKA by DARPP-32 allows convergent DA, glutamate, and adenosine 
signaling to alter the phosphorylation state of NMDA receptor subunits, the sodium and 
potassium adenosine triphosphatase (Na/K ATPase), and members of the extracellular 
regulated kinase (ERK) pathway (Bertorello, 1990; Blank, 1997; Fienberg et al., 1998; Snyder et 
al., 1998; Dudman et al., 2003; Hakansson et al., 2004). 
 
Given the wide range of cellular processes mediated by DA, its interaction with DARPP-32 in 
the striatum, and the effect that DA action at its different receptor systems have on PFC and 
hippocampal function, it is clear that even minor disturbances in DA function could have 
significant implications for CNS function.   
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1.4.  ALTERATIONS IN DAERGIC SYSTEMS AFTER TBI 
 
The efficacy of DA receptor agonists suggests that TBI patients benefit from the promotion of 
central DAergic transmission. This could be a sign that DA release is suppressed after injury, 
that DA uptake is over active, or some combination of the two. Alternatively, it might be the case 
that DA activity remains normal after injury, but that basal DA activity is inadequate in the face 
of the injury-induced disruptions. Given that a few studies have also shown benefits with DA 
antagonists it must also be recognized that TBI possesses a complex series of temporally 
specific injuries to a wide range of different brain structures. It is important to acknowledge that 
any systemic treatment without a well defined window of therapy could be both beneficial and 
detrimental to the recovery process. For this reason, understanding the effect of TBI on DA 
transmission is crucial for proper therapeutic management and for promoting optimal recovery.  
 
Evidence that DA systems are altered in humans after TBI is predominantly based on reports 
that neurostimulants are beneficial in attenuating cognitive deficits (Goldstein, 2003; McAllister 
et al., 2004) and data showing altered DA transporter binding after TBI (Donnemiller et al., 
2000).  Donnemiller et al., (2000) used single photon emission computed tomography (SPECT) 
to show that striatal DAT binding is decreased in patients 4-5 months after severe TBI, even in 
cases where no anatomical evidence of direct striatal injury exists. 
 
After experimental TBI, alterations in catecholamine systems have been found in various brain 
regions and have been shown to be time-dependent (Huger and Patrick, 1979; Dunn-Meynell et 
al., 1994; McIntosh et al., 1994; Massucci et al., 2004). For example, regional increases in DA 
levels at acute time points after acceleration-deceleration brain injury were reported by Huger 
and Patrick (1979). A transient increase in DA in both the striatum, up to 6 hours, and the 
hypothalamus, up to 24 hours, have been identified utilizing microdialysis (McIntosh et al., 
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1994).  Interestingly, in the McIntosh et al., 1994 study cortical tissue DA levels are actually 
depressed for up to 2 weeks post FPI.  In a CCI model of brain injury, there were significant 
increases in rat brain tissue DA levels and metabolism at 1 hour in the contralateral frontal 
cortex and 1 day in the ipsilateral frontal cortex (Massucci et al., 2004). Tissue DA levels were 
also elevated in both the ipsilateral and contralateral striatum at 1 hour compared to sham 
animals. Metabolism of DA was measured by the dihydroxyphenylacetic acid (DOPAC)/DA 
ratios demonstrating a bilateral increase in DA metabolism at 1 hr in the striatum of CCI injured 
rats (Massucci et al., 2004). TH activity and catecholamine increases (both DA and NE) have 
also been seen in the prelimbic and infralimbic cortices, areas critical to PFC function, up to 2 
weeks following CCI (Kobori et al., 2006). Increases in human cerebrospinal fluid (CSF) DA and 
its metabolites post TBI have been shown to depend on both gender and genetic variations in 
the DAT. Furthermore, the systemic administration of DA as an inotropic agent in TBI patients 
was also associated with higher CSF DA (Wagner et al., 2007c). Increased DA metabolism may 
represent a compensatory response to increased tissue DA levels or may be due to further 
direct effects of TBI on DA regulation. The consequences of these changes can be either 
beneficial in that DA neurotransmission is restored after TBI or could potentially be deleterious 
due to DA-induced oxidative stress.  
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Figure 3 shows a summary of noted changes in DA at the cellular level after TBI in both the 
striatum and prefrontal cortex, which includes alterations in TH, DAT, and DA receptors. 
Schematic of alterations in DA cellular signaling following TBI. Changes in DA at the cellular 
level both pre and post-synaptically have been observed in the PFC and striatum of rats. These 
alterations include changes in tissue DA levels, DA receptors, TH, and the DAT. Current 
research suggests that acutely there is a transient increase in DA tissue levels followed by 
chronic DAergic hypofunction, as indicated by reduced DAT levels, and decreased evoked DA 
release. However, it remains unclear what the consequences of acute versus chronic changes 
are and how to best manage these changes in a clinical setting. 
 
Given the importance of DA receptors to cognition, alterations in receptor expression has been 
another area of interest following TBI. Henry et al. (1997) reported a transient decrease in 
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striatal D1 receptors immediately after injury, followed by an increase at 1 day, and a 
subsequent return to pre-injury levels. No significant alterations in D2 receptor binding was 
reported in the study by Henry and colleagues.  Direct analysis of DA D2 receptor protein via 
Western blots has shown no significant reduction in striatal D2 receptor or D1 receptor 
expression at 2 weeks in a rat model of TBI (Wagner et al., 2005, 2009). This finding suggests 
that DAergic dysfunction following TBI is not entirely mediated by changes in DA receptors.   
   
In addition to temporal alterations in tissue DA levels there have also been changes observed in 
TH, the rate-limiting enzyme in catecholamine synthesis. TBI has been shown to increase TH 
protein in the rat frontal cortex at 28 days post-injury (Yan et al., 2001).  Measured increases in 
TH protein are most likely due to enhanced synthesis as phospho-TH is also increased (Kobori 
et al., 2006). In contrast, DA beta hydroxylase protein levels were not altered after TBI 
suggesting that the increase in TH occurred predominantly in DAergic axons (Yan et al., 2001). 
The absence of a decrease in TH positive SN neurons further differentiates TBI from PD. 
Increases in TH protein have also been observed in the striatum with a similar temporal profile 
(Wagner et al., 2005; Yan et al., 2007; Wagner et al., 2009).   
 
DAT is a crucial protein in the regulation of DA neurotransmission, playing a central role in 
determining the duration of action of DA by rapidly taking up extracellular DA into pre-synaptic 
terminals after release (Horn, 1990; Gainetdinov et al., 1998). Studies in animals lacking 
expression of the DAT gene (Gainetdinov, 2008; Wu et al., 2007) suggest that this protein is 
perhaps the single most important determinant of the extraneuronal concentration and duration 
of DA.  Differences in the number of uptake sites (Nirenberg et al., 1997; Sesack et al., 1998) in 
different brain regions provide DA with different extracellular lifetimes (Garris et al., 1994).  
Regional decreases in total DAT expression have been reported after CCI (Wagner et al., 2005, 
2009). Alterations in DAT expression suggest that improvements in cognition and 
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neurobehavioral recovery reported in experimental (Kline et al. 1994, 2000; Goldstein, 2003) 
and clinical (Whyte et al. 1997, 2004) TBI studies with the use of DAT inhibitors may, in part, 
confer their beneficial effects by increasing striatal extracellular DA in a post-injury environment 
where cortical influences on striatal DA neurotransmission may be impaired.  
 
Recent work suggests that both frontal cortex and striatal decreases in total DAT expression 
post-TBI are gender specific and occur primarily in males (Wagner et al., 2005). Estrogen is 
known to have both a developmental and signaling role in DA systems so it is not surprising that 
TBI has different effects on DA signaling in males versus females. Specifically Wagner et al. 
(2005) showed that, when compared to gender-matched controls, male rats demonstrated a 
proportionally larger decrease in DAT expression compared to females. Furthermore, it was 
shown that environmental enrichment, which improves cognitive recovery (Hamm et al., 1996a; 
Passineau et al., 2001; Wagner et al., 2002; Kline et al., 2007b; Hoffman et al., 2008b) exerted 
bigger effects on post-injury DAT reductions in females compared to males. What remains 
unclear is whether the DAT changes that occur in males and females following TBI are 
beneficial or detrimental. Interestingly there is evidence that other members of the 
catecholamine metabolism system being altered post TBI.  Specifically there have been noted 
increases in catechol-O-methyl transferase expression 24 hours post TBI that persists for up to 
14 days in the microglia of the injured hippocampus, suggesting a possible compensation for 
observed changes in DAT activity and providing further evidence of DA dysfunction (Redell and 
Dash, 2007).     
 
Studies examining DA neurotransmission have demonstrated reduced evoked DA overflow and 
altered kinetics of DA clearance in the striatum when assessed utilizing fast scan cyclic 
voltammetry and using a medial forebrain bundle stimulation paradigm (Wagner et al., 2005). 
Recent work suggests that daily treatment with MPD for two weeks after CCI reverses deficits in 
29 
 
DA neurotransmission. Interestingly, after two weeks of MPD treatment, there were no 
significant changes noted in DAT expression despite robust changes in DA neurotransmission 
and kinetics parameters (Wagner et al., 2009). Functional changes in DAT activity and 
trafficking, as well as other changes in DA receptor function may be responsible for the MPD 
mediated effects in DA neurotransmission observed. 
 
What effect these alterations in DAT, evoked DA release, and TH increases have on DA 
signaling has just begun to be elucidated.  Ongoing research into these molecular events will 
help researches develop targeted therapeutic strategies that specifically address TBI induced 
deficits in DA signaling.  
 
1.5.  DOPAMINE IN THE CLINIC:  THE PAST AND FUTURE ROLE OF DA AGONISTS AND 
ANTAGONISTS 
 
In 2006 the Neurotrauma Foundation (NTF) published an excellent review of current clinical 
recommendations for TBI management in both the acute and rehabilitative phases (Warden et 
al., 2006).  As part of its review the NTF identified three drugs with DAergic effects as current 
viable options to assist with cognitive recovery. The identified pharmacotherapies were MPD, 
Amantadine hydrochloride (AMH), and bromocriptine. MPD was recommended to enhance 
attentional function and speed of processing.  Both MPD and AMH were considered reasonable 
options to enhance general cognitive function after TBI.  Bromocriptine was recommended to 
enhance executive function after TBI. The NTF also acknowledged that there remains limited 
clinical evidence for long term benefits with DAergic medications, but that initial clinical case 
reports and clinical studies have shown promise for stimulants (e.g., MPD), AMH, and 
bromocriptine. Both clinical data concerning the efficacy of DA agonists and a substantial 
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amount of literature in animal models demonstrate improved functional recovery with DA 
agonists post TBI.   
 
1.5.1 CNS Stimulants (Amphetamine and Methylphenidate) 
  
1.5.1.1: Mechanism of action.  Stimulants are often employed to assist in the rehabilitation of 
individuals with TBI. The most commonly used stimulants are amphetamine (AMPH) and MPD. 
Both AMPH and MPD have been used as drugs of choice for the treatment of ADHD.  AMPH is 
a CNS stimulant that possesses two main mechanisms of action.  AMPH acts on presynaptic 
nerve terminals to inhibit the reuptake of serotonin, norepinephrine (NE), and DA by blocking 
monoamine transporters, including the DAT. AMPH also increases monoamine secretion via 
exchange diffusion and reverse transport (Haracz et al., 1998; Volkow et al., 2002a,b; 
Fleckenstein et al., 2007).  In contrast MPD’s predominant mechanism of action is via blockade 
of the DAT (Volkow et al., 2002a,b, 1998).  Cognitive benefits on attention observed with AMPH 
and MPD treatment have been associated with the effective increase in DA caused by their 
administration (Volkow et al., 2001, 2004; Schiffer et al., 2006). 
  
1.5.1.2: AMPH and MPD in the clinic.  The administration of AMPH in the clinic to treat TBI is 
not as widely practiced as is the accepted pharmacotherapeutic strategy of providing MPD. 
Thus, this section will focus almost entirely on MPD. However, we would be remiss if we did not 
mention a report by Evans et al. (1987) who administered d-AMPH following closed head TBI 
and found that the treatment enhanced processing speed and improved memory. Regarding 
MPD, multiple studies have demonstrated its effectiveness in treating cognitive dysfunction after 
brain trauma (Table 1). In a double blind study, Gualtieri (1988) found that MPD treatment 
improved performance on measures of nonverbal fluency and selective attention as well as self-
report measures in a subset of TBI “responders”. Another clinical trial found that low dose MPD 
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treatment following moderate to severe TBI improved functional outcome at day 30 over 
controls as measured through the Disability Rating Scale (DRS) (Plenger et al., 1996).  Kaelin et 
al. (1996) showed a trend toward improved DRS and a significant improvement in attention with 
low does MPD treatment after TBI. Other recent studies have demonstrated beneficial effects of 
MPD on attention (Whyte et al., 1997) and information processing speed (Whyte et al., 2004) in 
individuals with TBI. However, a few studies have shown no effect on cognitive outcomes with 
MPD treatment (Mooney and Haas, 1993; Speech et al., 1993; Tiberti et al., 1998).  It must be 
noted that for the Speech et al. (1993) study, the authors noted that statistical power was low, 
and in the Tiberti et al. (1998) study, the outcome measurement was memory function following 
organic amnesia, which may not be as profoundly influenced as attentional processing. 
 
To better understand the mechanism of action responsible for the cognitive benefits gained with 
CNS stimulant treatment, specifically MPD, animal studies have examined both the behavioral 
and biochemical aspects of MPD treatment post TBI. 
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1.5.1.3:  AMPH and MPD in animal models.  Peak levels of MPD in the plasma and brain 
following intravenous injection occur within 20 minutes in awake animals and correspond with 
peak striatal DA levels as measured by microdialysis (Huff and Davies, 2002).  Intraperitoneal 
and oral administration of MPD in rodents shows peak striatal DA levels after 40 minutes 
(Gerasimov et al., 2000). It has also been demonstrated that MPD has a shorter half-life in rats 
than in humans (Kuczenski and Segal, 2005).  In order to overcome these limitations, doses are 
often larger to maintain drug levels at a therapeutic target over longer time intervals.  
Regardless of these limitations, experimental models utilizing a MPD treatment paradigm have 
been able to demonstrate cognitive benefit after both cortical ablation and TBI injuries (Kline et 
al., 1994, 2000). Specifically, a single administration of MPD followed by significant symptom 
relevant experience (i.e., beam walking experience) enhanced recovery of motor function 
following sensorimotor cortex lesions (Kline et al., 1994). Moreover, daily MPD treatments 
beginning as late as 24 hours after TBI in rats reveal significantly less spatial memory 
performance deficits versus saline treatment (Kline et al., 2000). Wagner et al. (2009) showed 
that daily treatment with MPD (5 mg/kg) post-CCI resulted in increased DA overflow and Vmax. 
There was no associated effect of MPD treatment on DAT localization, or DA receptor 
expression, however there was a significant increase in c-fos expression with MPD treatment.   
 
Interestingly, while the exact mechanisms of MPD benefit on cognition after TBI are still not 
understood, gender differences have been observed. Wagner et al. (2007a) showed that injured 
males treated with MPD had no change in active behaviors and displayed significant 
improvements in a MWM task indicating that daily treatment with MPD results in enhanced 
cognition without noticeable motor enhancement. However, MPD treated female rats did not 
show significant improvement on the MWM task, but did exhibit increased swim speed, which 
was not observed in males. The researchers note that the dosing regimen was based on 
previous studies using male rats (5 mg/kg; Kline et al., 2000), and a lower dosing of MPD for 
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injured females may be required to augment learning and memory pathways without inducing 
stereotypical behaviors that may interfere with attention and learning processes. The finding of 
increased motor sensitivity to MPD in females may be due to hormonal influences on regional 
DAT densities post-TBI and/or differences in DAT modification/function (Bosse et al., 1997). In a 
previous paper Wagner et al. (2005) demonstrated gender specific alterations in DAT 
expression after TBI. Furthermore, estrogen is known to exert effects on DAergic neuron 
development (Kipp et al., 2006) and has neuroprotective properties independent of other drug 
treatments (Gibson et al., 2008). Estrogen has also been shown to act as a signaling molecule 
within the DA system (Kuppers and Beyer, 1999; Kuppers et al., 2000).   
 
AMPH use in experimental models of TBI and selective cortical injury models has also been 
shown to accelerate recovery. The positive benefits of AMPH have been reported in FP (Dhillon 
et al, 1998) and selective lesion studies (Feeney et al 1981; Hovda et al., 1989; M’Harzi et al., 
1988; Chudasama., 2005).  AMPH treatment has been shown to reduce the accumulation of 
free fatty acids and lactate following FP in the cortex and hippocampus (Dhillon et al., 1998) and 
attenuate decreases in cerebral glucose utilization (Queen et al., 1997). AMPH treatment can 
also induce hippocampal brain derived neurotrophic factor (BDNF) following brain injury 
(Griesbach et al., 2008). This is not surprising given that AMPH treatment is known to induce 
use dependent plasticity and synaptogenesis (Butefisch et al., 2002) and has been strongly 
linked to plastic alterations following brain injury (Goldstein, 2003; Ramic et al., 2006). 
Interestingly, when combined with exercise, AMPH treatment no longer increased BDNF 
(Griesbach et al., 2008).  This finding suggests that the positive benefits of AMPH treatment 
may be associated with its ability to enhance plastic responses in an injured brain and that 
combinational therapies are not necessarily more beneficial.  
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An important caveat to AMPH studies is that while AMPH treatment does increase levels of all 
monoamines (Fleckenstein et al., 2007), the beneficial effects of AMPH on motor recovery have 
only been reproduced by intraventricular administration of NE (Boyeson and Feeney, 1990). 
This does not rule out a positive role for DA facilitation with AMPH treatment on other cognitive 
processes, but simply suggests that DA mediated benefits on motor recovery may not be due 
simply to increases in DA release. This is supported by evidence that DA antagonists, such as 
haloperidol (which will be discussed later), can block the beneficial effects of AMPH treatment 
(Feeney et al., 1982; Hovda and Feeney, 1985). 
 
1.5.2 Amantadine Hydrochloride 
 
1.5.2.1: Mechanism of action.  AMH is a water soluble salt that has the capability of crossing all 
cellular membranes including those of the CNS. AMH was originally used as an antiviral agent 
for influenza type A.  Subsequent studies showed it to be effective in treating PD and multiple 
sclerosis (Godwin-Austen et al., 1970; Rinne et al., 1972; Cohen and Fisher, 1989). Though the 
mechanism of action for AMH treatment of PD and multiple sclerosis is not completely 
understood, biochemical studies have demonstrated that AMH increases extracellular DA 
concentrations by blocking reuptake and by facilitating the synthesis of DA (von Voigtlander and 
Moore, 1971; Bak et al., 1972; Gianutsos et al., 1985). In addition to acting at pre-synaptic 
targets, AMH has been demonstrated to act post-synaptically by increasing post-synaptic DA 
receptor density (Gianutsos et al., 1985) or altering their conformation (Allen, 1983). Evidence of 
a post-synaptic mechanism is clinically promising because the mechanisms of actions may not 
depend solely on the presence of surviving pre-synaptic terminals. Because the mechanism of 
action of AMH differs from other DA releasing drugs (see Gualtieri et al., 1989 for review), it is 
likely that the DAergic effects of AMH are a combination of pre-synaptic and post-synaptic 
effects.   
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1.5.2.2: AMH in the clinic.  AMH has been found to be effective at treating cognitive dysfunction 
post TBI in both clinical trials and case reports (Table 2). While the level of evidence for AMH 
benefit is not as well developed as for MPD in adult TBI, clinical studies suggest general 
cognitive improvements with AMH administration after TBI.  Zafonte et al (1998) and Wu & 
Garmel (2005) reported improved scores on the activities of daily living scales in case reports of 
patients treated with AMH.  Case reports (Chandler et al., 1988; Kraus and Maki, 1997) also 
indicate general improvements in global functioning.  In patients demonstrating indications of 
diffuse axonal injury after TBI, AMH appeared to be effective in improving cognition independent 
of the timing of administration (Meythaler, 2002). Kraus et al. (2005) showed that improvements 
in executive function measurements correlated with increases in left PFC glucose metabolism in 
TBI patients receiving AMH treatment.  As reported with other pharmacotherapies (e.g., MPD) 
AMH did not confer benefits in all studies conducted (Schneider, 1999; Hughes et al., 2005). 
However, in a review of reports of AMH use after TBI, Sawyer et al., (2008) concluded that it 
appears to safely improve both arousal and cognition.   
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1.5.2.3: AMH in animal models.  The mechanisms of AMH effects are still poorly understood 
making animal studies of its effects an important step in improving clinical use. In humans, AMH 
has variable absorption rates and steady state plasma concentrations are typically reached 
within 4 to 7 days. Doses of AMH given to patients are also somewhat variable due to a lack of 
correlation between plasma concentrations and therapeutic effects (Aoki and Sitar, 1988). In-
vitro studies have shown that doses required to affect DA uptake are higher than those used 
clinically with no significant difference in DA kinetics until concentrations of 40 mg/kg to 80 
mg/kg were given (Baldessarini et al., 1972; Brown et al., 1976; Page et al., 2000).  In brain 
injury patients the optimal dose of AMH has ranged from 50 to 400 mg/day given orally 
(Gualtieri et al., 1989). Unfortunately, AMH has not been as extensively researched in 
experimental models of TBI as CNS stimulants have. However, one study using daily treatment 
of AMH (10 mg/kg) did show significantly improved spatial memory performance compared to 
saline treated rats following TBI (Dixon et al., 1999).  
 
1.5.3 Bromocriptine 
 
1.5.3.1: Mechanism of action.  Bromocriptine is a specific D2 receptor agonist that possesses a 
rather complex mechanism of action.  At high doses (above 10 mg/kg) bromocriptine binds to 
both highly sensitive presynaptic D2 autoreceptors and less sensitive postsynaptic D2 receptors 
causing an expected inhibition in DA release and metabolism.  Interestingly at lower doses (2.5 
and 5 mg/kg) bromocriptine has been shown via microdialysis to increase extracellular DA 
levels in rats (Brannan et al., 1993).  However, even at low doses of bromocriptine there is an 
associated delayed reduction in DA metabolites consistent with autoreceptor activation 
(Brannan et al., 1993; Pagliari et al., 1995).  In vitro studies have suggested that at low 
concentrations bromocriptine can act as a partial D2 antagonist (Lieberman and Goldstein, 
1985), which may explain an initial increase in DA release.  In vivo studies have not been able 
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to provide conclusive evidence of bromocriptine antagonist activity. However, low doses of 
bromocriptine are characteristically associated with inhibition of DA neuronal firing (Jackson et 
al., 1990).  Consequently, the reason behind this concentration dependent effect of 
bromocriptine remains unclear.  It may be a consequence of D2 receptor location, affinity, or 
bromocriptine’s activity as a partial D1 antagonist and mixed agonist-antagonist at D2 receptors 
(Lieberman and Goldstein, 1985; Tan and Jankovic, 2001).  What has been shown consistently 
is that bromocriptine requires DA in order to produce any behavioral effects (Jackson et al., 
1988), and alterations in DA concentration effectively alter bromocriptine’s activity at pre versus 
post-synaptic D2 receptors (Maruya et al., 2003).  Furthermore, a single administration of 
bromocriptine can cause an alteration in D2 receptor binding for further treatments (Jackson et 
al., 1988).  These are important caveats to consider in TBI research evaluating bromocriptine as 
a potential treatment strategy.  
  
1.5.3.2: Bromocriptine in the clinic.  In humans bromocriptine has an oral availability of 
approximately 30-40% and reaches peak levels about 1-2 hours after administration.  Following 
discontinuation, bromocriptine remains in the system for up 12 hours.  Low dose treatments for 
PD range from 5-30 mg/day while high dose treatments for more advanced PD are within 31-
100 mg/day (Lieberman and Goldstein, 1985; Deleu et al., 2002).  Bromocriptine is less well 
studied in clinical research compared to AMH and MPD (Table 3).  Past case reports (Ben 
Smail et al., 2006; Karli et al., 1999) showed improvements in executive function after 
administering bromocriptine. McDowell et al (1998) also demonstrated improvements in 
executive function with a single 2.5 mg bromocriptine administration. Improvements in digit 
span, list learning, and motivation in bromocriptine treated patients (maximum of 10 mg per day) 
that persisted for at least two weeks after bromocriptine withdrawal were also reported (Powell 
et al., 1996). Bromocriptine did not appear to be effective in addressing moderate to severe TBI 
patients’ attentional difficulties during a postacute phase of recovery at a dose of 5 mg twice 
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daily (Whyte et al., 2008).  However, the study employed a relatively high dose of steady state 
bromocriptine at 10 mg per day for a more prolonged treatment timeline than previously studied 
in TBI (Whyte et al., 2008). It may be that the dosing of bromocriptine in head trauma patients 
needs to be specifically titrated given DAergic alterations caused by TBI. It is also possible that 
higher doses of bromocriptine for prolonged periods negatively impacts DA kinetics in this 
patient population.   
 
 
 
1.5.3.3: Bromocriptine in animal models.  In rats, plasma concentrations of bromocriptine peak 
at 15-30 minutes with delayed maximal D2 binding occurring for a period of up to three hours 
(Maurer et al., 1983; Atsumi et al., 2003).  Dosing for rats is generally lower than that for 
humans and is based on the findings from behavioral studies showing that higher doses (10-40 
mg/kg) induce motor activation in normal rats (Jackson et al., 1988; Brennan et al., 1993).  Rats 
receiving delayed (i.e., 24 hours post injury) and chronic (i.e., daily for 18 days) pharmacological 
treatment with bromocriptine (5 mg/kg) exhibited both enhanced WM and acquisition of spatial 
learning in a MWM task (Kline et al., 2002).  In a follow up study, Kline et al. (2004) 
demonstrated that bromocriptine-treated rats exhibited enhanced spatial learning as they were 
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more adept at locating a hidden platform in a MWM task and also displayed increased 
hippocampal neuronal protection following TBI compared to vehicle-treated controls. 
Furthermore, the data showed that bromocriptine attenuated TBI-induced oxidative stress (Kline 
et al., 2004). 
 
1.5.4 Other DAergic drugs 
   
The administration of selegiline (L-deprenyl) once daily for seven days beginning 24 hr following 
FP injury has been reported to improve cognitive function in the MWM and enhance 
neuroplasticity (Zhu et al., 2000). L-deprenyl is used to enhance the action of DA by inhibiting its 
main catabolic enzyme in the brain, monoamine oxidase-B. Additionally, Newburn and Newburn 
(2005) showed that selegiline has potential clinical benefits in the treatment of post-TBI apathy.   
 
Atomoxetine administered at a dose of 1mg/kg one day following lateral FP injury in rats 
showed improvement in Morris water maze performance compared to vehicle (Reid and Hamm, 
2008).  Atomoxetine is typically used as a non-stimulant drug for treatment of ADHD.  While its 
mechanism of action is predominantly through inhibition of the NE transporter it has been shown 
to increase extracellular DA in the PFC (Bymaster et al., 2002).  
 
1.5.5 The negative impact of DA antagonists following TBI 
 
Antipsychotic drugs, in particular haloperidol and risperidone, have been administered to TBI 
patients to treat agitation and psychotic symptoms that may be related to the injury. 
Unfortunately there are very few clinical studies on cognitive effects in TBI patients following 
antipsychotic administration, which has limited conclusions on potential consequences of 
antipsychotic use in TBI populations (Elovic et al., 2008).  However, animal studies have 
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demonstrated negative consequences of antipsychotic administration following TBI, in particular 
with administration of typical antipsychotics.  
 
Haloperidol and risperidone have multiple CNS effects, but one of the predominant effects is a 
strong central DA receptor inhibition that can produce akinesia and pseudoparkinsonism. Given 
this profound DAergic component of these antipsychotics, the question about what effect they 
might have on the recovery process after TBI is important.  Animal models have demonstrated 
that antipsychotics impair the recovery process and in some instances exacerbate the TBI-
induced behavioral deficits. For instance, Feeney and colleagues demonstrated that even a 
single administration of haloperidol provided after TBI to adult rodents delayed motor recovery 
(Feeney et al., 1982). Moreover, administration of haloperidol after the rats were recovered, as 
indicated by normal beam-walking, led to a reinstatement of the deficits (Feeney et al., 1982). 
Similar findings were reported by Goldstein and Bullman (2002). Other studies have shown that 
antipsychotic drugs after brain trauma not only impair motor recovery, but also cognitive 
function. Wilson et al. (2003) showed that haloperidol led to slower acquisition of spatial learning 
in a water maze task. Interestingly there was no impairment noted with the administration of the 
atypical antipsychotic olanzapine following TBI by Wilson et al (2003).  One possible 
explanation is the relatively low activity of olanzapine at the D2 receptor relative to haloperidol 
(Tauscher et al., 2004).    
 
Recent studies from our laboratory have demonstrated that prolonged exposure to the typical 
and atypical antipsychotics, haloperidol and risperidone, respectively, after TBI impairs motor 
recovery and hinders the acquisition of spatial learning and memory retention (Kline et al., 2007; 
Hoffman et al., 2008; Kline et al., 2008). Risperidone and haloperidol also impaired performance 
in uninjured controls when given prior to behavioral testing, but not after, suggesting that 
sedation may play a role in performance deficits (Hoffman et al., 2008; Kline et al., 2008). 
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Haloperidol has also been shown to block the positive benefits of AMPH treatment (Hovda and 
Feeney., 1985). Interestingly, while single or multiple low doses of risperidone and haloperidol 
appear to be innocuous to recovery after TBI, chronic high-dose treatments are uniformly 
detrimental (Kline et al., 2007).    
 
A number of studies have also shown positive improvements in WM and spatial memory with 
both early (Tang et al., 1997) and late (Kobori and Dash, 2006) administration of DA 
antagonists.  For example, Kobori and Dash (2006) demonstrated that a single administration of 
the DA D1 antagonist (SCH23390) at 14 days post injury in rats improved WM for up to a week.  
Tang et al. (1997) showed an improvement in functional recovery with D2 receptor specific 
antagonists given immediately post injury and a synergistic effect when combined with D1 
receptor antagonism in mice. Given that both haloperidol and risperidone have a higher affinity 
for the D2 receptors (Cohen, 1994; Reimold et al., 2007), it may be that specific blockade of D2 
receptors is the event most associated with negative outcomes when antagonized at later time-
points. This is not unreasonable as it has been shown that D1 receptor activation is also 
important for inflammatory and immunological responses including phosphoinositide hydrolysis 
and arachidonic acid release as discussed previously in this review. A potential explanation is 
that inhibition of D1 receptors after TBI beneficially affects the injury response while DA agonists 
at later time-points provide cognitive benefits. 
 
1.6. FUTURE AVENUES OF DA RESEARCH IN TBI: DA REGULATION, SIGNALING, AND 
STRUCTURAL PLASTICITY 
 
There remains a significant amount of work in TBI research to explore completely the realities 
and consequences of DAergic dysfunction after TBI.  Are the observed alterations in DAT and 
TH protein levels a result of injury and ongoing biochemical damage or are they a response to 
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initial changes in DA levels in the cortex and subcortical layers?  Furthermore, although no overt 
cellular damage has been identified within nigrostriatal and mesocortical DAergic pathways, 
there remains the possibility of axonal disruptions and biochemical alterations.  Interestingly, in 
the PD literature it has been suggested that there exist subtle changes in oxidative stress 
related to DA signaling within the SN occurring prior to significant cell loss. 
 
Animal models of TBI consistently produce widespread excitotoxic damage and increased 
amounts of oxidative stress in a number of different brain regions (Palmer et al., 1993; Rao et 
al., 1999).  DA is known to possess excitotoxic properties (Olney et al., 1990), and DAergic 
fibers have been shown to modulate striatal glutamatergic excitotoxicity (Chapman et al., 1989; 
Filloux and Wamsley, 1991).  The initial increases in DA observed post TBI may precipitate 
excitotoxic disruption and oxidative damage to DAergic cellular function that leads to the 
observed alterations in DA kinetics and decreased evoked DA release at later time-points.   
 
Observed changes in DAT expression in TBI also raise an intriguing set of considerations.  As 
discussed in the section concerning DAT activity, the DAT is regulated by a number of genetic 
factors and shows variation in activity and expression with both age and gender.  Alterations in 
DAT expression can alter the kinetics of DA release as demonstrated in DAT knockdown 
models (Zhuang et al., 2001), as can changes in DAT cellular localization (Pristupa et al., 1998).  
Decreases in evoked DA overflow Vmax following CCI may be explained by either changes in 
expression or changes in membrane bound DAT associated with DAT trafficking (Wagner et al., 
2005, 2008). Given that a number of the current DA receptor agonist therapies act through a 
DAT mediated mechanism, it is necessary to fully understand the role of DAT changes in TBI in 
order to provide efficacious DA therapies. 
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In addition to documented biochemical alterations in DA signaling following TBI, there remains 
the possibility of structural changes. TBI is known to cause diffuse white matter injury and 
significant axonal disruptions throughout the CNS (Smith et al., 2003). However, it remains 
unclear if similar effects can be observed within DAergic systems.  Increases in TH staining in 
both the PFC and striatum may represent regrowth of DAergic fibers that occur as a 
consequence of DA synapse or axonal pathology that occurred acutely following TBI.      
 
Regrowth or collateral sprouting of catecholaminergic axons has already been demonstrated in 
experimentally induced lesions of adult CNS neurons (Katzman et al., 1971; Gilad and Reis, 
1979; Fritschy and Grzanna, 1992). Moreover, in both PD patients and animals with 
experimental Parkinsonism, neural transplants or the supply of neurotrophic factors may 
promote regrowth of DAergic fibers in the striatum and reverse lesion-induced behavioral 
deficits (Kordower et al., 1991; Kopin, 1993; Tomac et al., 1995). The occurrence of 
spontaneous regrowth of DAergic fibers after partial nigrostriatal denervation has already been 
suggested (Onn et al., 1986) and a long-term increase in the amount of striatal TH has been 
observed after 6-hydroxydopamine injection in the SN pars compacta (Pasinetti et al., 1991; 
Blanchard et al., 1995). It is thus possible that the TBI-induced expression of TH in the 
nigrostriatal system might share similar mechanisms. However, further studies evaluating DA 
turnover, TH activity, DOPAC/DA and DA/TH in the nigrostriatal system after TBI are needed to 
confirm whether there is such a compensatory mechanism after TBI. 
 
Furthermore the striatum is a heterogeneous region and a varied profile of DA kinetics has been 
reported within different areas of the dorsal (caudate and putamen) and ventral (NAcc) striatum 
(May and Wightman, 1989a,b; Bergstrom et al., 2001).  It is possible that caudate subregions 
are differentially affected by CCI. Differences may also exist in damage to the NAcc core versus 
the shell.  Subregion damage could also differentially affect PFC function given the regionally 
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specific cortical connections that exist within basal ganglia anatomy (Grahn et al., 2008). While 
many studies have also identified alterations in the PFC associated with TBI, future studies will 
likely need to evaluate DA neurotransmission in multiple DA regions outside the caudate 
putamen, as well as subregions within the caudate to characterize fully the effects of trauma on 
these heterogeneous structures.  
 
DAergic dysfunction after TBI may not be limited to neurotransmitter release, concentration, and 
metabolism. Preliminary research in our group suggests that TBI can cause alterations in 
DARPP-32 phosphorylation altering a number of important intracellular signaling molecules. The 
importance of DARPP-32 to DAergic synaptic plasticity and modulation of other 
neurotransmitter systems has broad reaching implications for medium spiny neuron function in 
the striatum and represents another possible level of DA dysfunction following TBI.   
 
Alterations in receptor expression also remain an area where further research is necessary.  
While studies to date have not demonstrated any overt alteration in DA receptors, there are a 
number of areas that require further consideration. D1 and D2 receptors depend upon a 
complex interplay with other receptor systems within the striatum and other DA systems. In 
particular, recent research in PD has identified a series of heterodimeric complexes of the D2 
receptor with other neurotransmitter receptor systems including the adenosine A2a and Mglut5 
receptors. It has been proposed in PD research that A2a antagonists can augment DAergic 
treatments. Interestingly, both A2a and Mglut5 receptors have also been shown to play heavily 
into DA’s role on striatal plasticity and intracellular calcium signaling.   
 
Given that TBI causes damage to areas known to be involved in DAergic processing and that 
research in other disease states have established that DA is important for cognitive outcomes, it 
is logical that TBI should produce clinical outcomes similar to what is observed in other 
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disorders of DAergic function. Indeed, the clinical picture of behavioral and cognitive 
dysfunctions after TBI shares a number of commonalities with other disorders of DA 
dysfunction, such as PD and HD. 
 
To date, clinical studies have consistently demonstrated that pharmacotherapies that enhance 
DA post-TBI are beneficial to memory, attention, and executive function. However, clinical 
studies examining DAergic therapies have a number of limitations.  Small patient populations, 
variations in treatment protocols, lack of proper controls including the absence of randomized 
clinical trials, and a poor definition of TBI make it difficult to identify who would benefit the most 
from DA enhancement therapy and the proper time-course of therapeutic intervention.  
 
Ongoing animal and clinical studies have better characterized DAergic dysfunction following 
TBI, which is still difficult due to the diffuse nature and variable presentation of TBI. However, 
studies in both animals and humans have identified a series of temporally specific alterations in 
DA neurotransmission that occur after TBI (Figure 3). An acute hyperactive phase, 
characterized by increases in tissue DA levels and an initial increase in D1 receptors, is 
subsequently followed by hypofunction in DA signaling characterized by decreases in evoked 
DA overflow and alterations in both DAT and TH expression.  Animal studies demonstrating the 
benefit of D1 antagonists and D2 agonists would suggest that the critical event in DAergic 
dysfunction following TBI is related primarily to signaling through the DA D2 receptor population. 
 
Understanding the temporal alterations in DA following TBI and the mechanism of dysfunction at 
a cellular and systems level will allow DAergic therapies to be better tailored to specifically 
address the character of dysfunction in TBI populations during recovery.  Furthermore, given the 
importance of genetic differences in DA kinetics and the role of gender in DA signaling, it is 
important to utilize animal models of injury to better understand how these factors affect 
48 
 
potential treatments. Doing so will help answer long standing questions in TBI rehabilitation in 
how to best optimize neuropharmacology strategies. Understanding the role of DA in cognitive 
recovery following TBI also adds another layer of consideration to the use of acute phase 
medicines that may affect CNS DA systems. 
 
Effective treatment of cognitive dysfunction post-TBI remains a weakness in the care of TBI 
patients, in particular as critical care management improves and patient survival improves. 
Current rehabilitation strategies do not address the underlying deficits in CNS function that 
cause prolonged deficits in learning, memory, executive function, and behavior. Even given the 
limitations of current clinical research in DA therapies evidence indicates that the use of a DA 
enhancing drugs during rehabilitation benefits cognitive recovery. In particular the use of MPD, 
AMH, or bromocriptine to enhance learning, memory, attention, and executive function should 
be considered in TBI patients that present with deficits in these areas.  
 
While some studies have suggested that administration of DAergic therapies may be beneficial 
even at timepoints beyond the recovery phase of TBI, typically within the first year post injury for 
humans and 2-4 weeks post injury in rats, in general early treatment within the recovery period 
has shown the most consistent benefits in both animals and humans. What remains unclear is 
at what dose and for what time period these drugs should be given.  It is also unclear if there 
are patients who should not be given DAergic drugs due to potential negative side effects.  
Further, is it unclear how management should change if patients require other DA targeted 
therapies such as antipsychotics or pressors.  Unfortunately, until these issues are resolved a 
large randomized therapeutic trial, even one that utilized different dosing protocols, would most 
likely provide more confusion then answers.  Without understanding what is happening in our 
patients any results would be difficult to interpret particularly in such a heterogenous patient 
population. 
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To reach the level of an effective clinical trial three stages must occur in TBI DA research. 
1) First there needs to be animal research to specifically identify temporal alterations in DA, the 
DAT and other metabolic proteins, DA anatomy, and DA responsive proteins within the 
hippocampus, striatum, and PFC.  While striatal and PFC analysis of DA and DAT have been 
performed there remains a paucity of information regarding the hippocampus and other DA 
metabolic proteins.  Furthermore, while other DA diseases such as PD have clearly described 
anatomical alterations what occurs post TBI in DAergic systems is unknown. In analyzing these 
four areas we will be able to fully understand the timecourse of DA changes post TBI, identify 
specific areas of potential manipulation that can be translated into drug studies, and most 
importantly begin to be able to appropriately analyze patient outcomes when DA therapies are 
employed. 
2) Second, based upon our analysis of changes within animals we need to develop targeted 
treatment strategies that utilize both direct DA enhancement and indirect DA signaling 
manipulation.  Ultimately, efforts need to be made to establish combination therapies that take 
advantage of the natural dichotomy in DA anatomy that is provided by D1 versus D2 receptor 
populations and functional location.  Also by utilizing adjunct therapies that facilitate DAergic 
function without specifically altering DA tissue levels many of the negative consequences of DA 
therapies can be avoided.    
3) Third, an understanding of DA effects within patient populations must be understood both 
following injury and in the presence of pharmacological agents.  There must be efforts to 
promote small dosing studies in TBI patients to determine how providing DA therapy effects DA 
tissue concentrations and metabolites within human populations.  In addition, efforts within TBI 
clinical studies need to be made to promote stratification of results based upon gender, genetic 
markers, in particular DAT expression profiles, and injury profiles.   
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1.7 SUMMARY AND AIMS 
 
The first step in understanding the complexities of subcortical striatal signaling is to identify a 
common event that can be monitored to determine striatal dysfunction. Prior examination of the 
DA system following TBI has demonstrated acute and chronic alterations in DA release and 
metabolism. In addition pharmacotherapeutics whose action enhances DAergic 
neurotransmission within the CNS have been shown to enhance cognitive recovery in both 
animal models of TBI and clinical studies of TBI patients. While a number of neurotransmitter 
systems including glutamatergic, cholinergic, and GABAergic have been implicated in acute and 
chronic deficits; the DA system, through the interplay of DA receptors D1 and D2, has the ability 
to modulate each of the other systems.  
 
This modulation is uniquely governed by the DAergic regulation of dopamine- and cAMP-
regulated phosphoprotein, Mr 32 kDA (DARPP-32) (Figure 2). The convergent properties of 
DARPP-32 are related to two distinct phosphorylation sites, Threonine 34 (Thr34) and 
Threonine 75 (Thr75), which act to regulate two key intracellular signaling molecules PKA and 
PP-1 (Greengard et al., 1999). While DARPP-32 has been predominantly characterized in the 
striatum, research has identified DARPP-32 expression in the frontal cortex. Alterations in 
DARPP-32 phosphorylation state influence NMDA receptor activity, structural plasticity, cell 
homeostasis, cell signaling, and general medium spiny neuron function (Greengard et al., 1999; 
Nairn et al., 2004).  
 
The purpose of the studies presented in this thesis were to test the hypothesis that TBI 
produces a dysfunction in DA signaling pathways and subsequent alteration in DARPP-32 
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phosphorylation which is functionally responsible for chronic alterations in molecular signaling 
events in medium spiny neurons relevant to cognitive function, including alterations in ERK and 
CREB cell survival signaling. Furthermore we evaluated DARPP-32 as a potential therapeutic 
target for a combined drug treatment strategy following TBI. 
 
We hypothesized that alterations in DARPP-32 following TBI are partially responsible for chronic 
cognitive deficiencies. We hypothesized that treatments aimed at reversing TBI induced 
dysfunctions in DARPP-32 signaling can provide alleviation of chronic cognitive dysfunction 
following TBI.  
 
Aim 1.  Determine the effect of TBI on DARPP-32. 
The phosphorylation state of DARPP-32 at Thr34 is important to PKA and PP1 activity which 
are responsible for altering the phosphorylation state of numerous targets including ERK and 
CREB which are relevant to cell survival signaling, NMDA receptor subunits which are relevant 
to glutamate responses and synaptic plasticity, the Na/K ATPase which is relevant to 
maintenance of membrane potential and osmotic homeostasis, and structural proteins involved 
in synaptic density and dendritic complexity. 
 Aim 1a. Determine the effect and timecourse of TBI on the expression of DARPP-32 
and the phosphorylation of DARPP-32 at Thr34 and Thr75.  
 Aim 1b. Determine the effect and timecourse of TBI on the expression and activity of the 
immediate DARPP-32 targets, PP1 and PKA. 
  
Aim 2.  Characterize the effect of TBI on injury relevant DARPP-32 responsive cell 
signaling systems. 
Deficiencies common to tissue affected by TBI include alterations in cell osmotic homeostasis 
and membrane potential, cell survival, and changes in cell glutamate response.  Measureable 
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representative molecular events include protein phosphatase-1 activity, ERK and CREB 
phosphorylation, and STEP expression and phosphorylation.  Prior research has found that 
DARPP-32 phosphorylation state is important to each of the stated molecular events. 
 Aim 2a. Determine the effect and timecourse of alterations in ERK and CREB 
phosphorylation, protein phosphatase-1 activity, and striatally enriched protein phosphorylation. 
 
Aim 3: Assess the contribution of the changes in phosphorylation of DARPP-32 following 
TBI to long term cognitive outcomes. 
Effectively treating the persistent cognitive disorders seen in TBI sufferers will need to employ a 
more complete strategy that affects multiple potential therapeutic targets.  DARPP-32 
represents one target of therapeutic intervention with the potential to have multiple downstream 
benefits. However, if there is persistent structural damage to synaptic formations any treatment 
of molecular targets may not provide optimal recovery.  Due to this we are proposing the 
utilization of two separate drug treatment paradigms to assess the role of clinically relevant 
pharmaceuticals on DAergic systems after TBI and cognitive recovery. Amantadine has been 
shown to be beneficial in TBI patients and effectively increases DAergic tone within the striatum 
and FC. FK506 has also been shown to provide benefit to outcomes in TBI patients, but is 
theorized to act predominantly through beneficial effects on structural damage. 
 Aim 3a. Determine the effect of Amantadine on DARPP-32 phosphorylation and 
cognitive outcome as assessed utilizing the Morris water maze (MWM). 
 Aim 3b.  Determine the effect of FK506 on DARPP-32 phosphorylation and cognitive 
outcome as assessed utilizing the Morris water maze (MWM). 
 Aim 3c. Determine the effect of combined Amantadine and FK506 on DARPP-32 
phosphorylation and cognitive outcome as assessed utilizing the Morris water maze (MWM). 
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These studies represent the first to examine DARPP-32 phosphorylation and its substrates in 
TBI. The concept that DARPP-32 phosphorylation and its substrates are altered following TBI is 
novel. A therapeutic approach to synergistically target DAergic dysfunction within the striatum 
represents a plausible combination therapy that may overcome current therapeutic limitations.  
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2. THE HIPPOCAMPAL CONUNDRUM: ALTERATIONS IN CALCINEURIN SUBUNITS POST 
TBI 
 
 
2.1 INTRODUCTION 
 
The hippocampus has been the predominant focus of TBI research into cognitive deficits. 
Learning and memory difficulties following TBI are thought to be caused by significant 
hippocampal cell loss, dysfunction in long term potentiation, and disruptions in normal 
hippocampal architecture. The hippocampus is a logical target for analysis of learning and 
memory disruptions given the history of hippocampal learning and memory deficits with ablation. 
Furthermore the hippocampus possesses a well characterized and understood form of synaptic 
plasticity that is disrupted following TBI and can be recovered with drug administration. The 
issue with a hippocampal focus in TBI is that histologic recovery of hippocampal neurons and a 
significant sparing of the hippocampus in injury models that would typically cause hippocampal 
loss are not consistently associated with cognitive benefit in experimental models of TBI. In fact 
numerous drugs have been utilized in TBI models that show significant neuroprotection, yet fail 
to translate to either improvements in animal behavior or benefits in clinical studies. The 
reasons for this particular failure is unknown, but is most likely due to a number of reasons. The 
hippocampus does not represent the sole brain region involved in cognitive processing. As 
mentioned in the introduction, a number of other brain areas are important to a variety of 
cognitive events that are significantly affected following TBI. Also, the sparing of neuronal 
bodies may not represent a significant recovery of normal hippocampal function. 
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Prior research into calcineurin inhibitors have demonstrated that both FK-506 and cyclosporine 
are able to provide cellular protection following TBI. In addition calcineurin inhibitors provide 
protection to structural damage and have positive benefits on post-TBI long term potentiation. 
These results have been shown predominantly in a FP model of TBI and have not been well 
examined in CCI.  
 
TBI leads to significant behavioral, physical, and cognitive disability. Neuronal cell death occurs 
both at the site of contusion and in secondary areas due to excitotoxicity and oxidative stress 
(DeKosky et al., 1998; Kochanek, 1993). Animal models of brain injury have consistently 
demonstrated cellular death and dysfunction in the hippocampus (Colicos et al., 1996; 
Tehranian et al., 2008). In addition there is persistent dysfunction in hippocampal potentiation 
(Sanders et al., 2000). However, the cellular mechanisms which contribute to deficits are not 
well understood. Protein phosphorylation is a dynamic, rapidly reversible post translational 
modification, known to be involved in neuronal activation, plastic remodeling, and memory. 
 
Calcineurin, also known as protein phosphatase-2B (PP2B), is a calcium/calmodulin dependent 
phosphatase that is highly sensitive to, and preferentially activated by, minor changes in 
intracellular calcium (Ca2+) (Rusnak and Mertz, 2000). Calcineurin dephosphorylates several 
key cytoskeletal and synaptic vesicle proteins (Rusnak and Mertz, 2000), modulates the activity 
of the transcription factors, nuclear factor of activated T-cells (NFAT) and cAMP response 
element binding (CREB) (Yang and Klee, 2000), and regulates neuronal excitability through 
modulation of gamma-aminobutyric acid (GABA) (Huang and Dillon, 1998) and N-methyl-D-
aspartic acid (NMDA) receptors (Tong et al., 1995). 
 
The phosphorylation state of AMPA and NMDA receptors is regulated by the interaction of 
protein kinase A (PKA) and calcineurin (Banke et al., 2000; Beattie et al., 2000) which directly 
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affects long term potentiation (LTP) (Lee et al., 2003) and long term depression (LTD) (Lee et 
al., 2002); cellular functions linked to memory and learning (Li et al., 2003; Lemon and 
Manahan-Vaughan, 2006). Calcineurin, through its interaction with kinase-anchoring proteins 
(AKAPs) has also been shown to regulate structural proteins important for synaptic remodeling 
(Dell’Acqua et al., 2006).   
 
Calcineurin is composed of a 57-61kDA catalytic subunit (CnA) and a 19kDA regulatory subunit 
(CnB) (Rusnak and Mertz 2000; Groth et al., 2003; Klee et al., 1979). Following neuronal 
activation, Ca2+ binds to high affinity EF hand Ca2+ binding motifs on the CnB subunit, allowing 
calmodulin (CaM) association with CaM binding domains on CnA (Griffith et al., 1995). This 
Ca2+ induced interaction of CnB with CnA results in conformational changes in the protein, 
removal of an autoinhibitory domain and exposure of the calcineurin active site needed for full 
activity of the phosphatase (Rusnak and Mertz 2000; Griffith et al., 1995; Guerini and Klee, 
1989).  
 
Pathologically, excessive calcineurin has been linked to mitochondrial dysfunction, and 
apoptosis (Asai et al., 1999). Increases in basal and maximal calcineurin activity (Kurz et al., 
2005b) and alterations in calcineurin subunit A subcellular distribution (Kurz et al., 2005a) have 
been reported in the hippocampus following fluid-percussion (FP) TBI which can persist for 2-3 
weeks following injury. Increases in calcineurin activity following TBI may be due to significant 
increases in intracellular Ca2+ that occurs early in brain injury (Fineman et al., 1993; Shapira et 
al., 1989). Calcineurin activity following TBI is generally considered to be pathologically altered 
and has been associated with increases in cellular death and dysfunction in both ischemia and 
TBI (Morioka et al., 1999). Inhibition of calcineurin activity is neuroprotective in ischemia and 
TBI models (Butcher et al., 1997; Friberg et al., 1998; Okonkwo et al., 1999; Okonkwo et al., 
2003). 
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Both the CnA and CnB subunits consist of several different isoforms (CnAα, CnA β, CnAγ, and 
CnB1 and CnB2 respectively), which may offer unique substrate specificity, localization and/or 
recognition properties to the phosphatase. 
 
 The over-expression of CnA (Asai et al., 1999) has been shown to cause apoptosis through CN 
dependent dephosphorylation of BAD (Wang et al., 1999), and also cause mitochondrial 
dysfunction, elevated superoxide levels and increased production of reactive oxygen species 
(Manalan and Klee, 1983; Morioka et al., 1999; Wu et al., 2004). The levels of the CnA have 
also been found to change in synaptic membrane fractions for up 2 weeks following FP injury in 
the rat (Kurz et al., 2005a). Divergent changes were found in CnAα, CnAβ after ischemia in the 
gerbil (Hashimoto et al., 1998) and in CnA α, β, & γ in schizophrenia (Liu et al., 2007). CnA 
subunits are particularly important for the initiation and maintenance of LTP (Wang and Kelly, 
1996; Kayyali et al., 1997; Winder and Sweatt, 2001) and play an active role in structural 
plasticity of cortical circuits (Victor et al., 1995; Yakel, 1997). Mice, which have a selective, 
forebrain specific knockout of the CnB subunit show impaired LTD and working memory, with 
LTP, extinction, and memory for multi-trial tasks remaining intact (Zeng et al., 2001). Forebrain 
CnB knockout mice also show behavioral abnormalities similar to those found in schizophrenia 
(Miyakawa et al., 2003). 
 
Although CnA isoforms have been located in brain tissue, little is known about the relative 
expression of the CnA isoforms in brain and how they are altered by trauma. The aim of this 
study was to determine how the CnA isoforms are distributed in the rat hippocampus and to 
elucidate how CnA isoforms are affected acutely and chronically following TBI. Furthermore, 
little is known about the expression of the CnB isoforms in the hippocampus and how they are 
altered by trauma. The aims of this study were also to determine how the CnB isoforms are 
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distributed in the rat hippocampus, to elucidate how CnB isoforms are affected acutely and 
chronically following TBI, and determine how a CCI injury affects calcineurin activity.  
 
2.2 METHODS AND MATERIALS 
 
2.2.1 Animals 
 
Adult male Sprague-Dawley rats (n=36) were used in the study. Rats were purchased from 
Hilltop Laboratories (Scottsdale, PA, USA) and housed in pairs under a 12:12 light/dark cycle. 
Rats were given food and water with ad libitum throughout the study. All experiments were 
carried out in accordance with the University of Pittsburgh’s guidelines for the Care and Use of 
Laboratory Animals. All experiments were approved by the Institutional Animal Care and Use 
Committee of the University of Pittsburgh.     
 
2.2.2 Surgery 
 
On the day of surgery anesthesia was initiated with 4% isofluorane (IsoFlo; Abbott Laboratories, 
North Chicago, IL, USA) and 2:1 N2O/O2. Rats were intubated and maintained on 1.5-2% 
isofluorane during the surgical procedure. Following intubation, rats were placed on a thermal 
blanket to regulate body temperature (37oC) and the animals head placed in a stereotaxic 
frame. An incision was made down the midline of the skull and the soft tissues and periosteum 
deflected. A craniotomy was then performed over the right parietal bone to expose the dura. 
Controlled cortical injury (CCI, Pittsburgh Precision Instruments, Inc.) at a depth of 2.4mm at 
4m/sec was carried out according to the Dixon method (1991). A total of 18 rats were injured, 
and the remaining 18 rats were shams. Righting reflex (Dixon et al., 1991) was monitored in the 
immediate post-surgical period to assess acute recovery.  
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2.2.3 Immunohistochemistry for the CnA subunit 
 
Following a 2 hr (6 shams; 6 TBI) or 2 week (6 shams; 6 TBI) recovery period, animals were 
given an overdose of sodium pentobarbital (100 mg/kg; i.p), and perfused intra-aortically with 
0.1M heparinized PBS in 4% PFA/0.1M PBS. Brains were dissected, submerged in increasing 
concentrations of sucrose, and stored at -80oC. Brains were then sectioned at 35µm in a 
cryostat, and free floating sections collected in tissue plate wells containing 0.1M TBS (pH 7.5).  
 
All immunohistochemical procedures and incubations were carried out with agitation with the 
exception of the chromogen step. All treatment groups were stained together within each 
immunohistochemical session. Sections were matched by region, rinsed 3x 5 min in washing 
buffer (0.1%Triton-X in 0.1M TBS) and blocked in a mixture of 10% normal donkey serum in 
washing buffer for 2 hours at room temperature. Sections were then incubated overnight at 4oC 
in (one only) primary goat antibodies (Santa Cruz Biotechnology, CA) specific to CnAα (1:150), 
CnAβ (1:150), CnAγ (1:100) subunit isoforms diluted in washing buffer/5% normal donkey 
serum. Following incubation, sections were then washed 3 x 8 minutes in washing buffer and 
endogenous peroxidase activity was quenched with 0.3% H2O2 in methanol for 10 minutes. 
Following 5 x 5 minutes washing in TBS, sections were incubated for 1hr at RT in HRP 
conjugated donkey anti-goat secondary antibody (Jackson ImmunoResearch, PA) at 1:200 in 
0.1M TBS. Immunoreactivity (IR) was then visualized using 0.01% 3’ 3’ Diaminobenzidine 
(DAB) after an extensive wash. The DAB reaction was terminated with dH2O and sections were 
rinsed in 0.1M TBS, mounted onto slides, air dried and cover-slipped for light microscope 
analysis. All sections within the reaction were exposed to each of the reagents for the same 
time period. Control sections pre-adsorbed with their homologous peptides were negative for IR.  
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2.2.4 Immunohistochemistry for the CnB subunit 
 
Following a 2 hr (6 shams; 6 TBI) or 2 week (6 shams; 6 TBI) recovery period, animals were 
given an overdose of sodium pentobarbital (100 mg/kg; i.p.), and perfused intra-aortically with 
0.1M heparinized PBS in 4% PFA/0.1M PBS. Brains were dissected, submerged in increasing 
concentrations of sucrose, and stored at -80oC. Brains were then sectioned at 35µm in a 
cryostat, and free floating sections collected in tissue plate wells containing 0.1M TBS (pH 7.5).  
 
All immunohistochemical procedures and incubations were carried out with agitation with the 
exception of the chromogen step. All treatment groups were stained together within each 
immunohistochemical session. Sections were matched by region, rinsed 3x 5 min in washing 
buffer (0.1%Triton-X in 0.1M TBS) and blocked in a mixture of 10% normal donkey serum in 
washing buffer for 2 hours at room temperature. Sections were then incubated overnight at 4oC 
in (one only) primary goat antibodies (Santa Cruz Biotechnology, CA) specific to CnB1 (1:100), 
CnB2 (1:100) subunit isoforms diluted in washing buffer/5% normal donkey serum. Following 
incubation, sections were then washed 3 x 8 minutes in washing buffer and endogenous 
peroxidase activity was quenched with 0.3% H2O2 in methanol for 10 minutes. Following 5 x 5 
minutes washing in TBS, sections were incubated for 1hr at RT in HRP conjugated donkey anti-
goat secondary antibody (Jackson ImmunoResearch, PA) at 1:200 in 0.1M TBS. 
Immunoreactivity (IR) was then visualized using 0.01% 3’ 3’ Diaminobenzidine (DAB) after an 
extensive wash. The DAB reaction was terminated with dH2O and sections were rinsed in 0.1M 
TBS, mounted onto slides, air dried and cover-slipped for light microscope analysis. All sections 
within the reaction were exposed to each of the reagents for the same time period. Control 
sections pre-adsorbed with their homologous peptides were negative for IR.  
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2.2.5 Western Blot Analysis  
 
At 2 hours or 2 weeks (3 sham; 3 TBI per timepoint) animals were deeply anesthetized with 
pentobarbital (Nembutal, 80-100 mg/kg; Abbott Laboratories, North Chicago, IL). Animals were 
decapitated and the brains quickly removed and chilled on ice.  Both the right and left 
hippocampi were exposed by careful dissection and the dentate gyrus from each side was 
excised.  Following the removal of the dentate gyrus the remainder of the hippocampal 
formation was cut removing the CA1 region from the CA1-2/CA3 regions.  The DG, CA1 region, 
and CA1-2/CA3 regions from three animals were combined and collected into separate tubes 
for each region. Tissue from both the hippocampus ipsilateral to injury and the hippocampus 
contralateral to injury was collected separately.  Tissue was immediately placed into liquid 
nitrogen and then into a -80 oC freezer until processed. Tissue was homogenized in Lysis buffer 
(suspension buffer) which contains 0.1M NaCl, 0.01M Tris-Cl (pH 7.6), 0.001 M EDTA (pH 8.0), 
1 µg/ml aprotinin, 100 µg/ml phenylmethylsulfonyl fluoride (PMSF), and protein concentrations 
were determined using a BCA protein Assay Kit (PIERCE, Rockford, IL). Samples containing 20 
g of protein were subjected to SDS-polyacrylamide gel electrophoresis through a 10% 
acrylamine gel, and then transferred to nitrocellulose membranes and immunolabeled with 
antiserum followed by donkey anti-goat immunoglobulin G conjugated to peroxidase (1:5,000; 
PIERCE, Rockford, IL). Proteins were visualized with a chemiluminescence detection system 
(SuperSignal, PIERCE, Rockford, IL). To assure equal loading, the membrane was restriped 
and reblotted with rabbit anti-actin antibody (1:15,000, Sigma, St. Louis, MO).  
 
2.2.6 Calcineurin Activity Assay 
 
Pooled protein samples prepared for western blot analysis were also utilized for the calcineurin 
assay. Calcineurin phosphatase activity was measured using the CALCIOCHEM Calcineurin 
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assay kit (EMD Biosciences, San Diego, CA). Each reaction (50 µl total) contained 50 mM Tris, 
pH 8.0, 100 mM NaCl, 6 mM MgCl2, 0.5 mM dithiothreitol, 0.1 mM CaCl2, 1 µM bovine 
calmodulin, and 0.3 mM RII phosphopeptide substrate. In wells where calcineurin activity was 
inhibited 2 mM EGTA was included in the reaction mixture. The amount of phosphate released 
was calculated using the standard curve with the equation; phosphate released = (A620 – 
Yint)/slope. Data is reported as the total amount of phosphate released in nMols.   
 
2.2.7 Selection of Timepoints for Analysis 
 
Two hours corresponds to acute alterations after TBI, including rapid increases in Ca2+ that 
occur immediately post injury and persist (Hovda et al., 1990; Shapira et al., 1989). Given the 
role of Ca2+ in the control of Calcineurin activity an acute examination of isoform alterations at 2 
hours post injury was chosen to examine the affect of acute Ca2+ increases. Two weeks 
corresponds to the timepoint used to assess cognitive outcomes following CCI in rats (Yan et 
al., 2000; Kline et al., 2002).  
 
2.2.8 Scoring for Wilcoxon-Mann-Whitney Rank-Sum Analysis 
 
A six point scoring scale (0 = no IR, 6 = heavy IR) was utilized to assess the level of CnA and 
CnB isoform expression in DAB stained sections from separate subregions (CA1, CA1-2, CA3, 
dentate gyrus hilus, dentate gyrus hidden blade, dentate gyrus exposed blade) of the ipsilateral 
and contralateral hippocampi. To assess dendritic staining in the stratum radiatum of the 
ipsilateral and contralateral CA1 and CA1-2, a three point scoring scale was employed (1 = few, 
3 = numerous). An independent observer blinded to timepoint and isoform stain scored each 
tissue section utilizing both scoring paradigms. Following scoring the data were organized by 
CnA or CnB isoform stain, timepoint (2 hour or 2 week), and ipsilateral or contralateral. Scores 
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were ranked (blinded to sham or TBI) from 1-12 (ipsilateral separate from contralateral) for each 
sub region and dendrite score. Following ranking, sham and TBI designations were revealed. 
Outcomes of sham versus injury were compared using the non-parametric Wilcoxon-Mann-
Whitney (WMW) two-sample rank-sum test with a p value for significance set at p≤0.05. 
Comparisons were only made between comparable sham and injured regions in order to 
discuss regional alterations in injury.        
 
2.3 RESULTS 
 
2.3.1 Regional Calcineurin Activity in Rat Hippocampus Following a TBI. 
 
Calcineurin enzyme activity was determined utilizing a commercially available Calcineurin 
activity assay kit that measures the amount of phosphate release when sample is incubated 
with the Calcineurin specific RII phosphopeptide. At 2 hours post injury there is about a two-fold 
increase in phosphate released (Figure 4) indicating increased Calcineurin activity in the CA3 
and DG fractions of injured hippocampus compared to sham. The increase in activity is 
observed in both the contralateral and ipsilateral, with respect to injury, hippocampi. Within the 
contralateral DG, at 2 hours, there is nearly a four-fold increase in phosphate release relative to 
sham levels. Activity within the injured CA1 region is also increased relative to sham, but to a 
lesser degree then seen in the other two regions assayed. 
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Figure 4: Qualitative analysis of calcineurin activity by measuring the amount of total phosphate 
released in the presence of the calcineurin specific RII phosphopeptide demonstrates an 
increase in calcineurin activity post injury compared to sham. Homogenates were made from 
pooled resection tissue from N=3 rats per group. Increases in phosphate release are detected 
at 2 hours post injury in all regions examined (CA1, CA3, and DG) in both the ipsilateral and 
contralateral, with respect to injury, hippocampi. At the acute timepoint (2 hours) the increase in 
activity is greatest in the contralateral DG. The injury induced increase in calcineurin activity 
persists chronically and can still be appreciated at 2 weeks post injury. At the chronic timepoint 
(2 weeks) the pattern of increase in phosphate release is maintained with increased calcineurin 
activity in all three regions (CA1, CA3, and DG) in both the contralateral and ipsilateral 
hippocampi. Error bars represent standard deviation of technical repeats. Abbreviations: DG = 
Dentate Gyrus. 
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The increase in phosphate release seen at the acute 2 hour timepoint is also present at 2 weeks 
post injury (Figure 4). Consistent with the results seen at 2 hours, the CA3 and DG regions 
show a two to three-fold increase in phosphate release relative to sham in both the ipsilateral 
and contralateral hippocampi. Also consistent with results seen at 2 hours, the CA1 region 
shows a lesser increase in phosphate release.  
 
Samples incubated with RII phosphopeptide in the presence of EGTA showed no difference in 
nMol of phosphate released indicating that increases in Calcineurin activity were responsible for 
the increased amount of phosphate release in injured samples. 
 
2.3.2 CnA Isoform Distribution in Rat Hippocampus. 
 
CnA isoform distribution within the rat hippocampus was determined utilizing 
immunohistochemical staining in sham rats. Both isoforms CnAα and CnAβ showed similar 
distribution patterns with higher expression in the CA1 neuropil and cell bodies than CA1-2 
regions and noticeable columnar patterns of pyramidal neuron dendritic staining within the 
stratum radiatum of both the CA1 and CA1-2. Within the CA3 the CnAα isoform appears to be 
predominantly in the stratum lucidum with little expression within cell bodies of the stratum 
pyramidale layer. However the CnAβ isoform is not as layer specific within the CA3 region and 
appears to have more widespread expression throughout the layers of CA3. In general the 
CnAβ isoform shows relatively lower expression within the CA1, CA1-2, and CA3 regions of the 
hippocampus compared to the CnAα isoform. However, both isoforms show marked staining 
within the exposed blade of the dentate gyrus (DG) in both the cell bodies of the stratum 
granulosum and neuropil of the stratum moleculare layers. There was relatively little expression 
within the DG hidden blade or hilus of either the CnAα or CnAβ isoforms. The CnAγ isoform 
showed no distribution within the rat hippocampus.  
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2.3.3 CnB Isoform Distribution in Rat Hippocampus. 
 
CnB isoform distribution within the rat hippocampus was determined utilizing 
immunohistochemical staining in sham rats. Both isoforms CnB1 and CnB2 showed similar 
distribution patterns with higher expression in the CA1 and CA1-2 neuropil and cell bodies than 
CA3 regions. Within the CA3 the CnB1 and CnB2 isoforms appear to be predominantly in the 
stratum pyramidale with little expression within the dendritic and axonal layers of the stratum 
radiatum and stratum oriens. In general the two CnB isoforms show relatively similar expression 
within the CA1, CA1-2, and CA3 regions of the hippocampus. Both isoforms also show marked 
staining within the exposed blade of the dentate gyrus (DG) in both the cell bodies of the 
stratum granulosum and neuropil of the stratum moleculare layers. There was relatively little 
expression within the DG hidden blade or hilus of either the CnB1 or CnB2 isoforms.   
 
2.3.4 TBI Induced Alterations in CnA Isoform Expression within the Rat Hippocampus 
 
There were clear changes in CnA isoform distribution in the rat hippocampus at 2h post TBI with 
persistent alterations lasting until 2 weeks post TBI (See summary: Table 4).   
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Table 4: Summary of statistical analysis utilizing Wilcoxon-Mann-Whitney rank-sum test to 
assess median rank differences of scored DAB stained histological sections.  Analysis of 
regional alterations in CnA isoform immunoreactivity within the rat hippocampus demonstrates 
significant alterations in the regional immunoreactivity of both isoforms 2 hours following injury.  
Some of these alterations persist to 2 weeks following injury.  Abbreviations: C = Contralateral, 
I = Ipsilateral, SR = Stratum Radiatum (Dendrite Counts), DG = Dentate Gyrus, H = Hilus, HB = 
Hidden Blade, EB = Exposed Blade, NC = No Change, ↓ = Denotes a Decrease, ↑ = Denotes 
an Increase. 
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2.3.5 TBI Induced Alterations in CnB Isoform Expression within the Rat Hippocampus 
 
There were changes in CnB isoform staining within regions of the rat hippocampus at 2 hours 
post TBI with persistent alterations lasting until 2 weeks post TBI as determined by sham versus 
injury comparison using the Wilcoxon-Mann-Whitney two-sample rank-sum test with a p value 
for significance set at p≤0.05. (See summary: Table 5).   
 
Table 5: Summary of statistical analysis utilizing Wilcoxon-Mann-Whitney rank-sum test to 
assess median rank differences of scored DAB stained histological sections. Analysis of 
regional alterations in CnB isoform immunoreactivity within the rat hippocampus demonstrates 
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significant alterations in the regional immunoreactivity of both isoforms 2 hours following injury.  
Many of these alterations persist to 2 weeks following injury.  Abbreviations: C = Contralateral, 
I = Ipsilateral, SR = Stratum Radiatum (Dendrite Counts), DG = Dentate Gyrus, H = Hilus, HB = 
Hidden Blade, EB = Exposed Blade, NC = No Change, ↓ = Denotes a Decrease, ↑ = Denotes 
an Increase. 
 
2.3.6 TBI Resulted in Acute Regionally Specific Alterations in CnAα Distribution 
 
CnAα staining in the injured ipsilateral CA1 region was in cell bodies within the stratum 
pyramidale (SP) layer and in the stratum oriens (SO) layer without localization to cell bodies and 
no clear dendritic distribution (Figure 5). There was a loss of the columnar distribution of CnAα 
staining within dendrites of the stratum radiatum (SR) layer compared to sham (Figure 6). 
Within the contralateral CA1 of injured animals there is a noticeable difference in cellular 
distribution of the CnAα isoform (not pictured) with significant staining of dendrites and cell 
bodies throughout the SR and SP layers that is similar to sham animals. There appears to be a 
general decrease in contralateral expression of CnAα within the CA1 and an increase in 
contralateral expression of CnAα within the exposed blade of the DG in injured versus sham 
animals that did not reach significance (Figure 5). 
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Figure 5: CnAα immunohistochemistry demonstrating alterations in CnAα isoform distribution 2 
hours following TBI (right panels). Arrows indicate side of cortex ipsilateral to injury or sham 
surgery. There is a noticeable loss of dendrite staining within the SR of CA1 and CA1-2 in TBI 
(1a and 2a) versus sham (1 and 2). There is a significant loss of CnAα expression within the EB 
of the DG in TBI (4a) versus sham (4). Scale bars, 50 µm for regional sections. Abbreviations: 
SO= Stratum Oriens; SP= Stratum Pyramidale; SR= Stratum Radiatum; SL= Stratum Lucidum; 
SM= Stratum Moleculare; SG= Stratum Granulosum; HB= Hidden Blade; H=Hilus; EB= 
Exposed Blade. 
 
The majority of CnAα staining in ipsilateral CA1-2 and CA3 regions of injured animals are in the 
surrounding neuropil of the SO and SR, with a few cell bodies within the SP showing expression 
that is not seen in sham animals.  There was also decreased dendritic staining in the SR of the 
CA1-2 region compared to sham.  Increases in staining within the hidden blade and hilus of the 
DG are predominantly in the neuropil with some localization to cell bodies (the stratum 
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granulosum (SG) in the hidden blade). Decreases in CnAα staining within the exposed blade of 
the DG is localized to cell bodies within the SG layer and neuropil of the stratum molecular (SM) 
layer (Figure 6). The loss of CnAα isoform expression within the exposed blade of the DG is 
predominantly lateral to midline with a relative sparing of expression in the genu of the DG.      
 
 
Figure 6: Representative higher power images demonstrating the loss of isoform dendrite 
staining in the deep SR of TBI animals (B – white arrow) compared to sham (A – white arrow) 
at 2 hours post injury, with a relative sparing of dendrites immediately adjacent to the neuronal 
somas (A and B – black arrows). There is also a noticeable decrease in the exposed blade of 
the dentate in the SG cell body layer as seen in TBI animals (D – white arrow) compared to 
sham (C – white arrow).  There appears to be some cell loss in the dentate which may explain 
some of the decreases with both isoforms.   
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2.3.7 TBI Resulted in Acute Regionally Specific Alterations in CnB1 Distribution 
 
CnB1 staining in the injured ipsilateral CA1 region was in cell bodies within the stratum 
pyramidale (SP) layer and in the stratum oriens (SO) layer without localization to cell bodies 
(Figure 7). The columnar distribution of CnB1 staining within dendrites of the stratum radiatum 
(SR) layer remained intact in injured animals compared to sham and there appeared to be 
increased expression (Figure 8). CnB1 staining within the contralateral CA1 of injured animals 
did not differ from sham animals (not pictured) with significant staining of dendrites and cell 
bodies throughout the SR and SP layers.  
 
 
Figure 7: CnB1 immunohistochemistry demonstrating alterations in CnB1 isoform distribution 2 
hours following TBI (right panels). Arrows indicate side of cortex ipsilateral to injury or sham 
surgery. There is a noticeable increase of staining within CA1 and CA1-2 in TBI (1a and 2a) 
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versus sham (1 and 2). There is a significant loss of CnB1 expression within the EB of the DG in 
TBI (4a) versus sham (4). Scale bars, 50 µm for regional sections. Abbreviations: SO= 
Stratum Oriens; SP= Stratum Pyramidale; SR= Stratum Radiatum; SL= Stratum Lucidum; SM= 
Stratum Moleculare; SG= Stratum Granulosum; HB= Hidden Blade; H=Hilus; EB= Exposed 
Blade. 
 
The majority of CnB1 staining in ipsilateral CA1-2 and CA3 regions of injured animals are in the 
surrounding neuropil of the SO and SR. There was no change in dendritic staining in the SR of 
the CA1-2 region compared to sham. Increases in staining within the hilus of the DG are 
predominantly in the neuropil with some localization to cell bodies. A significant decrease in 
CnB1 staining within the exposed blade of the DG was localized to cell bodies within the SG 
layer and neuropil of the stratum molecular (SM) layer (Figure 8). The loss of CnB1 isoform 
staining within the exposed blade of the DG is predominantly lateral to midline with a relative 
sparing of staining in the genu of the DG.      
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Figure 8: Representative higher power images demonstrating the increase of CnB1 isoform 
staining in CA1 of TBI animals (B – white arrow) compared to sham (A – white arrow) at 2 
hours post injury, with a relative sparing of dendrites (A and B – black arrows). There is also a 
noticeable decrease in the exposed blade of the dentate in the SG cell body layer as seen in 
TBI animals (D – white arrow) compared to sham (C – white arrow).  There appears to be 
some cell loss in the dentate which may explain some of the decreases with both isoforms.   
 
2.3.8 TBI Resulted in Chronic Regionally Specific Alterations in CnAα Distribution 
 
At 2 weeks post injury staining within the ipsilateral CA1 appears to be localized to the SP layer 
within the cell somas (Figure 9). In many sections there is a loss of CnAα dendritic expression 
within the ipsilateral CA1 consistent with what occurs at 2 hours post injury, however the 
variability in dendritic expression among animals indicates no statistical significance in SR 
dendrite staining of the CA1 in injured hippocampus compared to sham. CnAα expression in 
injured CA1-2 and CA3 regions of the ipsilateral hippocampus is in the neuropil of the SO and 
SR.  Similar to the ipsilateral CA1-2 region at 2 hours at 2 weeks very little CnAα staining of 
dendrites can be appreciated within the SR. There is also a loss of staining within the stratum 
lucidum (SL) layer of the ipsilateral CA3 region at 2 weeks compared to sham that is not seen at 
2 hours.  
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Figure 9: CnAα immunohistochemistry demonstrating alterations in CnAα isoform distribution 2 
weeks following TBI (right panels). Arrows indicate side of cortex ipsilateral to injury or sham 
surgery. There is a loss of dendrite staining within the SR of CA1 and CA1-2 in TBI (1a and 2a) 
versus sham (1 and 2) that did not reach significance. There is a significant loss of CnAα 
expression within the EB of the DG in TBI (4a) versus sham (4). Scale bars, 50 µm for regional 
sections. Abbreviations: SO= Stratum Oriens; SP= Stratum Pyramidale; SR= Stratum 
Radiatum; SL= Stratum Lucidum; SM= Stratum Moleculare; SG= Stratum Granulosum; HB= 
Hidden Blade; H=Hilus; EB= Exposed Blade.  
 
There is higher expression in the hilus and hidden blade of the injured ipsilateral DG in both cell 
somas and surrounding neuropil compared to sham, however it does not reach statistical 
significance. In the exposed blade of the ipsilateral DG CnAα demonstrates reduced expression 
predominantly within cell somas of the SG with some decreases in the surrounding neuropil 
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compared to sham.  Similar to 2 hours post injury there remains relatively high expression of 
CnAα within the genu of the ipsilateral DG.   
 
2.3.9 TBI Resulted in Chronic Regionally Specific Alterations in CnB1 Distribution 
 
At 2 weeks post injury staining within the ipsilateral CA1 appears to be localized to the SP layer 
within the cell somas and dendrites of the SR layer (Figure 10). CnB1 staining is increased in 
injured CA1-2 region of the ipsilateral hippocampus in the neuropil of the SO and SR. There is 
also an increased amount of CnB1 staining within the contralateral CA 1-2 and an increase in 
dendritic staining within the SR which was not present at 2 hours post injury compared to sham. 
 
 
Figure 10: CnB1 immunohistochemistry demonstrating alterations in CnB1 isoform distribution 
2 weeks following TBI (right panels). Arrows indicate side of cortex ipsilateral to injury or sham 
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surgery. There is an increase in staining within the CA1, CA1-2, and CA3 in TBI (1a, 2a, 3a) 
versus sham (1, 2, 3). There is a significant loss of CnB1 expression within the EB of the DG in 
TBI (4a) versus sham (4). Scale bars, 50 µm for regional sections. Abbreviations: SO= 
Stratum Oriens; SP= Stratum Pyramidale; SR= Stratum Radiatum; SL= Stratum Lucidum; SM= 
Stratum Moleculare; SG= Stratum Granulosum; HB= Hidden Blade; H=Hilus; EB= Exposed 
Blade.  
 
In the exposed blade of the ipsilateral DG CnB1 demonstrates reduced staining predominantly 
within cell somas of the SG with some decreases in the surrounding neuropil compared to 
sham.  Within the contralateral DG there is an increase in CnB1 staining within the hilus and HB 
not seen at 2 hours post injury compared to sham (Figure 10). 
  
2.3.10 TBI Resulted in Acute Regionally Specific Alterations in CnAβ Distribution 
 
Acute changes in staining of the CnAβ subunit are similar to alterations seen with CnAα subunit 
staining. CnAβ staining is in the neuropil of the SO and SR of both the CA1 and CA1-2 regions 
with a noticeably less dendritic staining in the SR of both regions (Figure 11). Unlike CnAα 
there does not appear to be as much distribution of CnAβ to the cell somas of the SP layer in 
either CA1 or CA1-2. CnAβ distribution within the CA3 region is distinct from that seen with 
CnAα as there is more CnAβ staining within the cell somas of the SP layer of CA3 that is not as 
apparent following injury, however it is not a significant difference. There are non-significant 
decreases in CnAβ staining within the SL of CA3 and increases within the SO layer. There is 
less CnAβ staining of both the cell somas of the SG and neuropil of the SM layer in the exposed 
blade of the injured ipsilateral DG compared to sham. Similar to CnAα there is also a non-
significant decrease in CnAβ expression within both the CA1 and CA1-2 regions that only 
appears to occur at acute timepoints. 
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Figure 11: CnAβ immunohistochemistry demonstrating alterations in CnAβ isoform distribution 
2 hours following TBI (right panels). Arrows indicate side of cortex ipsilateral to injury or sham 
surgery. There is a significant loss of dendrite staining within the SR of CA1 and CA1-2 in TBI 
(1a and 2a) versus sham (1 and 2). There is a significant loss of CnAβ expression within the EB 
of the DG in TBI (4a) versus sham (4). Scale bars, 50 µm for regional sections. Abbreviations: 
SO= Stratum Oriens; SP= Stratum Pyramidale; SR= Stratum Radiatum; SL= Stratum Lucidum; 
SM= Stratum Moleculare; SG= Stratum Granulosum; HB= Hidden Blade; H=Hilus; EB= 
Exposed Blade.  
 
2.3.11 TBI Resulted in Acute Regionally Specific Alterations in CnB2 Distribution 
 
Acute changes in staining of the CnB2 subunit are similar to alterations seen with CnB1 subunit 
staining. CnB2 staining is in the neuropil of the SO and SR of both the CA1 and CA1-2 regions 
with a noticeable increase in staining in the SR of the CA1-2 region (Figure 12). There is less 
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CnB2 staining of both the cell somas of the SG and neuropil of the SM layer in the exposed 
blade of the injured ipsilateral DG compared to sham (Figure 12).  
 
Unlike CnB1 there are significant increases in CnB2 in contralateral CA1-2 SR dendritic staining 
acutely (not pictured).  
 
Figure 12: CnB2 immunohistochemistry demonstrating alterations in CnB2 isoform distribution 
2 hours following TBI (right panels). Arrows indicate side of cortex ipsilateral to injury or sham 
surgery. There is a significant increase in staining within the CA1 and CA1-2 in TBI (1a and 2a) 
versus sham (1 and 2). There is a significant loss of CnB2 expression within the EB of the DG in 
TBI (4a) versus sham (4). Scale bars, 50 µm for regional sections. Abbreviations: SO= 
Stratum Oriens; SP= Stratum Pyramidale; SR= Stratum Radiatum; SL= Stratum Lucidum; SM= 
Stratum Moleculare; SG= Stratum Granulosum; HB= Hidden Blade; H=Hilus; EB= Exposed 
Blade.  
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2.3.12 TBI Resulted in Chronic Regionally Specific Alterations in CnAβ Distribution 
 
In sham animals at 2 weeks post injury the staining of the CnAβ subunit in the CA1 region of 
both hippocampi appears to be less than that appreciated in the 2 hour post injury sham 
animals. There is less CnAβ staining within dendrites of the SR of both the CA1 and CA1-2 
regions, although neither reaches significance owing to the variability of dendrite expression in 
injured CA1 and CA1-2 at 2 weeks post injury (Figure 13). At 2 weeks changes within the CA3 
region of the CnAβ subunit mirror those seen at 2 hours with apparently less staining within the 
cell somas of the SP layer and increases within the neuropil of the SO and SR layers which do 
not reach statistical significance. Similar to 2 hour post injury there is less CnAβ expression 
within the exposed blade of the injured ipsilateral DG compared to sham, predominantly in the 
SG layer.   
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Figure 13: CnAβ immunohistochemistry demonstrating alterations in CnAβ isoform distribution 
2 weeks following TBI (right panels). Arrows indicate side of cortex ipsilateral to injury or sham 
surgery. There is a significant loss of CnAβ expression within the EB of the DG in TBI (4a) 
versus sham (4). Scale bars, 50 µm for regional sections. Abbreviations: SO= Stratum Oriens; 
SP= Stratum Pyramidale; SR= Stratum Radiatum; SL= Stratum Lucidum; SM= Stratum 
Moleculare; SG= Stratum Granulosum; HB= Hidden Blade; H=Hilus; EB= Exposed Blade.  
 
2.3.13 TBI Resulted in Chronic Regionally Specific Alterations in CnB2 Distribution 
 
There is more CnB2 staining within dendrites of the SR of both the ipsilateral and contralateral 
CA1-2 as well as increases in CnB2 staining within the SO and SP regions of both the ipsilateral 
CA1 and CA1-2 regions (Figure 14). At 2 weeks changes within the CA3 region of the CnB2 
subunit seen at 2 hours are no longer present. Similar to 2 hours post injury there is less CnB2 
staining within the exposed blade of the injured ipsilateral DG compared to sham, predominantly 
in the SG layer, and an increase in CnB2 staining within the ipsilateral hilus of injured animals 
compared to sham.   
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Figure 14: CnB2 immunohistochemistry demonstrating alterations in CnB2 isoform distribution 
2 weeks following TBI (right panels). Arrows indicate side of cortex ipsilateral to injury or sham 
surgery. There is a significant increase in CnB2 isoform expression within both the CA1 and 
CA1-2 regions in injured (1a and 2a) compared to shame (1 and 2). There is a significant loss of 
CnB2 expression within the EB of the DG in TBI (4a) versus sham (4). Scale bars, 50 µm for 
regional sections. Abbreviations: SO= Stratum Oriens; SP= Stratum Pyramidale; SR= Stratum 
Radiatum; SL= Stratum Lucidum; SM= Stratum Moleculare; SG= Stratum Granulosum; HB= 
Hidden Blade; H=Hilus; EB= Exposed Blade.  
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2.3.14 Changes in CnA Subunit Staining Appreciated with Immunohistochemistry are not Due to 
Changes in Protein Concentration within Hippocampal Regions 
 
Western blot analysis of ipsilateral and contralateral DG, CA1, and CA1-2/CA3 regions indicates 
no difference between sham and injured animals in the protein concentrations of the CnAα 
isoform relevant to each region. This suggests that the alterations in CnAα isoform staining seen 
in immunohistochemistry is due predominantly to a redistribution in the regions of interest and 
not due to altered protein synthesis (Figure 15). However, there is an apparent decrease in 
protein expression of CnAβ in the ipsilateral DG which is consistent with the 
immunohistochemistry. There are no other apparent differences in CnAβ protein expression in 
other regions.   
 
Figure 15: Qualitative western blot analysis of specific hippocampal regions. Homogenates 
were made from pooled resection tissue from N=3 rats per group. There is no change in CnAα 
protein expression in injured versus sham at either 2 hours (15a) or 2 weeks (15b) post injury. 
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However, there does appear to be a relative decrease in the expression of CnAβ in the injured 
DG ipsilateral to injury compared to sham at both timepoints. Abbreviations: Sh-C= Sham 
Contralateral; TBI-C= Traumatic Brain Injury Contralateral; Sh-I= Sham Ipsilateral; TBI-I= 
Traumatic Brain Injury Ipsilateral. 
 
2.3.15 Changes in CnB Subunit Staining Appreciated with Immunohistochemistry are in Part 
Due to Changes in Protein Concentration within Hippocampal Regions 
 
Western blot analysis of ipsilateral and contralateral DG, CA1, and CA1-2/CA3 regions indicates 
a visible difference between sham and injured animals in the protein concentrations of the CnB1 
and CnB2 isoforms relevant to each region. At both 2 hours and 2 weeks post injury there is an 
increase in the expression of both CnB isoforms within the injured contralateral and ipsilateral 
CA1 regions compared to sham. There is also a decrease in both isoforms expression within the 
injured contralateral and ipsilateral DG compared to sham at 2 hours and 2 weeks. This 
suggests that the alterations in CnB isoform staining seen in immunohistochemistry is due in 
part to changes in protein expression and possibly also to a redistribution in the regions of 
interest (Figure 16).  
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Figure 16: Qualitative western blot analysis of specific hippocampal regions. Homogenates 
were made from pooled resection tissue from N=3 rats per group. There is a noticeable 
increase in both CnB1 and CnB2 expression within the CA1 region at both timepoints examined. 
There is also a noticeable decrease in both CnB subunit isoforms expression within the DG of 
injured animals compared to sham, which is consistent with immunohistochemistry. Results of 
western blot analysis of the CA2-CA3 region do not completely agree with 
immunohistochemistry suggesting that there may be an alteration in distribution within these 
regions as well as changes in total expression. Abbreviations: Sh-C= Sham Contralateral; TBI-
C= Traumatic Brain Injury Contralateral; Sh-I= Sham Ipsilateral; TBI-I= Traumatic Brain Injury 
Ipsilateral. 
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2.4 DISCUSSION 
 
Following CCI there are regionally specific alterations in CnA subunit isoform distribution. 
Acutely there is a loss of both CnAα and CnAβ expression within the exposed blade of the DG 
and a decrease in dendritic expression within both the CA1 and CA1-2 regions of the ipsilateral 
hippocampus in CCI versus sham. Alterations in expression within the DG persists chronically 
as do changes in dendritic expression, although not consistently.  
 
Following CCI there are also regionally specific alterations in CnB subunit isoform distribution. 
Acutely there is decreased IR in both CnB1 and CnB2 within the exposed blade of the DG and 
an increase in IR within the CA1, CA1-2, and CA3 regions of the ipsilateral hippocampus in CCI 
versus sham. Alterations in IR within the DG persist chronically as do changes in the CA1-2 
region. There are also significant increases in the IR of the CnB2 isoform in the contralateral 
CA1-2 region that persists chronically. 
 
Furthermore, consistent with research in FP (Kurz et al., 2005b), CCI produces an increase in 
calcineurin activity in all regions examined in injured hippocampus compared to sham. The 
increase in calcineurin activity was seen acutely and persisted chronically (Figure 4). The 
greatest increase in calcineurin activity occurred in the DG, both ipsilateral and contralateral, 
compared to sham. In nearly all areas examined, even in the contralateral side of the 
hippocampus there were increases in calcineurin activity suggesting that alterations in 
calcineurin function are not limited to the injured side of the brain. 
 
In the acute phase after TBI, elevations in Ca2+ (Shapira et al., 1989) can lead to abnormal 
neuronal activation leading to excitoxicity, increased superoxide levels, oxidative stress and cell 
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death (Hovda et al., 1992). Although calcineurin appears be a key mediator in many of these 
processes there needs to be a greater understanding of how calcineurin is specifically 
modulated after injury, particularly with regard to the individual calcineurin subunits and 
isoforms. The present study showed that CnA isoforms are differentially modulated in the 
hippocampus in a regionally specific manner after TBI. Indeed, both up- and down-regulation of 
the same CnA isoform can occur in regionally distinct areas of the hippocampus within the same 
post-injury time period. This suggests that individual calcineurin isoforms may have different 
roles within select hippocampal areas in the post-injury period. Whether these changes are a 
short term response to injury, the initiation of long term neuronal destabilization mechanisms or 
a counter-regulatory mechanism awaits further studies conducted in a temporal manner using 
specific calcineurin inhibitors.  
 
Beyond alterations in the catalytic subunit, the changes in regulatory subunit expression are 
important given the increased use of drugs designed to block Calcineurin activity which typically 
inhibit activity by limiting the ability of the regulatory subunit (CnB) to bind to and activate the 
catalytic subunit (CnA). The present study showed that CnB isoforms are differentially 
modulated in the hippocampus in a regionally specific manner after TBI. This suggests that 
individual Calcineurin regulatory isoforms may have different roles within select hippocampal 
areas in the post-injury period and may have implications for regional effects of Calcineurin 
inhibitors. This study also shows that following a CCI there is nearly a two-fold increase in 
Calcineurin activity in all regions of the hippocampus, both ipsilateral and contralateral, in 
injured animals versus sham. This increase in Calcineurin activity persists to the two week 
timepoint indicating that there is ongoing Calcineurin dysfunction in both regulatory subunit 
regional expression and in activity.  
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The present study illustrates that changes in Calcineurin appear as early as 2 hours post TBI 
and persist until at least 2 weeks post injury. Changes in hippocampal expression as assessed 
utilizing immunohistochemical staining of CnA isoforms were noticeable in all but the CnAy 
isoform, which had little to no expression within the hippocampus. Western blot data suggest 
that the visualized alterations in expression were not associated with changes in protein 
concentrations within hippocampal regions, but rather in cellular distribution or perhaps in 
divergent expression within subsets of different cell types throughout the hippocampus (Figure 
15). Changes in hippocampal IR, as assessed utilizing immunohistochemical staining, were 
noticeable in both of the CnB isoforms. Western blot data suggest that the visualized alterations 
in IR were associated with changes in protein concentrations within gross hippocampal regions, 
however this does not rule out possible changes in cellular distribution or perhaps in divergent 
expression within subsets of different cell types throughout the hippocampus (Figure 16).  
  
The expression of the CnA subunit has been linked to mitochondrial dysfunction and cell death 
signaling through BAD (Asai et al., 1999). CnA isoform expression, specifically CnAα, is known 
to be important in both oxidative stress and mitochondrial dysfunction which may play a role in 
both acute and chronic dysfunction within the hippocampus following TBI (Uchino et al., 2008). 
The level of cellular death was not assessed in this injury paradigm. However, given the 
regionally specific and variable alteration of CnA cellular distribution within the CA1, CA1-2, CA3 
and the hilus and hidden blade of the DG acutely and chronically, there may be broader 
implications then simply cell death signaling (Figures 5,9,11,13).  
 
While the expression of the CnA subunit has been linked to mitochondrial dysfunction and cell 
death signaling through BAD (Asai et al., 1999), alterations in the expression of the regulatory 
CnB subunit have not. Rather, changes in CnB expression have been shown to cause 
alterations in hippocampal cellular potentiation and depression (Zeng et al., 2001) and have 
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been implicated in schizophrenia (Miyakawa et al., 2003). Mbye et al., 2009 demonstrated that a 
non-Calcineurin inhibitory analog of cyclosporin A demonstrates cellular protection by acting 
upon mitochondrial integrity. This suggests that the cellular death and cytoskeletal degradation 
seen post TBI may be independent of Calcineurin activity. The increases in Calcineurin activity 
seen predominantly within the CA3 and DG fractions in both ipsilateral and contralateral 
hippocampi (Figure 4) also suggest that Calcineurin is playing a role beyond cell death 
signaling post-TBI given that, in the CCI model, cellular death is reported within the ipsilateral 
CA1 region with dystrophic neurons seen in the ipsilateral CA3 and DG (Colicos et al., 1996).    
 
Another possible explanation for changes in Calcineurin isoform subunit distribution is related to 
the structural function of hippocampal cell signaling (Buzsaki, 1996; Muller et al., 1996). The 
entorhinal cortex sends projections through two separate pathways into the hippocampus. The 
perforant pathway synapses within the DG and CA3 regions which then send projections into 
the CA1 region while another separate pathway from the EC directly synapses within the CA1 
region. The CA1 then sends its axonal outputs back into the deep layers of the EC.  
 
Both the DG and CA1 dendritic field receive input from the EC through two separate pathways. 
Alterations in isoform expression in these regions may be due to excitatory glutamate release 
from cortical structures occurring post injury. Isoform alterations in contralateral isoform 
expression appreciated acutely in both the CA1 and DG (Figures 5 and 11) that are no longer 
present at 2 weeks post injury (Figures 9 and 13), suggest a potential cortical component. 
Given that there is extensive crossover signaling between the right and left EC and hippocampi, 
excitotoxic glutamate release could explain isoform alterations in the areas that receive cortical 
input either ipsilateral or contralateral to injury (the DG and CA1 regions) (Buzsaki, 1996). 
Sustained low levels of Ca2+ caused by increased cellular excitability due to increased 
glutamate release in the postinjury period may activate CnA and be responsible for the 
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persistent changes in isoform expression in the CA1, CA1-2, and DG regions.  Alterations in 
Ca2+ concentration and flow, both acutely and chronically, have been appreciated within the 
hippocampus following TBI (Deshpande et al., 2008; Sun et al., 2008). 
 
At two weeks alterations in CnA isoform distribution within the SR of CA1 and CA1-2 did not 
reach significance (Figures 9 and 13). This may indicate that after a period of recovery there is 
a reversal of initial alterations in isoform distribution and a possible recovery of Calcineurin 
subunit function chronically. This may be partially responsible for the recovery post TBI. This 
was not seen in the dentate, however, and acute alterations in isoform distribution persisted into 
the chronic phase. What consequences regionally specific changes have on global hippocampal 
function is unclear, however given the extensive cortical connections throughout the dentate it is 
possible that persistent ipsilateral dentate loss of CnA is related to changes in synaptic inputs 
from cortical neurons. 
 
Several studies have suggested that subunits may possess action independent of Calcineurin 
activity (Kayyali et al., 1997; Asai et al., 1999; Zhou et al., 1999). The CnA subunit can become 
constitutively active if proteolytic cleavage removes the autoinhibitory site (Manalan et al., 1983) 
and the expression of the CnAα isoform has been shown to be important to LTP and synaptic 
plasticity of the CA1 and CA1-2 pyramidal neurons (Victor et al., 1995; Zhuo et al., 1999; Zeng 
et al., 2001; Groth et al., 2003). Following TBI there is a chronic failure in LTP induction 
(Sanders et al., 2000) that can be ameliorated with Calcineurin inhibition (Albensi et al., 2000). 
Alterations in Calcineurin subunit distribution may provide a potential mechanism for this loss of 
synaptic plasticity. Following TBI there is a persistent dysfunction in learning and memory 
(Dixon et al., 1996; Hamm, et al., 1996; Dixon et al.,1997; Scheff et al., 1997; Kline et al., 2000, 
2002). Alterations in LTP (Reeves et al., 1995), LTD (Albensi et al., 2000) following TBI could 
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be, in part, due to rapid, persistent alterations in Calcineurin A subunit expression demonstrated 
in this study. 
 
Changes in CnA expression profiles throughout the hippocampus have important implications 
for cellular function independent of cellular death pathways. There is a consistent loss in 
dendrite staining of both isoforms, within the ipsilateral CA1 and CA1-2 regions at 2 hours, 
which partially reverses by 2 weeks (Figures 5,9,11,13). This is in contrast to prior results 
demonstrating persistent increases in CnAα isoform staining within the apical dendrites of CA1 
neurons (Kurz et al., 2005a).  However, it must be noted that the previous study used a FP 
model and there may be a different alteration in Calcineurin distribution with CCI. It is also 
important to recognize that while there is reduced dendritic staining in the deep layers of the 
CA1 and CA1-2 SR there remains significant CnAα expression in areas closer to the cell soma 
which is consistent with the results presented by Kurz et al (2005a).   
 
Differences in CnAα distribution alterations compared to CnAβ have implications for isoform 
specific actions following TBI. CnAβ staining appears to be primarily localized to dendrites within 
the SR of the CA1 and CA1-2 and within the exposed blade of the dentate suggesting that 
CnAβ function may be more important to plastic events relevant to synaptic connections within 
these regions. Prior developmental studies have suggested that both CnAα and CnAβ have 
important roles in synaptic organization and synaptogenesis (Eastwood et al., 2005).  
 
There were decreases at both 2 hours and 2 weeks in both CnA isoforms expression within the 
ipsilateral exposed blade of the DG (Figures 6,9,11,13). Given the projections of the DG 
through CA3 and into the CA1 region, decreases in isoform expression may not be due to acute 
alterations in hippocampal regions, but rather a loss of expression throughout projecting 
neurons. This would be consistent with recent experimental results demonstrating significant 
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axonal loss throughout the gray matter of the hippocampus (Hall et al., 2008). Losses in 
projecting dendrites and subsequent alterations in synaptic targets would also provide a 
possible explanation for the reduction of CnA isoform expression within the SR of the CA1 and 
CA1-2 regions given that a loss of synaptic input would preclude the necessity for Calcineurin 
activity at synapses. 
 
Changes in CnB distribution and expression profiles throughout the hippocampus have 
important implications for cellular potentiation and depression. Unlike the CnA subunit, CnB 
isoforms are generally upregulated throughout the CA1 and CA1-2 regions ipsilaterally and the 
acute changes in the regulatory CnB subunit isoforms nearly all persist into the chronic phase 
(Table 5). The CnB2 isoform also shows a significant increases in dendritic IR within the CA1-2 
region both acutely and chronically (Figures 12 and 14). The TBI related up-regulation of CnB 
IR in the present study may be involved in modulating synaptic depression, given that a 
knockout of CnB impairs LTD. Zeng and colleagues (2001) suggest from their studies that the 
selective loss of the CnB subunit hypothetically impairs bidirectional signaling mechanisms 
between LTP and LTD during very specific memory tasks. The increase in the regulatory 
subunit expression coincides with increases in Calcineurin activity in the CA1 and CA3 regions 
suggesting a potential link between subunit alterations and activity.  However, Calcineurin 
activity is highest within the DG following injury (Figure 4) which coincides with a significant 
decrease in the expression of the regulatory subunit (Table 5; Figure 16) and decrease in CnA 
distribution (Table 4; Figure 6, 13). The persistent change in regulatory subunit expression and 
catalytic subunit distribution cannot account for the persistent increases in Calcineurin activity 
within the DG, but may play a role in the ongoing deficiencies in hippocampal potentiation after 
TBI within the CA1. 
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The down-regulation of the CnB regulatory subunit isoforms (Figure 16) may be a counter 
regulatory response to eliminate non-specific neuronal activity after TBI occurring within the DG. 
This may be more pertinent in TBI given that following a brain injury the CnA subunit can 
become constitutively active if proteolytic cleavage removes the autoinhibitory site (Manalan et 
al., 1983). Perhaps downregulation of the regulatory subunit is a cellular response to the 
increases in catalytic Calcineurin activity seen both in FP (Kurz et al., 2005b) and shown for the 
first time in CCI in the present study (Figure 4). This would suggest that there may be a two-fold 
dysfunction in Calcineurin following a TBI, both an increase in potentially harmful activity, and 
an alteration in subunit distribution important for synaptic function, in particular altering dendritic 
stability (Halpain et al., 1998) and affecting the growth of neurites (Chang et al., 1995).  
 
For normal Calcineurin activity it is necessary, in the presence of Ca2+, for the regulatory CnB 
subunit to bind to its binding site on the catalytic CnA subunit (Griffith et al., 1995). Both of the 
calcineurin inhibitors, FK-506 and cyclosporin A, rely upon the disruption of this interaction to 
limit Calcineurin activity (Kay et al., 1989; Wiederrecht et al., 1993). Regionally distinct changes 
in the two subunits create a situation whereby these two drugs may have different effects within 
different regions of the hippocampus, which have yet to be appreciated. Given the increase in 
activity within the DG (Figure 4), but loss of regulatory expression (Figure 16), Calcineurin 
inhibitors may not be effective in curtailing DG damage post TBI. Understanding how 
Calcineurin activity and structure is altered post injury may help to better develop and target 
treatment strategies for TBI.   
 
In summary, Calcineurin subunit isoforms are differentially modulated by injury in a regionally 
specific manner. Regional alterations in CnA and CnB isoforms within the hippocampus 
ipsilateral to injury persist chronically. Further studies are needed to examine exactly how 
isoform changes relate to increases in Calcineurin activity in regions of the hippocampus. It is 
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also unclear what the functional implications are of specific subunit isoform alterations. While 
studies have shown cellular potentiation and depression dependent upon CnB expression, it 
remains unclear what the CnB subunit’s function is independent of the activity of the Calcineurin 
heterodimer. These regionally specific alterations in isoform expression also have important 
implications for the clinical use of Calcineurin inhibitors in TBI. This study is the first step in 
identifying these alterations and characterizing specific Calcineurin subunit changes following 
TBI that will allow for better targeted therapeutic strategies to assist in patient recovery from 
TBI. 
 
2.5 CONCLUSION 
 
Cellular death within the hippocampus is a well described feature of experimental TBI (Lighthal 
et al., 1989; Sanders et al., 2001; Jennings et al., 2008). The causes of cell death are many 
including oxidative stress, glutamatergic excitotoxicity, mechanical damage, and persistent 
apoptotic cell signaling activation (Kochanek, 1993). We examined calcineurin subunits within 
the hippocampus to evaluate how CCI alters calcineurin post TBI. There was an acute alteration 
in the distribution of both the regulatory and catalytic subunits that persisted into the chronic 
phase post TBI throughout the hippocampal architecture. In addition there was an increase in 
activity in all areas examined both acutely and chronically. The level of injury chosen for this 
study was mild-moderate in severity in order to preserve the hippocampus. A more severe CCI 
has the effect of causing significant hippocampal loss, as seen in chapter 4 of this thesis. Even 
with a milder injury the hippocampus still shows significant ongoing cellular pathology. This 
suggests that neuroprotection strategies designed to spare hippocampal architecture may 
preserve cellular numbers, but not reduce cellular pathology. It is for this reason that it has 
become critically important to look beyond the hippocampus to other brain structures in order to 
effectively treat behavioral dysfunction after TBI.  
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3.  DYSFUNCTION IN STRIATAL SIGNALING PATHWAYS FOLLOWING TBI 
 
 
3.1 INTRODUCTION 
 
TBI causes persistent cognitive deficiencies. A complex etiology makes the identification of 
therapeutic targets difficult in TBI (Kochanek, 1993; DeKosky et al., 1998). Subcortical regions 
represent novel areas for therapeutic targeting in TBI given their importance to functional 
deficits and integration with other brain regions (Donnemiller et al., 2000; Vertes, 2006). To date 
few studies have examined the effect of TBI upon subcortical neuronal signaling and potential 
treatment targets remain unknown.       
 
The basal ganglia are involved in executive function, emotional control, and memory and 
learning (Ridley et al., 2006; Baldo and Kelley, 2007). The striatum represents the major entry 
into the basal ganglia. Striatal medium spiny neurons (MSN) receive glutamatergic inputs from 
the cerebral cortex and DAergic innervation from the midbrain (Pennartz and Kitai, 1991). The 
interaction of glutamate and DA within MSNs modulate the plasticity of corticostriatal synapses 
(Calabresi et al., 2007).  
 
Acutely, following a TBI there is an increase in glutamatergic release leading to excitotoxicity 
and oxidative stress (Palmer et al., 1993). Alterations in glutamate receptor subunit composition 
and expression contribute to persistent dysfunction in plasticity (Osteen et al., 2004). What 
effect glutamatergic signaling alterations has in the striatum is unknown, however DA signaling 
in striatal neurons has been examined. Dysfunctions in DAergic signaling after TBI include 
increases in DA (Massucci et al., 2004; Kobori et al., 2006), alterations in dopamine transporter 
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(DAT), chronic reductions in evoked DA release (Wagner et al., 2009), and alterations in 
tyrosine hydroxylase (Yan et al., 2007). Pharmacotherapies that enhance DA have clinical 
(McAllister et al., 2004; Warden et al., 2006) and experimental (Kline et al., 2000; Dixon et al., 
1999) benefit in TBI. The exact mechanism of many of these therapeutic strategies, however, 
remains unknown.         
 
The DA and cAMP regulated phosphoprotein-32 (DARPP-32) is a cytoplasmic phosphoprotein 
found in 95% of MSNs. Two phosphorylation sites, threonine-34 (Thr34) and threonine-75 
(Thr75), make DARPP-32 a bifunctional signal transduction molecule that controls the activities 
of protein phosphatase-1 (PP-1) and protein kinase A (PKA) (Greengard et al., 1999; Nishi et 
al., 2002; Valjent et al., 2005).  
 
DA acting at D1 receptors promotes DARPP-32 phosphorylation at Thr34, leading to inhibition 
of PP1. DA and glutamate act on protein phosphatase 2B (PP2B) and protein phosphatase 2A 
(PP2A) to decrease phosphorylation at Thr34. A reduction in phosphorylation at Thr34 removes 
the inhibitory affect of DARPP-32 on PP1 (Nairn et al., 2004; Svenningsson et al., 2004). The 
regulation of PP1 and PKA by DARPP-32 allows DA and glutamate to regulate striatal neuronal 
signaling, protein transcription, and potentiation (Fienberg et al., 1998; Hakansson et al., 2004). 
 
Given the importance of DARPP-32 to striatal function and the role it plays as an integrator of 
multiple signaling pathways, DARPP-32 represents a unique therapeutic target in TBI. 
Understanding the role of DARPP-32 in post-TBI striatal dysfunction is necessary to 
understanding subcortical effects of TBI and designing effective therapeutic interventions. 
 
This study represents the first to examine DARPP-32 phosphorylation in TBI. We hypothesize 
that following TBI there will be a decrease in the phosphorylation of DARPP-32 at Thr34 and 
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subsequent increase in PP-1 activity within the striatum that persists. We also predict that the 
increase in PP-1 activity post TBI will be associated with alterations in downstream signaling 
including decreases in ERK 1/2 and CREB phosphorylation. 
 
3.2 METHODS AND MATERIALS 
 
3.2.1 Animals 
 
Adult male Sprague-Dawley rats (N = 188) were used in the study. Rats (300-325 g) were 
purchased from Hilltop Laboratories (Scottsdale, PA, USA) and housed in pairs under a 12:12 
light/dark cycle. Rats were given food and water with ad libitum throughout the study. All 
experiments were carried out in accordance with the University of Pittsburgh’s guidelines for the 
Care and Use of Laboratory Animals. All experiments were approved by the Institutional Animal 
Care and Use Committee of the University of Pittsburgh.     
 
3.2.2 Surgical Procedures for TBI 
 
On the day of surgery anesthesia was initiated with 4% isoflurane (IsoFlo; Abbott Laboratories, 
North Chicago, IL, USA) and 2:1 N2O/O2. Rats were intubated and maintained on 1.5-2% 
isofluorane during the surgical procedure. Following intubation, rats were placed on a thermal 
blanket to regulate body temperature (37oC) and the animals head placed in a stereotaxic 
frame. An incision was made down the midline of the skull and the soft tissues and periosteum 
deflected. A craniotomy was then performed over the right parietal bone to expose the dura. 
Controlled cortical injury (CCI, Pittsburgh Precision Instruments, Inc.) at a depth of 2.6mm-
2.8mm at 4m/sec was carried out as previously reported (Dixon et al., 1991; Yan et al., 2000). A 
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total of 91 rats were injured, and the remaining 97 rats were shams. Righting reflex44 was 
monitored in the immediate post-surgical period to assess acute recovery. 
  
3.2.3 Tissue Preparation, Immunohistochemistry, and Immunofluorescence Staining 
 
Animals (N = 3 in each group for each time point for a total N = 30) were given an overdose of 
sodium pentobarbital (100 mg/kg; i.p), and perfused intra-aortically with 0.1M heparinized PBS 
in 4% PFA/0.1M PBS. Brains were dissected, submerged in increasing concentrations of 
sucrose, and stored at -80oC. Brains were then sectioned at 35µm in a cryostat, and free 
floating sections collected in tissue plate wells containing 0.1M TBS (pH 7.5).  
 
All immunohistochemical procedures and incubations were carried out with agitation with the 
exception of the chromogen step. All treatment groups were stained together within each 
immunohistochemical session. Sections were matched by region, rinsed 3 x 5 min in washing 
buffer (0.1%Triton-X in 0.1M TBS) and blocked in a mixture of 10% normal donkey serum in 
washing buffer for 2 hours at room temperature. Sections were then incubated overnight at 4oC 
in (one only) primary rabbit antibodies specific to DARPP-32 (1:1000; Cell Signaling), p-DARPP-
32-Thr34 (1:600; Chemicon International), p-DARPP-32-Thr75 (1:600; Chemicon International) 
diluted in washing buffer/5% normal donkey serum. Following incubation, sections were then 
washed 3 x 8 minutes in washing buffer and endogenous peroxidase activity was quenched with 
0.3% H2O2 in methanol for 10 minutes. Following 3 x 5 minutes washing in washing buffer, 
sections were incubated for 2hrs at RT in biotin conjugated goat anti-rabbit secondary antibody 
(Jackson ImmunoResearch, PA) at 1:400 in 5% normal donkey serum in washing buffer. 
Sections were then washed 3 x 5 minutes in washing buffer and incubated in ABC reagent 
(Vector Industries) for 30 minutes. Immunoreactivity (IR) was then visualized using 0.01% 3’ 3’ 
Diaminobenzidine (DAB) following 5 x 5 minutes washing in washing buffer. The DAB reaction 
99 
 
was terminated with dH2O and sections were rinsed in 0.1M TBS, mounted onto slides, air dried 
and cover-slipped for light microscope analysis. All sections within the reaction were exposed to 
each of the reagents for the same time period. 
 
For double labeling, sections (N = 4 in each group for each timepoint for a total N = 32) were 
incubated with primary antibody (DARPP-32 1:100; Cell Signaling; p-DARPP-32-Thr34 1:50; 
Chemicon International; p-DARPP-32-Thr75 1:200; Chemicon International) in 10% normal 
donkey serum in washing buffer with mouse anti-NeuN (1:2000) at 4°C for 16-24 hours. Alexa 
fluorescent dyes (488, 594) conjugated to goat anti-rabbit or donkey anti-mouse secondaries, 
respectively, were used for double labeling of DARPP-32/p-DARPP-32-Thr34/p-DARPP-32-
Thr75 and NeuN. At least 3 sections of brain tissue through the striatum were processed for 
each experiment. Control experiments omitting primary antibodies were run in parallel to confirm 
antibody specificity. Images were captured using a confocal microscope (LSM 510; Zeiss, Jena, 
Germany). 
 
Semi-automated computer assisted threshold cell count analysis of DAB stained 
immunohistochemistry sections: Pictures of mounted sections were taken using a Nikon 
microscope. Two sections from each animal for a total of six pictures per group were used for 
analysis. Based upon techniques presented in (Brey et al., 2003; Leal et al., 2006) a semi-
automated, computer-assisted, cell count based upon a set threshold of DAB IR was used to 
count positive cell bodies in the two regions of interest (Nucleus Accumbens; NAcc, and 
Dorsolateral Striatum; DLStr). For detailed description of methodology see Appendix A: 
Supplemental figure 1. Briefly, the DLStr and NAcc were identified with visual inspection and 
pictures of each area were taken utilizing an appropriate magnification (20x for DLStr and 10x 
for NAcc). For the NAcc section the shell of the NAcc was outlined and cell counts were limited 
to the core and shell. Images were captured as tiff files. ImageJ (NIH, USA) software for 
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windows was utilized to analyze images. The blue image was used for analysis as previous 
studies have shown that DAB IR provides the greatest contrast in the blue spectrum. Images 
were converted grayscale and then to binary data by setting a threshold for positive DAB 
staining selected by an examiner blinded to injury. Once thresholds (Typically the top 15-20% of 
most intense staining) were selected for a specific area (DLStr or NAcc) using a randomly 
selected section image these thresholds were maintained throughout each section for that 
particular area ensuring that the criteria for a DAB positive cell body remained consistent 
throughout all examined sections. Following conversion to binary images, ImageJ (NIH, US) 
analysis software was used to count positive pixels defined as having a size of 100-500 for 
DLStr and 50-300 for the NAcc; which limited artifacts while identifying positive neuronal cell 
bodies (Supplemental figure 1).  
 
3.2.4 Western Blot Analysis 
 
Animals (N = 6 in each timepoint for each group for a total N = 60 for DARPP-32 and p-DARPP-
32 timecourse analysis; N = 6 for each group for a total of N = 42 for Amantadine hydrochloride 
studies). After deeply anesthetized with pentobarbital (Nembutal, 80-100 mg/kg; Abbott 
Laboratories, North Chicago, IL), animals were decapitated and the brains quickly removed and 
chilled on ice. Tissue from the striatum was excised and frozen in liquid nitrogen. Tissue was 
stored at -70°C until used for analysis. Striatal tissue was homogenized in 400 µl of Lysis buffer 
containing 0.1M NaCl, 0.01M Tris-Cl (pH 7.6), 0.001 M EDTA (pH 8.0), 1 µg/ml aprotinin, 100 
µg/ml phenylmethylsulfonyl fluoride (PMSF) and phosphatase inhibitor cocktail 1 (Sigma, St. 
Louis, MO) was added to samples used for western blot. Protein concentrations were 
determined using a BCA protein Assay Kit (PIERCE, Rockford, IL). Samples containing 20-100 
g of protein were subjected to SDS-polyacrylamide gel electrophoresis through a 10% 
acrylamide gel, and after were transferred to nitrocellulose membranes. Membranes were 
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blocked with 5% bovine serum albumin (Sigma, St. Louis, MO) in tris-buffered saline (TBS-T). 
Following block membranes were washed 3 x 10 minutes in TBS-T and immunolabeled with 
antibodies (1:10,000 DARPP-32; 1:2000 p-DARPP-32-Thr34; 1:2000 p-DARPP-32-Thr75; Cell 
Signaling, Danvers, MA) in 5% BSA in TBST for 18-24 hours. Following primary incubation 
membranes were washed 3 x 10 minutes in TBS-T and incubated for 2 hours in by goat anti-
rabbit immunoglobulin G conjugated to peroxidase (1:10,000; PIERCE, Rockford, IL). Proteins 
were visualized with a chemiluminescence detection system (SuperSignal, PIERCE, Rockford, 
IL). To assure equal loading, all membranes were striped and re-blotted with rabbit anti-actin 
antibody (1:20,000, Sigma, St. Louis, MO). Blots were exposed to autoradiographic X-ray film 
for 10 s to 2 min and bands were semi-quantified using ImageJ (NIH, USA) software. Values are 
given as a ratio (percentage change) of optical density of injured samples versus sham control 
within individual blots. All optical densities were normalized to β-actin. 
 
3.2.4.1 Preparation of nuclear extracts used in western blot analysis.  Nuclear fractions were 
prepared utilizing a nuclear extraction kit (Active motif,Carlsbad, CA). Briefly, frozen tissue was 
homogenized on ice with 250 ul of 1x Hypotonic buffer with DTT and detergent. Homogenized 
tissue was centrifuged for 10 minutes at 850 x g at 4°C. Cells were resuspended in 250 ul of 1x 
Hypotonic buffer by pipetting up and down and incubated on ice for 15 minutes. 15 ul of 
detergent was added and the suspension was vortexed for 10 seconds. Suspension was then 
centrifuged for 30 seconds at 14,000 x g at 4°C. Supernatant was collected (cytoplasmic 
fraction). The remaining pellet (nuclear fraction) was resuspended in 100 ul of complete lysis 
buffer and vortexed for 10 seconds. Suspension was incubated for 30 minutes on ice on a 
rocking platform. Suspension was then vortexed for 30 seconds and centrifuged for 10 minutes 
at 14,000 x g at 4°C. Supernatant was collected (nuclear fraction). Fractions were used for 
western blot analysis as described above. 
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3.2.5 Protein Phosphatase-1 Activity Assay 
 
Animals (N = 6 in each timepoint for each group for a total N = 42). Striatal tissue was prepared 
following the same protocol as used for western blots, with the exception of the use of the 
phosphatase inhibitor cocktail in the lysis buffer. The following protocol utilized a modified PP-
2A activity assay kit (Millipore, Temecula, CA) (Appendix A: Supplemental figure 2). 100 µg 
of protein, determined via BCA assay, was added to an eppendorf tube with 25 µl of agarose 
A/G beads and 6 µl of anti-PP-1δ rabbit antibody (Millipore, Temecula, CA). Following overnight 
incubation in 4°C and 3 min spin down at 10,000 g, beads were washed 3 times with ice cold 
TBS and once with Ser/Thr phosphopeptide buffer. Beads were spun down in between each 
wash for 1 min in 4°C. Following the final wash, 30 µl of phosphopeptide and 20 µl of Ser/Thr 
phosphopeptide buffer was added to the eppendorf tube. The eppendorf tube was then 
incubated for 10 minutes in a water bath at 30°C. 25 µl of supernatant was placed in a 96 well 
plate (in duplicates) and malachite green detection assay was utilized to visualize free 
phosphates. Plate was read on a plate-reader at 650 nm. A standard curve was calculated and 
the level of phosphatase activity is reported in picomoles of phosphate released per 25 µl of 
supernatant. 10 µl of TBS and 10 µl of 2x loading buffer were then added to the eppendorf. The 
eppendorf tube was then heated to 95°C for 5 minutes and western blots were run to determine 
the relative amount of PP-1 protein in each tube. Final values are normalized to western data to 
ensure equal protein for each sample.    
 
3.2.6 Protein Kinase A Activity Assay 
 
To analyze PKA activity the PepTag PKA assay was employed (Promega, Madison, WI). For 
each sample 5 ul of reaction buffer, 5 ul of the A1 peptide, 5 ul of the PKA activator, and 10 ul of 
protein sample were added. For a positive control the catalytic subunit of cAMP protein kinase 
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was added, for a negative control sample and the catalytic subunit were excluded. Mixed 
samples were incubated at room temperature for 30 minutes. Reaction was stopped by placing 
the reaction tubes on a heating block at 95°C for 10 minutes. Samples were then run for 30 
minutes at 100 volts on a 0.8% agarose gel (mixed in 50 mM Tris-HCL). Pictures were taken 
with a kodak blacklight image camera. Density of bands was analyzed utilizing ImageJ analysis 
software (NIH) and corrected for the concentration of protein loaded per sample. Data is 
represented as percentage of density versus sham ± standard deviation and was analyzed 
using ANOVA with significance set at p≤0.05.  
 
3.2.7 Statistics 
 
Cell counts using the semi-automated cell count method were analyzed according to analysis of 
variance (ANOVA) with a significance level set at p ≤ 0.05. Cell count data is expressed as the 
mean ± standard error (SEM) of the mean. Optical density of western blot bands from each 
group were compared according to a two-factor ANOVA (time versus injury) followed by 
Bonferroni post-hoc comparison with a significance level of p ≤ 0.05. Western blot data are 
expressed as the group means ± standard error (SEM) of the mean. Phosphatase and kinase 
activity data are expressed as the group means ± standard deviation of injury compared to the 
appropriate sham. Statistical evaluations were performed according to ANOVA with a 
significance level of p ≤ 0.05 used for all tests. Two-way ANOVA was not run on phosphatase or 
kinase activity assays due to the limited timepoints analyzed. The effect of interest was any 
alterations in activity at each timepoint assessed compared to sham. 
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3.3 RESULTS 
 
 
3.3.1 TBI Causes a Specific Decrease in the Phosphorylation of DARPP-32 at Threonine-34 
Within the Striatum 
 
Following a TBI there is an acute decrease in DA tissue levels and chronic increase (McIntosh 
et al., 1994; Massuci et al., 2004). Alterations in DA have been shown to affect the 
phosphorylation state of DARPP-32 in MSNs (Nishi et al., 2003). We therefore examined 
whether, following a TBI, there was a change in DARPP-32 phosphorylation state at the Thr34 
and Thr75 phosphorylation sites (Figure 17). TBI caused an acute decrease in the 
phosphorylation of DARPP-32 at Thr34 (p-DARPP-32-Thr34) as assessed utilizing western 
blots (N=6 for each group) (Figure 17) (At 6hrs p<0.05). This decrease in p-DARPP-32-Thr34 
persisted through all timepoints examined in the ipsilateral striatum (1Day p<0.0001; 1week 
p<0.05; 2week p<0.01; 4week p<0.05) and at 2 and four weeks in the contralateral striatum 
(2week p<0.01; 4week p<0.05), relevant to injury (Figure 17) indicating that TBI causes a 
persistent dysfunction in striatal intracellular signaling that persists beyond the initial insult. The 
decrease in p-DARPP-32-Thr34 was not due to changes in DARPP-32 expression (Figure 17). 
Furthermore, this was a site specific alteration that was not accompanied by any change in the 
phosphorylation state of the Thr75 site (p-DARPP-32-Thr75) (Figure 17), indicating that the loss 
of p-DARPP-32-Thr34 was not due to non-specific increases in phosphatase activity upon 
DARPP-32. To assess the regionality of this alteration we also examined the frontal cortex. 
Examination of the frontal cortex demonstrated decreases in p-DARPP-32-Thr34 at 1 week and 
2 weeks post injury (Appendix A: Supplemental figure 3), however the decrease in p-DARPP-
32-Thr34 was only identified in the ipsilateral cortex, relative to injury, did not appear acutely, 
and did not persist past 2 weeks. No alterations in DARPP-32 protein expression or p-DARPP-
32-Thr75 were appreciated in the frontal cortex. 
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Figure 17. Timecourse of TBI effect on DARPP-32 protein expression and phosphorylation 
state in rat striatum (N=6 per group at each timepoint). A, Representative western blot of 
ipsilateral striatum (above) and optical density (below) of DARPP-32 protein expression showing 
no significant effect of TBI on DARPP-32 expression. B, Representative western blot of 
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ipsilateral striatum (above) and optical density (below) of p-DARPP-32-T34 showing a 
significant reduction in p-DARPP-32-T34 in the striatum ipsilateral to injury at all timepoints 
examined and in the striatum contralateral to injury at 1 day-4 weeks post injury. C, 
Representative western blot of ipsilateral striatum (above) and optical density (below) of p-
DARPP-32-T75 showing no significant change in p-DARPP-32-T75 following TBI. *p≤0.05 
normalized to β-actin and compared to sham; ANOVA with Bonferroni correction. Data 
represented as a percentage of sham following normalization to β-actin ± SEM. Abbreviations: 
SC = Sham Contralateral to Injury; IC = Injured Contralateral; SI = Sham Ipsilateral to Injury; II = 
Injured Ipsilateral; S = Sham; I = Injured.  
 
3.3.2 Striatal Sub-Region Analysis of DARPP-32 Phosphorylation Following TBI 
 
The striatum in rats is comprised of regions that differ in functional relevance to cognitive and 
motor tasks. The NAcc is important for reward learning (Jones et al., 1990) and addiction 
(Piazza et al., 1991). The DLStr is important to motor learning and motor control (Nakamura et 
al., 2001). The phosphorylation state of DARPP-32 plays a critical role in these striatal specific 
tasks (Meyer-Lindenberg et al., 2007). Utilizing DAB immunohistochemistry of free-floating rat 
striatal slices we examined the effects of TBI on various sub-region p-DARPP-32-Thr34 (Figure 
18) levels to assess region specific alterations and validate the decreases in p-DARPP-32-
Thr34 identified by western blot analysis (Figure 17). Immunohistochemistry for non-
phosphorylated DARPP-32 demonstrated no alteration in regional immunoreactivity of DARPP-
32 confirming that following TBI there is no change in DARPP-32 expression at examined 
timepoints (Figure 18). Immunohistochemistry for p-DARPP-32-Thr34 showed noticeable 
reductions in immunoreactivity in the injured ipsilateral and contralateral DLStr compared to 
sham at 1 day and 2 weeks (Figure 18). There appears to be significant decrease in p-DARPP-
32-Thr34 reactivity in the NAcc of TBI versus sham, however immunoreactivity in the VMStr 
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appears increased in injured versus sham (Figure 18). In order to better understand the cellular 
distribution of p-DARPP-32-Thr34 changes following injury an unbiased, computer assisted, 
threshold, cell counting method was used to characterize the level of cell soma staining in 
injured versus sham (Appendix A: Supplemental Figure 1). Analysis of positive p-DARPP-32-
Thr34 in various subregions (N=3 brains, 2 sections from each for a total N=6 for each group) 
demonstrated no difference between cell staining in the DLStr of injured versus sham, however 
there was a decrease in the number of p-DARPP-32-Thr34 positive cells in the NAcc of injured 
versus sham (Figure 18) (1day p<0.01; 2week p<0.01.) No p-DARPP-32-Thr34 cell bodies 
were appreciated in either sham or injured VMStr. Immunohistochemistry for p-DARPP-32-
Thr75 showed no changes between sham and injured animals in any striatal sub-region 
assessed. The computer-assisted, cell counting method did not show any difference in positive 
DARPP-32 (Figure 18). DAB immunohistochemistry confirms the specific alteration in p-
DARPP-32-Thr34 seen by western blot (Figure 18) following TBI and demonstrates striatal sub-
region specific alterations that may have significance for specific persistent striatal deficits after 
a TBI. No significant alteration in the number of DARPP-32 positive cells indicates that the 
difference between sham and injured p-DARPP-32-Thr34 cell counts is most likely due to the 
decrease in DARPP-32 phosphorylation and not due to cellular loss within the NAcc. 
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Figure 18. Timecourse of TBI effect on DARPP-32 and p-DARPP-32-T34 DAB 
immunoreactivity in rat striatum (N=3 per group at each timepoint; boxes indicate area of higher 
power view shown below). A, Representative sections of rat striatum at 1 day and 2 weeks post 
injury showing no effect of TBI on DARPP-32 expression in either the DLStr or NAcc. B, 
Representative sections of rat striatum at 1 day and 2 weeks showing a reduction in p-DARPP-
32-T34 in the neuropil of the DLStr (indicated by black arrows) both contralateral and ipsilateral 
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to injury (side indicated by grey arrow). There also appears to be reduced IR in DLStr MSN cell 
body staining (indicated by white arrows) in both the DLStr and NAcc at 1 day and 2 weeks post 
injury. C, Semi-automated cell count analysis of 1 day and 2 week timepoints in the ipsilateral 
DLStr and Nacc showing no significant difference in the number of DARPP-32 positive cells at 
either timepoint in the DLStr or NAcc. There is a significant difference in the number of p- 
DARPP-32-Thr34 positive cells in the NAcc in injured compared to sham at both 1 day and 2 
weeks post injury. Data represents means ± standard deviation. p≤0.01 compared to sham; 
ANOVA. Abbreviations: Ipsi = Ipsilateral to injury; DL = Dorsolateral; NAcc = Nucleus 
Accumbens.  
 
3.3.3 Changes in DARPP-32 Phosphorylation in Sub-populations of Medium Spiny Neurons 
Following a TBI 
 
Within the striatum there are two independent outflow tracts comprised of two morphologically 
indistinct MSN populations (Bertran-Gonzalez et al., 2008). It has been shown that these two 
subpopulations of MSN respond differently to drugs that induce alterations in DARPP-32 
phosphorylation (Bateup et al., 2009). We used confocal immunofluorescence to assess if there 
appeared to be a difference in MSN p-DARPP-32-Thr34 response to TBI (Figure 19). At all 
timepoints post injury there is a noticeable decrease in the immunofluorescence of p-DARPP-
32-Thr34 within the injured ipsilateral DLStr compared to sham (Figure 19). 
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Figure 19. Timecourse of TBI effect on p-DARPP-32-T34 immunofluorescence in rat striatum 
(N=4 per group at each timepoint). Representative sections of rat striatum at 1 day, 1 week, 2 
weeks, and 4 weeks post injury showing a reduction in p-DARPP-32-Thr34 
immunofluorescence (green) in injury compared to sham within the DLStr. There does not 
appear to be a subset of MSN (NeuN red marker) in injured tissue that show a greater reduction 
in p-DARPP-32-Thr34 cell soma fluorescence.  Abbreviations: D = Day; W = Week; I = injured; 
S = Sham; MSN = Medium Spiny Neurons; p-DARPP-32-Thr34 = Phosphorylated Dopamine 
and cAMP regulated phosphoprotein 32 at Threonine-34; TBI = Traumatic Brain Injury.  
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3.3.4 Protein Phosphatase-1 Activity is Increased Following TBI 
 
The phosphorylation state of DARPP-32 directly regulates protein phosphatase-1 (PP-1) activity 
(Hemmings & Greengard 1986). Increases in p-DARPP-32-Thr34 lead to a decrease PP-1 
activity while decreases in p-DARPP-32-Thr34 lead to an increase PP-1 activity (Hemmings et 
al., 1990). Given the decrease in p-DARPP-32-Thr34 seen following injury we analyzed PP-1 
activity utilizing a modified protein phosphatase 2A activity assay (Appendix A: Supplemental 
Figure 2) to determine the effect of decreased p-DARPP-32-Thr34 on PP-1 activity following 
TBI (Figure 20). There was a significant increase in PP-1 activity in injured ipsilateral striatum 
compared to sham at both 1 day (p<0.001) and 2 weeks (p<0.01) following injury (Figure 20). 
At 1 day following injury there was also a significant increase in PP-1 activity in the contralateral 
injured striatum compared to sham (p<0.01) that was not seen at 2 weeks post injury (Figure 
20). Increases in PP-1 activity are consistent with the loss of p-DARPP-32-Thr34 seen following 
TBI indicating that decreases in p-DARPP-32-Thr34 after TBI are part of a persistent 
dysfunction in intracellular signaling cascades. 
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Figure 20. Analysis of protein phosphatase-1 (PP-1) activity in homogenized rat striatum. There 
is a significant increase in PP-1 activity in both the contralateral (N=6/group; p<0.01; ANOVA) 
and ipsilateral (N=6/group; p<0.01; ANOVA) striatum compared to sham at 1 day post injury. By 
2 weeks post injury there remains a significant increase in PP-1 activity in the ipsilateral 
(N=6/group; p<0.01; ANOVA) striatum compared to sham. Increases in PP-1 activity are 
consistent with decreases in p-DARPP-32-T34. Data represents means ± standard deviation. 
Abbreviations: S = Sham, C =Contralateral, I = Ipsilateral; CCI = Controlled Cortical Impact. 
 
3.3.5 Acute decrease followed by a chronic increase in PKA activity following a TBI 
 
Protein kinase A (PKA) is a key modulator of DARPP-32 signaling, but also plays an intrinsic 
role in downstream signaling events independent of DARPP-32 action. This includes PKA 
mediated activation of ERK through the mitogen activated protein kinase pathway and PP1 
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through a rho kinase pathway (Waltereit et al., 2003; Nairn et al., 2004). Alterations in PKA 
activity could potentially explain changes in p-DARPP-32/Thr34 levels and could play a 
synergistic role in downstream dysfunction of nuclear signaling pathways. We utilized a 
commercially available PKA activity kit to determine PKA activity at 1 day and 2 weeks post 
injury (n = 6 animals per group). There was a significant decrease in PKA activity at 1 day post 
TBI in ipsilateral striatum (p<0.05) compared to sham ipsilateral striatum. There was also a 
significant decrease at 1 day in contralateral striatum PKA activity post TBI in injured (p<0.01) 
versus sham. At 2 weeks post injury PKA activity in injured striatum both contralateral (p<0.01) 
and ipsilateral (p<0.01) was increased significantly compared to the corresponding sham striatal 
PKA activity levels (Figure 21). An acute decrease in PKA activity post TBI is consistent with 
decreases in both p-DARPP-32/Thr34 and increases in PP1 activity. However, a chronic 
increase in PKA activity moves counter to the observed changes in DARPP-32 phosphorylation 
and PP-1 activity. A chronic increase in PKA activity may represent an attempt by the striatal 
system to normalize downstream dysfunction or ongoing upstream pathology.   
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Figure 21. Analysis of protein kinase A (PKA) activity in homogenized rat striatum. There is a 
significant decrease in PKA activity in both the contralateral (N=6/group; p<0.01; ANOVA) and 
ipsilateral (N=6/group; p<0.05; ANOVA) striatum compared to sham at 1 day post injury. By 2 
weeks post injury there is a significant increase in PKA activity in both the contralateral and 
ipsilateral (N=6/group; p<0.01; ANOVA) striatum compared to sham. Data represents means ± 
standard deviation. Abbreviations: S = Sham, C =Contralateral, I = Ipsilateral; CCI = CCI. 
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3.3.6 Significant decrease in ERK phosphorylation in the nuclear fraction of striatal 
homogenates chronically post TBI. 
 
ERK 1/2 and CREB phosphorylation are downstream targets of both PKA and PP-1 activity 
(Greengard et al., 1999; Waltereit et al., 2003). By assessing these two important cell signaling 
regulators we will be able to get a better idea of what signaling pathologies are associated with 
the observed changes in PKA activity and DARPP-32 phosphorylation alterations. Furthermore, 
changes in ERK 1/2 and CREB phosphorylation are important to nuclear transcription and 
synaptic plasticity. Western blot analysis of p-ERK 1/2 to ERK 1/2 and p-CREB (Ser133) to 
CREB levels in injured animals versus sham (n= 6 per group) demonstrated no significant 
differences between p-ERK or p-CREB levels at either 1 day or 2 weeks post injury. This may 
indicate that dysfunction in PKA and DARPP-32 signaling may be affecting a different set of 
downstream targets, may not be severe enough to overcome the multitude of other signaling 
events that regulate ERK and CREB, or we may not be able to detect alterations in p-ERK 1/2 
and p-CREB in whole cell lysates. 
 
Whole cell lysates demonstrated no difference in ERK 1/2 or CREB phosphorylation. 
Phosphorylated ERK 1/2 and CREB are predominantly within the nucleus so we prepared 
nuclear extracts in order to further examine potential alterations in phosphorylation state. An 
increase in PP-1 activity should theoretically lead to a reduction in ERK 1/2 phosphorylation and 
subsequent reduction in CREB phosphorylation. Western blot analysis of striatal nuclear 
extracts demonstrated a significant decrease in ipsilateral (relative to injury) ERK 1/2 
Thr202/Tyr204 (pERK 1/2) phosphorylation (p<0.05) in TBI animals versus sham (n=6 per 
group) at 3 weeks post injury (Figure 22). There was no significant decrease in CREB 
phosphorylation in injured versus sham animals (Figure 22).  
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Figure 22: Analysis of nuclear fraction ERK 1/2 expression and Thr202/Tyr204 (p-ERK 1/2) 
phosphorylation in the striatum at 3 weeks post experimental TBI. Densitometry of p-ERK 1/2 
normalized to total ERK 1/2 expression shown below with a representative western blot above. 
There was a significant decrease in p-ERK 1/2 expression in the injured ipsilateral striatum 
compared to sham (ANOVA; p<0.05). The decrease appears to be predominantly within the 
Thr202 form (p-ERK 1). Data represents mean + SEM; n = 6 per group.  
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Figure 23: Analysis of nuclear fraction CREB expression and p-CREB (Ser133) 
phosphorylation in the striatum at 3 weeks post experimental TBI. Densitometry of p-CREB 
normalized to total CREB expression shown below with a representative western blot above. 
There was no significant alteration in p-CREB expression after injury. Data represents mean + 
SEM; n = 6 per group.  
 
3.4 DISCUSSION 
 
TBI remains a leading cause of disability in industrial countries and has few effective therapies. 
Identification of novel, effective therapeutic targets that can be quickly translated into clinical 
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practice is necessary. The aims of the present study were to evaluate the striatally enriched 
phosphatase DARPP-32 as a novel target for TBI induced dysfunction. We tested the 
hypothesis that TBI induces an acute, persistent dysfunction in DARPP-32 signaling in the 
striatum. 
 
TBI induces a decrease in the phosphorylation of DARPP-32 at Thr34 within striatal MSN that 
occurs acutely and persists for all examined timepoints. The decrease in phosphorylation at 
Thr34 is not due to downregulation or loss of DARPP-32 protein expression (Figure 17), nor is it 
indicative of non-specific dephosphorylation of DARPP-32 as indicated by the lack of change in 
Thr75 phosphorylation (Figure 17). While loss of Thr34 phosphorylation is primarily observed in 
the striatum, it does become apparent in the FC at later timepoints (Appendix A: 
Supplemental Figure 3) indicating that the affect of TBI on the phosphorylation state of 
DARPP-32 is ubiquitous, with the striatum being the most profoundly affected.  
 
The loss of p-DARPP-32-Thr34 seen following a TBI is not restricted to a single area of the 
striatum (Figure 18). There is a noticeable decrease in p-DARPP-32-Thr34 immunoreactivity 
within both the DLStr and the NAcc (Figure 18). Interestingly cell count analysis (Figure 18) 
indicates that in the DLStr the reduction in immunoreactivity is predominantly within the neuropil 
suggesting that p-DARPP-32-Thr34 decreases in the DLStr are within the dendritic trees of the 
MSNs. However, within the NAcc, cell count analysis shows a persistent loss of cell soma 
immunoreactivity for p-DARPP-32-Thr34 (Figure 18) indicating that these two regions may be 
differentially affected by TBI. Analysis of DARPP-32 positive cells (Figure 18) shows that the 
loss of immunoreactivity is not due to TBI causing a loss of DARPP-32 positive neurons within 
the DLStr or NAcc.   
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The MSNs within the striatum are composed of populations that have distinct signaling 
pathways and function (Fink et al., 1992; Gerfen et al., 1990). Prior research has shown that 
drugs of abuse have predominant effects on one subset of neurons as opposed to the other. For 
example, both cocaine and haloperidol increase the phosphorylation of DARPP-32 at Thr34, 
however these two drugs have very different consequences on the ERK signaling pathways in 
the distinct MSN populations (Bertran-Gonzalez et al., 2008). Confocal fluorescent images 
suggest that in TBI the neuronal subpopulations are equally affected, indicating a global 
dysfunction in DARPP-32 phosphorylation which would be consistent with glutamatergic input to 
both sets of neurons (Figure 19). MSN decreases in p-DARPP-32-Thr34 within the DA receptor 
D2 predominant neurons could explain TBI literature indicating that while amphetamines are 
beneficial after TBI, haloperidol, a potent D2 inhibitor, is detrimental (Kline et al., 2008; Hoffman 
et al., 2008). This suggests that TBI induced alterations in DARPP-32 signaling may affect all 
striatal functions, both motor and cognitive, and further examination may help predict drugs with 
detrimental effects similar to haloperidol. 
 
Consistent with the alteration in DARPP-32 phosphorylation there is a significant increase in 
PP1 activity at examined timepoints (Figure 20), indicating that the loss of Thr34 
phosphorylation causes an alteration in relevant downstream DARPP-32 signaling and is not 
merely an isolated dephosphorylation event without effect on the signaling pathway. A 
persistent increase in PP-1 activity following injury has significant implications for MSN function. 
Increased PP-1 activity leads to a decrease in p-CREB and subsequent reduction in nuclear 
transcription of numerous proteins including neurotrophic factors and cell survival signals 
(Genoux et al., 2002; Choe et al., 2005). Furthermore, PP-1 activity is important to the 
regulation of glutamatergic signaling and synaptic plasticity (Centonze, et al., 2001; Kopnisky et 
al., 2003). We examined ERK 1/2 and CREB phosphorylation at both 1 day and 2 weeks post 
injury and found no significant difference in phosphorylation within injured animals compared to 
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sham in whole cell lysates. However, in a separate experiment we examined the nuclear 
fraction of striatal homogenates at 3 weeks and found significantly reduced ERK 1/2 
phosphorylation within the ipsilateral injured striatum compared to sham (Figure 22). Whole cell 
lysates may have hidden the alterations in CREB and ERK 1/2 phosphorylation after injury and 
the utilization of a nuclear extraction allowed us to examine potential phosphorylation alterations 
more carefully. Future examination of nuclear extracts at other timepoints may demonstrate 
CREB and ERK1/2 alterations acutely. A chronic decrease in ERK 1/2 phosphorylation indicates 
that there is ongoing cell signaling pathology that is critically relevant for synaptic plasticity and 
nuclear transcription.  
 
This is the first time that DARPP-32 and PP-1 have been examined following a TBI. Given the 
importance of the DARPP-32/PP-1 signaling pathway within the striatum and frontal cortex and 
its role in behavior, an alteration in function has significant implications for prolonged motor and 
cognitive dysfunction in TBI patients.  
 
Multiple lines of evidence have previously implicated DA as an important player in persistent 
cognitive dysfunction following TBI. Animal studies have consistently demonstrated benefits in 
post-TBI cognitive tasks including learning and memory following the administration of DAergic 
agonists (Dixon et al., 1999; Kline et al., 2004; Wagner et al., 2005).  
 
In this study we have shown an intrinsic alteration in signaling pathway of striatal MSN. The 
alteration in DARPP-32 phosphorylation causes the predicted alteration in the downstream 
signaling target PP1. Persistent loss of DARPP-32 Thr34 phosphorylation in the striatum and 
subsequent alterations in PP1 activity have widespread implications to striatal MSN function. 
After hypoxia-ischemia injury, DARPP-32 phosphorylation states were shown to be important to 
membrane potential, glutamate receptor activity, and oxidative stress (Yang et al., 2007).  
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DARPP-32 acts as a signal transduction molecule with multiple neurotransmitter groups 
modifying DARPP-32 phosphorylation and relevant downstream signaling. DA, glutamate, 
acetylcholine, and calcium signaling all play a role in modulating DARPP-32 within the striatum 
(Hamada et al., 2005; Valjent et al., 2005; Ahn et al., 2007). Following TBI there is well 
documented increases in glutamate release and calcium influx that occur almost immediately 
following injury and contribute to persistent cellular dysfunction (Hovda et al., 1990; Shapira et 
al., 1989; Fineman et al., 1993). Examination of DARPP-32 allows for the analysis of a central 
signaling molecule that is responsive to nearly all of the acute and secondary injuries that 
persist in TBI. The pathology of DARPP-32 alterations that persist following TBI allow for a 
better understanding of ongoing cellular pathology. We have demonstrated a specific decrease 
in the phosphorylation of DARPP-32-Thr34 and corollary increase in PP-1 activity (Figure 17 
and Figure 20) within the striatum. A number of possible mechanisms exist that could explain 
the alteration in DARPP-32 signaling including specific changes in neurotransmitter systems, 
such as a decrease in DA signaling or increases in glutamatergic release. There could also be 
neurotransmitter independent intracellular events such as calcium release or changes in 
phosphatase and kinase activity.  
 
Alterations in PKA activity could also lead to a change in DARPP-32 phosphorylation and could 
independently affect PP-1 activity (Waltereit et al., 2003). To evaluate this possibility we 
examined PKA activity at both 1 day and 2 weeks post TBI. Unlike DARPP-32 phosphorylation 
which stayed consistently depressed over the timecourse evaluated and PP-1 activity which 
stayed consistently increased at 1 day and 2 weeks, PKA demonstrated a timepoint dependent 
alteration in activity. At 1 day post injury PKA was significantly decreased in both the ipsilateral 
and contralateral striatum (Figure 21) which is consistent with both the decrease in p-DARPP-
32-Thr34 and an increase in PP-1 activity (Greengard et al., 1999; Nairn et al., 2004). However, 
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at the more chronic timepoint of 2 weeks PKA is significantly increased in both the ipsilateral 
and contralateral injured striatum compared to sham. This may explain why PP-1 activity within 
the contralateral striatum is not significantly increased at 2 weeks given that an increase in PKA 
activity would theoretically lead to decreased PP-1 activity. The increase in PKA activity in the 
ipsilateral striatum may be unable to overcome more significant pathology within this side of the 
injured striatum. Further evidence of ongoing pathology within the ipsilateral striatum is 
confirmed by a significant reduction in ERK phosphorylation within the ipsilateral nuclear fraction 
at a 3 week timepoint (Figure 22). This suggests that the ongoing dysfunction in DARPP-32/PP-
1 pathway signaling continues to play an important role in chronic cell signaling even with 
events that should act to increase downstream activity.  
 
Given the complexities of TBI, the identification of acute and persistent DARPP-32 alterations 
after TBI is most likely indicative of multiple ongoing disease processes. Thus, treatments aimed 
at molecular targets that are integrative, such as DARPP-32, allow for targeted therapeutics that 
can potentially correct signaling deficiencies through multiple mechanisms.  
 
3.5 CONCLUSION 
 
This study provides the first evidence of a TBI induced alteration in DARPP-32 signaling in the 
striatum of injured animals. The data presented indicates that the decrease in p-DARPP-32-
Thr34 following TBI leads to a functionally relevant alteration in downstream PP-1 activity and is 
relatively striatal specific. Furthermore, there appears to be a difference in the response of 
striatal subregions (DLStr vs. NAcc). The present results further implicate persistent striatal 
cellular dysfunction in prolonged cognitive difficulties seen following TBI.  
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4. TARGETING STRIATAL DYSFUNCTION: THERAPEUTIC INTERVENTIONS 
 
 
4.1 INTRODUCTION 
 
In the prior chapter we established that following TBI there is a significant, persistent 
dysfunction in striatal DARPP-32 signaling.  While the neurological and cognitive consequences 
of TBI are numerous and complex, the most common include memory impairment and 
difficulties with attention and concentration, functions that are mediated by multiple brain 
structures. The striatum is functionally important for both cognitive and motor behaviors (Divac 
et al., 1967; Ding et al., 2001). Focal damage to the striatum in non-human primates and rats 
results in difficulties with spatial working memory (Miyoshi et al., 2002). Studies investigating 
dementia in Parkinson’s (PD) and Huntington’s disease (HD) indicate the striatum is part of a 
neuronal network mediating prefrontal executive functions (Backman et al., 1997; Duchesne et 
al., 2002). The striatum is also particularly vulnerable to damage from TBI including axonal 
degeneration, neuronal cell loss, and ischemia (Dietrich et al.,1998). Functionally, the striatum 
acts as a convergence point for signals from multiple systems.  Glutamatergic projections from 
the frontal lobes of the cortex and DAergic projections from the substantia nigra pars compacta 
both synapse upon the predominant neuronal cell type within the striatum - medium-sized, 
spiny, GABA-ergic neurons (Nishi et al., 2002; Nairn et al., 2004).  
 
DA induced phosphorylation of ionotropic glutamate and GABA receptors is attenuated in 
DARPP-32 KO mice suggesting that DARPP-32 plays an important role in regulating 
excitotoxicity (Flores-Hernandez et al., 2002; Borgkvist al., 2007). Ethanol reinforcement, which 
is known to act through regulation of NMDA receptors, is also reduced in DARPP-32 KO models 
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(Risinger et al., 2001). Studies assessing the behavioral affects of other drugs of abuse, 
including cocaine and morphine, have shown that DARPP-32 KO mice demonstrate lower levels 
of psychomotor activation following drug administration compared to wild-type mice (Borgkvist 
et al., 2007).  Further evidence using KO mice indicates that DARPP-32 has an important role in 
long-term depression (LTD) and long-term potentiation (LTP), both important processes in 
models of memory acquisition and consolidation which represents areas of dysfunction common 
to TBI patients.   
 
This study represents the first to examine DARPP-32 phosphorylation as a therapeutic target 
following a TBI. DA targeted therapies assist in cognitive recovery, but remain unable to 
completely restore function and patient response can be variable. A therapeutic approach 
utilizing a combined drug strategy to affect multiple components of the DARPP-32 system as 
well as other brain regions may overcome current therapeutic limitations.  
 
DARPP-32 has previously been proposed as a therapeutic target in Parkinson’s Disease (PD) 
(Coccurello et al., 2004), given its importance to both motor and cognitive functions of the 
striatum. In addition to DA agonists, NMDA antagonists, such as Amantadine Hydrochloride 
(AMH), are potential mediators of DARPP-32 signaling in PD (Greenamyre and O’Brien, 1992).  
 
AMH has known DAergic action that has shown both experimental and clinical benefits in 
cognitive recovery following TBI (Table 2). The experimental administration of FK-506 has been 
shown to improve cognition following TBI through decreases in white matter damage with FK-
506 administration (Butcher et al., 1997; Reeves et al., 2007). Furthermore FK-506 is a potent 
calcineurin inhibitor and calcineurin is directly involved in regulating the phosphorylation state of 
DARPP-32. By utilizing a combined treatment approach with FK-506 acutely and AMH 
chronically we hypothesize that we will be able to produce a synergistic effect within the striatum 
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providing improvements in DARPP-32 phosphorylation state and cognitive outcome above 
either drug alone.  Figure 24 demonstrates the theoretical affect of a combined treatment 
strategy of FK-506 and AMH on DARPP-32 within the striatum.  
 
Figure 24: The combination therapy of Amantadine (AMH) and FK-506 should additively act to 
increase DARPP-32-Thr34 phosphorylation and decrease protein phosphatase-1 (PP-1) 
activity. The inhibition of NMDA receptors and activation of D1 receptors is a theoretical 
mechanism for AMH action that coupled with the known inhibition of calcineurin by FK-506, 
would theoretically increase DARPP-32-Thr34 phosphorylation above the use of either drug 
alone. 
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We hypothesize that chronic administration of AMH (10 mg/kg i.p.) will attenuate TBI induced 
alterations in DARPP-32 phosphorylation. We hypothesize that a single (at 5 mins post injury) 
administration of FK-506 (2 mg/kg i.p.) will reverse TBI induced alterations in DARPP-32 
phosphorylation. We hypothesize that the DARPP-32 phosphorylation effects of FK-506 and 
AMH will be dose dependent. We hypothesize that a combined treatment of chronic AMH with 
acute FK-506 will further reverse TBI induced alterations in DARPP-32 phosphorylation and its 
targets and show a synergistic improvement of cognitive recovery as assessed using the Morris 
water maze task. This represents the first study to analyze a combination therapy of FK-506 and 
Amantadine to address long term cognitive dysfunction following TBI. 
 
4.2 METHODS AND MATERIALS 
 
4.2.1 Animals 
 
Adult male Sprague-Dawley rats (N = 152) were used in the study. Rats (275-325 g) were 
purchased from Hilltop Laboratories (Scottsdale, PA, USA) and housed in pairs under a 12:12 
light/dark cycle. Rats were given food and water with ad libitum throughout the study. All 
experiments were carried out in accordance with the University of Pittsburgh’s guidelines for the 
Care and Use of Laboratory Animals. All experiments were approved by the Institutional Animal 
Care and Use Committee of the University of Pittsburgh.     
 
4.2.2 Surgical Procedures for TBI 
 
On the day of surgery anesthesia was initiated with 4% isoflurane (IsoFlo; Abbott Laboratories, 
North Chicago, IL, USA) and 2:1 N2O/O2. Rats were intubated and maintained on 1.5-2% 
isofluorane during the surgical procedure. Following intubation, rats were placed on a thermal 
127 
 
blanket to regulate body temperature (37oC) and the animals head placed in a stereotaxic 
frame. An incision was made down the midline of the skull and the soft tissues and periosteum 
deflected. A craniotomy was then performed over the right parietal bone to expose the dura. 
Controlled cortical injury (CCI, Pittsburgh Precision Instruments, Inc.) at a depth of 2.6mm at 
4m/sec was carried out as previously reported. A total of 100 rats were injured, and the 
remaining 52 rats were shams. Righting reflex was monitored in the immediate post-surgical 
period to assess acute recovery. 
 
4.2.3 Drug Treatment Protocols 
 
AMH Treated Animals for dosage study and protein phosphatase-1 assay: For the 6 hour AMH 
timepoint: 30 mins post CCI surgery animals received an i.p. injection of AMH (10 mg/kg; 
Sigma, St. Louis, MO) dissolved in 0.9% physiological saline (n = 6) or saline alone (n = 6); 
sham animals received only saline (n = 6). For the 2 week AMH timepoint: beginning one day 
post CCI surgery animals received daily i.p. injections of AMH (10 mg/kg or 5 mg/kg or 1 mg/kg; 
Sigma, St. Louis, MO) dissolved in physiological saline (n = 18) or saline alone (n = 6); sham 
animals received only saline (n = 6). AMH was made fresh weekly. 
 
FK-506 Treated Animals for dosage study: For the 6 hour FK-506 timepoint: 5 mins post CCI 
surgery animals received an i.p. injection of FK-506 (2.0 mg/kg) dissolved in 0.9% physiologic 
saline (n = 6) or saline alone (n = 6); sham animals received only saline (n = 6). For the 2 week 
FK-506 timepoint: 5 mins post CCI surgery animals received an i.p. injection of FK-506 (2.0 
mg/kg or 1.0 mg/kg or 0.5 mg/kg) dissolved in 0.9% physiologic saline (n = 18) or saline alone 
(n = 6); sham animals received only saline (n = 6). FK-506 was diluted from stock on day of use. 
 
Eighty rats (n = 20/treatment; 10 sham and 10 injured as described in Table 6) underwent CCI. 
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At 5 minutes post injury FK-506 (1.0 mg/kg i.p.) was administered to the FK-506 alone and 
combined groups (n = 40 total). Beginning at 24 hours post injury AMH (5 mg/kg i.p.) was 
administered to the AMH alone and combined group rats (n = 40 total) daily for 18 days. 
Combination therapy included the single injection of FK-506 with chronic AMH. Saline treated 
animals were used for controls. At days 1-5 post injury animals underwent motor testing at days 
14-19 post injury all animals underwent Morris water maze testing. 
 
TABLE 6: Protocol for 
combination therapy 
following TBI 
Treatment: 
Saline 
(daily i.p.) 
FK-506 
(1.0 
mg/kg i.p. 
once 5 
mins post 
injury) 
AMH 
(5.0 mg/kg 
i.p. daily) 
Combined 
(Single dose 
FK-506 plus 
daily AMH)  
 
Analysis:  
Histology N=4 N=4 N=4 N=4  
     
Excised tissue for western 
blot analysis of DARPP-32, 
PP1, PKA 
N=6 N=6 N=6 N=6 
Total N for motor and 
cognitive tasks: 
10 10 10 10 80 
total 
 
4.2.4 Motor Performance 
Established beam-balance and beam-walk tasks were used to assess motor function. Briefly, 
the beam-balance task consists of placing the rat on an elevated (90 cm) narrow beam (1.5 cm 
wide) and recording the time it remains on up to a maximum of 60 sec. The beam-walk task, 
originally devised by Feeney and colleagues (1982), consists of training/assessing rats using a 
negative-reinforcement paradigm to escape a bright light and white noise by traversing a narrow 
elevated beam (2.5× 100 cm), and entering a darkened goal box situated at the opposite end. 
When the rat entered the goal box the adverse stimuli (light and noise) were terminated, thus 
serving as negative reinforcement (reward) for completing the task. Performance was assessed 
by recording the time it took for the rat to traverse the beam. The rats were trained on both 
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motor tasks 1 day prior to surgery, and baseline performance was assessed on the day of 
surgery. Post-surgery motor function was assessed on postoperative days 1–5. Balance and 
traversal times were recorded. Each rat was given three trials (60 sec allotted time with an inter-
trial interval of 30sec) per day on each task. The average daily scores for each subject were 
used in the statistical analyses. 
4.2.5 Cognitive Function 
Spatial learning was assessed for five consecutive days (postoperative days 14–18) in a Morris 
water maze (MWM) task established as a sensitive measure of cognitive function after TBI 
(Hamm et al., 1992; Hoffman et al., 2008; Kline et al., 2001, 2002; Scheff et al., 1997). Briefly, 
the maze consisted of a plastic pool (180 cm diameter and 60 cm high) filled with tap water (26 ±
1°C) to a depth of 28 cm that was situated in a room with salient visual cues that remained 
constant throughout the study. The platform was a clear acrylic glass stand (10 cm diameter and 
26 cm high) that was positioned 26 cm from the maze wall in the southwest quadrant and held 
constant for each rat. Each rat was given a block of four daily trials (120 sec allotted time with an 
inter-trial interval of 4 min) to locate the platform when it was submerged 2 cm below the water's 
surface (i.e., invisible to the rat). To control for the contributions of non-spatial factors (e.g., 
sensorimotor performance, motivation, and visual acuity) on maze performance, each rat was 
provided with two additional day (postoperative days 19 and 20) of testing to locate the platform 
when it was raised 2 cm above the water's surface (i.e., visible to the rat). For each daily block 
of trials the rats were placed in the pool facing the wall at each of the four possible start 
locations (north, east, south, and west) in a randomized manner. Each trial lasted until the rat 
climbed onto the platform or until 120 sec had elapsed, whichever occurred first. Rats that failed 
to locate the platform within the allotted time were manually guided to it by the experimenter. All 
rats remained on the platform for 30 sec before being placed in a heated incubator between 
trials. The average time of the four daily trials for each rat were used in the statistical analyses. 
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To measure retention of spatial learning all rats were given a single probe trial on postoperative 
day 19, which was 1 day after the final acquisition training session. Briefly, the platform was 
removed from the pool and the rats were placed in the maze at a location most distant from the 
quadrant where the platform was previously situated (i.e., the target quadrant) and allowed to 
freely explore the pool for 30 sec. In principle, rats that have learned the specific location of the 
hidden escape platform will exhibit a spatial bias and thus spend significantly more time in the 
target quadrant. All the data, which included time to locate the platform, distance to the platform, 
time in the target quadrant, and swim speed (assessed during the visible platform test), were 
obtained using anymaze tracking software and system. 
4.2.6 Cortical Lesion Volume 
The area of the lesion (mm2) was calculated in a subset (n= 4) of TBI animals from each 
treatment condition by outlining the cortical lesion for each section taken at 0.7-mm intervals 
through the extent of the lesion (ImageJ; NIH). The volume (mm3) of the lesion was determined 
by summing the areas of the lesion obtained from each section, as previously reported (Cheng 
et al., 2008; Hoffman et al., 2008; Kline et al., 2004). 
4.2.7 Western Blot Analysis 
 
Animals (n = 6 in each timepoint for each group for a total n = 48 for animals used in behavioral 
analysis; n = 3-6 per group for AMH and FK-506 studies not part of behavioral studies). After 
deeply anesthetized with pentobarbital (Nembutal, 80-100 mg/kg; Abbott Laboratories, North 
Chicago, IL), animals were decapitated and the brains quickly removed and chilled on ice. 
Tissue from the striatum was excised and frozen in liquid nitrogen. Tissue was stored at -70°C 
until used for analysis.  
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Preparation of nuclear extracts used in western blot analysis.  Nuclear fractions were prepared 
utilizing a nuclear extraction kit (Active motif,Carlsbad, CA). Briefly, frozen tissue was 
homogenized on ice with 250 ul of 1x Hypotonic buffer with DTT and detergent. Homogenized 
tissue was centrifuged for 10 minutes at 850 x g at 4°C. Cells were resuspended in 250 ul of 1x 
Hypotonic buffer by pipetting up and down and incubated on ice for 15 minutes. 15 ul of 
detergent was added and the suspension was vortexed for 10 seconds. Suspension was then 
centrifuged for 30 seconds at 14,000 x g at 4°C. Supernatant was collected (cytoplasmic 
fraction). The remaining pellet (nuclear fraction) was resuspended in 100 ul of complete lysis 
buffer and vortexed for 10 seconds. Suspension was incubated for 30 minutes on ice on a 
rocking platform. Suspension was then vortexed for 30 seconds and centrifuged for 10 minutes 
at 14,000 x g at 4°C. Supernatant was collected (nuclear fraction). Fractions were used for 
western blot analysis as described below. 
  
Protein concentrations were determined using a BCA protein Assay Kit (PIERCE, Rockford, IL). 
Samples containing 20-100 g of protein were subjected to SDS-polyacrylamide gel 
electrophoresis through a 10% acrylamide gel, and after were transferred to nitrocellulose 
membranes. Membranes were blocked with 5% bovine serum albumin (Sigma, St. Louis, MO) 
in tris-buffered saline (TBS-T). Following block membranes were washed 3 x 10 minutes in 
TBS-T and immunolabeled with antibodies (1:10,000 DARPP-32; 1:2000 p-DARPP-32-Thr34; 
1:2000 p-DARPP-32-Thr75; Cell Signaling, Danvers, MA) in 5% BSA in TBST for 18-24 hours. 
Following primary incubation membranes were washed 3 x 10 minutes in TBS-T and incubated 
for 2 hours in by goat anti-rabbit immunoglobulin G conjugated to peroxidase (1:10,000; 
PIERCE, Rockford, IL). Proteins were visualized with a chemiluminescence detection system 
(SuperSignal, PIERCE, Rockford, IL). To assure equal loading, all membranes were striped and 
re-blotted with rabbit anti-actin antibody (1:20,000, Sigma, St. Louis, MO). Blots were exposed 
to autoradiographic X-ray film for 10 s to 2 min and bands were semi-quantified using ImageJ 
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(NIH, USA) software. Values are given as a ratio (percentage change) of optical density of 
injured samples versus sham control within individual blots. All optical densities were 
normalized to β-actin. 
 
4.2.8 Statistical Analysis 
 
Statistical analyses were performed on data collected using SPSS 12.0 (Abacus Concepts, Inc., 
Berkeley, CA). The motor and cognitive data were analyzed by repeated-measures analysis of 
variance (ANOVA). The data for acute neurological assessments, histology, probe trial, and 
swim speed were analyzed by one-factor ANOVAs. When the overall ANOVA revealed a 
significant effect, the data were further analyzed with the Bonferroni/Dunn post-hoc test to 
determine specific group differences. The data are presented as the mean ±standard error of 
the mean (SEM), and are considered significant when corresponding p values are ≤0.05, or as 
determined by the Bonferroni/Dunn statistic after adjusting for multiple comparisons. Optical 
density of western blot bands from each group were compared according to a two-factor 
ANOVA (time versus injury) followed by Bonferroni post-hoc comparison with a significance 
level of p ≤0.05. Western blot data are expressed as the group means ± standard error (S.E.) of 
the mean. Phosphatase activity data are expressed as the group means ± standard deviation. 
Statistical evaluations were performed according to ANOVA with a significance level of p ≤ 0.05 
used for all tests. 
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4.3 RESULTS 
 
4.3.1 Amantadine Treatment Post Traumatic Brain Injury Attenuates the Alteration in the Striatal 
DARPP-32 Signaling Cascade 
 
Clinically AMH has shown benefit in both Parkinson’s Disease (Brenner et al., 1989) and TBI 
(Kraus et al., 2005). AMH has also shown beneficial effects in the CCI model of TBI (Dixon et 
al.,1999), showing an improvement in Morris water maze following 2 weeks of treatment. 
However, it remains unclear what the exact mechanisms of AMH benefit in TBI is. Given AMH’s 
effects on DA and glutamate DARPP-32 represents a potential signaling molecule for AMH 
action. We therefore analyzed the effect of AMH on DARPP-32 following TBI (Figure 25). 6 
hours following injury a single dose of AMH (10 mg/kg i.p.) given at 30 mins post injury 
demonstrated a significant attenuation of the loss in p-DARPP-32-Thr34 (p<0.05) seen with TBI 
(p<0.001) (Figure 25). 2 weeks of AMH given daily (10 mg/kg i.p.), as described previously 
(Dixon et al., 1999), demonstrated an increase in p-DARPP-32-Thr34 over the level in sham 
animals in both the ipsilateral (p<0.001) and contralateral (p<0.01) striatum (Figure 25). There 
was also a significant reduction in p-DARPP-32-Thr75 with chronic AMH treatment compared to  
sham striatum (Contralateral p<0.05; ipsilateral p<0.05) (Figure 25). AMH effects on DARPP-32 
phosphorylation are consistent with the proposed mechanisms of AMH activity as both a partial 
DAergic agonist and partial NMDA receptor antagonist. In particular partial inhibition of NMDA 
receptors should reduce Ca2+ signaling within the MSN thus leading to an increase in DARPP-
32 phosphorylation at Thr34 while leading to a decrease in DARPP-32 phosphorylation at 
Thr75. To determine whether the attenuation of p-DARPP-32-Thr34 decreases was functionally 
significant the effect of daily AMH treatment for 2 weeks post injury on PP-1 activity was 
assessed. Rats treated with AMH daily (10 mg/kg i.p.) for 2 weeks showed significantly reduced 
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PP-1 activity compared to animals receiving vehicle (p<0.001) (saline injection) (Figure 25). 
There was no effect of AMH treatment on DARPP-32 protein expression 
 
 
Figure 25. Analysis of AMH effects on DARPP-32 signaling post TBI. A,  Single dose of AMH 
(10 mg/kg i.p.) given 30 mins post injury. Striatal DARPP-32 phosphorylation at 6 hours post 
injury. AMH effectively reduces the level of p-DARPP-32-Thr34 loss following TBI. 
Representative western blot of ipsilateral striatum (above) and optical density (below) of p-
DARPP-32-T34. (N=6/group; p<0.05 normalization to β-actin compared to TBI with vehicle; 
ANOVA). Data represented as  percentage of sham following normalization to β-actin ± S.E. B, 
Chronic AMH (10 mg/kg i.p. daily) on striatal DARPP-32 phosphorylation at 2 weeks post injury. 
Chronic AMH administration reverses the loss of p-DARPP-32-Thr34 seen with a TBI and 
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increases p-DARPP-32-Thr34 above sham levels. (N=6/group; p<0.01 normalization to β-actin 
compared to TBI with vehicle; ANOVA). Data represented as  percentage of sham following 
normalization to β-actin ± SEM C, Chronic AMH (10 mg/kg i.p. daily) on striatal PP-1 activity. 
Following chronic AMH administration there is a reduction in PP-1 activity compared to TBI with 
vehicle.  (N=6/group; p<0.01; ANOVA). Data represents means ± standard deviation. D, Chronic 
AMH (10 mg/kg i.p. daily) on striatal p-DARPP-32-Thr75 at 2 weeks post injury. Chronic AMH 
decreases the levels of p-DARPP-32-Thr75 compared to injury.. (N=6/group; p<0.01 
normalization to β-actin compared to TBI with vehicle; ANOVA). Data represented as  
percentage of sham following normalization to β-actin ± SEM. Abbreviations: AMH = 
Amantadine hydrochloride, DARPP-32 = Dopamine and cAMP regulated phosphoprotein 32; 
TBI = Traumatic Brain Injury.  
. 
4.3.2 The level of DARPP-32 phosphorylation at Thr34 is dose dependent with respect to AMH. 
 
We administered 1 mg/kg i.p., 5 mg/kg i.p., and 10 mg/kg i.p. of AMH to rats (n=3 per group for 
1 and 5 mg/kg groups) for 2 weeks to evaluate the dose dependent affect of AMH on DARPP-
32 phosphorylation post TBI. There was no significant effect of AMH 1 mg/kg i.p. on p-DARPP-
Thr34 levels post injury compared to injured vehicle. There appears to be a dosage dependent 
effect of 1 and 5 mg/kg i.p. on p-DARPP-32-Thr34 levels post injury compared to injured vehicle 
(Figure 26), however the effect was not as impressive as that seen with 10 mg/kg i.p. (Figure 
25).  
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Figure 26: Qualitative western blot demonstrating a dosage response of p-DARPP-32-Thr34 to 
AMH at 5.0 and 1.0 mg/kg i.p. given daily for 2 weeks (n=3 for AMH groups). 
 
4.3.3 FK-506 Given acutely post-TBI Attenuates the Alteration in DARPP-32-Thr34 
phosphorylation. 
 
FK-506 is a potent inhibitor of calcineurin that has demonstrated significant neuroprotection in 
experimental TBI (Butcher et al., 1997). Calcineurin is a key regulator of DARPP-32 
phosphorylation. Increases in calcineurin activity cause a dephosphorylation of DARPP-32 at 
Thr34. Therefore inhibition of calcineurin activity should reduce a loss of DARPP-32/Thr34 
phosphorylation if calcineurin is activated post TBI in the striatum. A single acute administration 
of FK-506 (2.0 mg/kg i.p.) given at 5 mins post TBI demonstrates a significant increase in p-
DARPP-32-Thr34 over TBI animals receiving vehicle (n=6 per group) at 6 hours post injury. This 
benefit of FK-506 administration extends into chronic timepoints with a demonstrated 
attenuation of p-DARPP-32/Thr34 loss at 2 weeks post TBI compared to vehicle treated animals 
(Figure 27). 
 
137 
 
 
Figure 27: Analysis of FK-506 effects on DARPP-32 signaling post TBI. Left, Single dose of 
FK-506 (2.0 mg/kg i.p.) given 5 mins post injury. Striatal DARPP-32 phosphorylation at 6 hours 
post injury. FK-506 effectively reduces the level of p-DARPP-32-Thr34 loss following TBI. 
Optical density of ipsilateral striatum p-DARPP-32-T34. (N=5/group; p<0.05 normalization to β-
actin compared to TBI with vehicle; ANOVA). Data represented as a percentage of sham 
following normalization to β-actin ± SEM. Right, Single dose of FK-506 (2.0 mg/kg i.p. 5mins 
post injury) on striatal DARPP-32 phosphorylation at 2 weeks post injury. Acute FK-506 
administration reverses the loss of p-DARPP-32-Thr34 seen with a TBI. (N=6/group; p<0.01 
normalization to β-actin compared to TBI with vehicle; ANOVA). Data represented as  
percentage of sham following normalization to β-actin ± SEM.  
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4.3.4 The level of DARPP-32 phosphorylation at Thr34 is dose dependent with respect to FK-
506. 
 
We administered 0.5 mg/kg i.p., 1 mg/kg i.p., and 2 mg/kg i.p. of FK-506 to rats (n=3 for 0.5 and 
1 mg/kg  groups) at 5 mins post TBI to evaluate the dose dependent affect of AMH on DARPP-
32 phosphorylation post TBI. There appears to be a dose response to FK-506 at 0.5 mg/kg i.p. 
and 1.0 mg/kg i.p. (Figure 28) which was more modest than the effect seen with FK-506 2.0 
mg/kg i.p. (Figure 27). 
 
 
Figure 28: Qualitative western blot demonstrating a dosage response of p-DARPP-32-Thr34 to 
a single dose FK-506 5 mins post injury at 1.0 and 0.5 mg/kg i.p. (n=3 for FK-506 groups). 
 
4.3.5 Combination therapy of FK-506 and AMH is able to restore DARPP-32-Thr34 
phosphorylation levels. 
 
To evaluate the effect of a combination therapy of FK-506 and AMH on striatal DARPP-32 
dysfunction after TBI we chose to utilize doses of both drugs that demonstrated minimal 
increases in DARPP-32-Thr34 phosphorylation independently to maximize the potential for 
synergistic evaluation. A combined therapy of a single acute administration of FK-506 given 5 
mins post injury (1.0 mg/kg i.p.) and AMH (5 mg/kg i.p.) given once daily for 2 weeks was 
utilized (n = 6 animals per group). Combination therapy demonstrated significant increases in p-
DARPP-32-Thr34 over vehicle treated animals (Figure 29).  
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Figure 29: Analysis of combined FK-506 (1.0 mg/kg i.p. once 5 mins post injury) plus AMH (5 
mg/kg i.p. daily) effects on DARPP-32 signaling post TBI. Left, p-DARPP-32-Thr34 levels 3 
weeks post injury with vehicle treatment. There is a significant decrease in p-DARPP-32-Thr34 
expression in the ipsilateral injured striatum compared to sham (p<0.01). Optical density of 
ipsilateral striatum p-DARPP-32-T34. (N=6/group; p<0.01 normalization to β-actin compared to 
sham with vehicle; ANOVA). Data represented as a percentage of sham following normalization 
to β-actin ± SEM. Right, Combined treatment of a single dose of FK-506 (1.0 mg/kg i.p. 5mins 
post injury) plus daily AMH (5 mg/kg i.p.) on striatal DARPP-32 phosphorylation at 3 weeks post 
injury. Combined treatment reverses the loss of p-DARPP-32-Thr34 seen with a TBI above 
sham levels. (N=6/group; p<0.01 normalization to β-actin compared to TBI with combination 
therapy; ANOVA). Data represented as percentage of sham following normalization to β-actin ± 
SEM. 
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4.3.6 Combination therapy of FK-506 and AMH attenuates ERK phosphorylation decreases in 
striatal nuclear fractions post TBI. 
 
Prior research examining drug therapies on DARPP-32 phosphorylation have shown significant 
increases in ERK 1/2 and CREB (Ser133) phosphorylation. Increases in the phosphorylation of 
these two nuclear signaling molecules are associated with increases in nuclear transcription 
associated with synaptic plasticity and learning. Prior evaluation in whole cell lysates discussed 
in the previous chapter demonstrated no effect of TBI on ERK or CREB phosphorylation. 
However, analysis of nuclear fractions demonstrated a significant decrease in ERK 1/2 
phosphorylation at 3 weeks following injury, consistent with increases in PP-1 activity seen at 2 
weeks following TBI. Utilizing nuclear extraction we evaluated the effect of the combination 
therapy on ERK 1/2 and CREB phosphorylation following TBI. There was no significant 
difference between sham and injured animals with combination drug therapy in either ERK 1/2 
(Figure 30) or CREB (Figure 31) phosphorylation indicating that combination therapy effectively 
attenuated the loss of ERK 1/2 phosphorylation seen with TBI. 
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Figure 30: Analysis of nuclear fraction ERK 1/2 expression and Thr202/Tyr204 (p-ERK 1/2) 
phosphorylation in the striatum at 3 weeks post experimental TBI with a combined treatment of 
FK-506 (1.0 mg/kg i.p. given 5 mins post injury) and AMH (5 mg/kg i.p. given daily). 
Densitometry of p-ERK 1/2 normalized to total ERK 1/2 expression shown below with a 
representative western blot above. There was no significant difference in p-ERK 1/2 expression 
in the injured ipsilateral striatum compared to sham. Data represents mean + SEM; n = 6 per 
group.  
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Figure 31: Analysis of nuclear fraction CREB expression and p-CREB (Ser133) 
phosphorylation in the striatum at 3 weeks post experimental TBI with combined FK-506 (1.0 
mg/kg i.p. given 5 mins post injury) and AMH (5 mg/kg i.p. given daily). Densitometry of p-CREB 
normalized to total CREB expression shown below with a representative western blot above. 
There was no significant decrease in p-CREB expression after injury. However, there was a 
significant increase in p-CREB expression in the ipsilateral injured side compared to sham 
(ANOVA p<0.05). Data represents mean + SEM; n = 6 per group.  
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4.3.7 Single therapy of FK-506 and combination therapy of FK-506 and AMH reduces lesion 
volume post TBI. 
 
To evaluate potential neuroprotective properties of our therapeutic approach we examined 
lesion volumes following CCI in vehicle versus combined therapy animals (n=4 per group). 
There was a significant difference (p<0.05) in the lesion volumes between TBI plus FK-506 
(27.9±1.53 mm3) versus vehicle and combination therapy (25.9±2.2 mm3) compared to TBI 
plus vehicle (33.4±1.5 mm3) (Figure 32). There was no difference between TBI plus AMH alone 
and vehicle groups. This suggests that FK-506 alone or in combination is able to provide a level 
of neuronal protection in CCI consistent with previous reports in FP injury (sample images in 
Appendix A: Supplemental Figure 4).   
 
 
Figure 32: Mean ± SEM of cortical lesion volume (mm3) 3 weeks after cortical impact injury. 
*p<0.05 versus TBI + vehicle. 
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4.3.8 No difference in acute neurological function amongst groups. 
 
No significant differences were observed amongst the TBI groups in latency to elicit a 
withdrawal reflex in response to a brief paw pinch of the left limb (range 365.25±20.5 sec to 
378±21.5), or for the return of righting ability (range 462±8.5 sec to 519±12.6 sec) after the 
cessation of anesthesia. The lack of significant group differences in these acute neurological 
indices suggests that all rats experienced an equivalent level of brain injury and anesthesia. 
 
4.3.9 Combination therapy of FK-506 and AMH reduces motor deficits following a TBI. 
 
No pre-surgical beam-balance differences were observed among groups, all rats were capable 
of balancing for the allotted 60 sec (Figure 33). However, a repeated-measures ANOVA on 
post-TBI data demonstrated significant group (p<0.001) and day (p<0.001) differences, as well 
as a significant group x day interaction (p<0.001). Bonferroni post-hoc analyses revealed that 
AMH alone (p<0.05), FK-506 alone (p<0.001), and vehicle treated (p<0.001) groups were able 
to balance for significantly shorter time periods over the testing period than sham controls, while 
the combined AMH and FK-506 treated group was not statistically different from sham (p>0.05). 
No other group comparisons were significant. Similar to the beam-balance task, there were no 
pre-surgical differences in beam-walking among groups (Figure 34). Following TBI a repeated-
measures ANOVA demonstrated significant group (p<0.001) and day (p<0.001) differences, as 
well as a significant group x day interaction (p<0.001). Bonferroni post-hoc analyses revealed 
that all injured groups had significantly longer latencies over the testing period than sham 
controls (p<0.001). 
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Figure 33: Beam balance task assessed at days 1-5 post injury. All sham groups compiled into 
a single line to clarify data due to significant differences between sham treatments. For repeated 
measures ANOVA analysis TBI groups were compared to their sham controls. All animals were 
pre-assessed on day 0 at the same level. Day 1 indicates 1 day post injury or sham surgery. 
The combined group demonstrated no significant difference from sham over time compared to 
other injury groups which demonstrated significance compared to sham (p<0.001). Data 
represents mean time on beam ± SEM. 
 
 
Figure 34: Beam walk latency on days 1-5 post injury. Sham groups were compiled into one to 
simplify the data presentation. All injured groups were compared utilizing a repeated measures 
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ANOVA with Bonferroni post-hoc analysis against their respective sham group. All injured 
groups took significantly longer to traverse the beam over the recovery period than sham 
(p<0.001). Data presented as mean latency ± SEM. 
  
4.3.10 Combination therapy of FK-506 and AMH improves spatial learning post TBI. 
 
Analysis of spatial learning revealed significant group (p<0.001) and day (p<0.001) effects. 
Bonferroni post-hoc analyses demonstrated the combination therapy group (AMH plus FK-506) 
was not statistically different from sham controls concerning the time to locate the escape 
platform over the testing period. All other injury groups (Vehicle, AMH alone, FK-506 alone) 
were significantly different (all p<0.001) from sham controls. No injury group was significantly 
different than any other (Figure 35). A repeated-measures ANOVA performed on the visible 
platform data revealed significant group (p<0.001) and day (p=0.001) effects, as well as a 
significant group x day interaction (p<0.001). Bonferroni post-hoc analyses demonstrated 
significantly increased time to find escape platform latencies for both the vehicle treated 
(p<0.001), AMH alone treated (p<0.001) groups compared to sham controls. There was no 
significant difference in the time to find platform for the FK-506 alone or combination of AMH 
and FK-506 groups compared to shams (Figure 35). No significant differences in swim speed 
(range= 27.8±0.88 cm/sec to 33.8±1.63 cm/sec) were observed between groups. 
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Figure 35: Morris water maze data assessed on days 14-18 for submerged (hidden) platform 
and days 19-20 for visible platform. All injury groups were significantly different from sham 
(p<0.001) except the combined treatment group for latency to find submerged platform. Sham 
groups were combined for ease of visualization but were not combined for analysis. Data 
represents mean latency to find the platform ± SEM.  
 
Analysis of probe trial data revealed no significant difference between any of the groups on 
percentage of time spent within the target quadrant (Figure 36). 
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Figure 36: Analysis of probe trial on day 19. Mean time spent in target quadrant as a 
percentage of total time ± SEM. No significant differences between any groups as analyzed with 
ANOVA. 
 
4.4 DISCUSSION 
 
Cellular death remains the most prominent target in post-TBI therapeutic research. However, 
often the ability to protect cells from death is not associated with significant improvements in 
behavioral function. In addition, many therapeutic strategies that have shown benefit 
demonstrate little to no neuroprotection. To address these concerns two areas of ongoing TBI 
research have arisen. One, identify novel therapeutic targets that may be more pertinent to 
behavioral dysfunction than neuronal death and two, utilize combination drug treatments in 
order to increase the level of neuroprotection and potentially treat other cellular pathology. In 
this study we have addressed both of these avenues of research. We evaluated DARPP-32 as 
a potential therapeutic target following TBI and we utilized a combined drug therapy approach to 
assess DARPP-32’s viability.   
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We have shown that AMH hydrochloride, a partial NMDA antagonist with catecholaminergic 
effects, can effectively restore sham levels of p-DARPP-32-Thr34 in injured animals (Figure 
25). AMH improves cognitive function in CCI injured animals (Dixon et al.,1999). The exact 
mechanism of AMH’s action following a TBI is unclear. Here we demonstrate that both acutely 
(Figure 25) and chronically (Figure 25), AMH is able to prevent the loss of p-DARPP-32-Thr34 
following a TBI. Furthermore, the increase in p-DARPP-32-Thr34 over vehicle treated animals, 
with 2 weeks of (10 mg/kg i.p.) AMH corresponds with significantly less PP-1 activity compared 
to injury (Figure 25). Chronic AMH treatment also showed significantly less p-DARPP-32-Thr75, 
compared to vehicle treated sham and injured animals (Figure 25). There is no effect of AMH 
treatment on DARPP-32 protein levels. Our results suggest that the effect of AMH on striatal 
signaling post TBI at 10 mg/kg is most likely a combination of DAergic effects and NMDA 
antagonism as the shift of p-DARPP-32 towards Thr34 phosphorylation and subsequent 
decrease in Thr75 phosphorylation is consistent with reduced Ca2+ signaling due to NMDA 
antagonism and activation of adenylyl cyclase via DA receptor D1 (Valjent et al., 2005; Nishi et 
al., 2005). Given the known effectiveness of AMH following a TBI this also provides the first 
evidence for DARPP-32 being a promising therapeutic target for the treatment of post-TBI 
cognitive dysfunction. Furthermore, we have demonstrated that reversing the TBI induced p-
DARPP-32-Thr34 decrease is associated with a reversal of the increase in PP-1 activity as well, 
suggesting that we can effectively treat dysfunctions in downstream signaling by targeting 
DARPP-32 phosphorylation.   
 
FK-506, a potent inhibitor of calcineurin, given once at 5 minutes post injury also demonstrated 
both acute and chronic (Figure 27) attenuation of p-DARPP-32-Thr34 decreases post TBI. The 
ability of a single dose of FK-506 to attenuate even chronic decreases in DARPP-32-Thr34 
phosphorylation suggests that immediately post TBI there is an increase in calcineurin activity 
within the striatum similar to what was shown in the hippocampus at 2 hours post injury in 
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chapter 2 of this thesis. This is consistent with evidence that the striatum is exposed to acute 
increases in glutamatergic tone that would theoretically act to upregulate calcium influx, to which 
calcineurin is extremely sensitive. By inhibiting the acute activation of calcineurin, FK-506 is 
able to prevent the loss of DARPP-32-Thr34 phosphorylation chronically as well suggesting that 
TBI induced DARPP-32 dysfunction is an acute event compounded by the inability of the post-
TBI striatum to correct the deficit.  
 
Both AMH and FK-506 showed a dose dependent effect on DARPP-32-Thr34 phosphorylation 
(Figures 26 and 28) further indicating that these drugs have a direct effect upon DARPP-32-
Thr34 phosphorylation following a TBI. Utilizing these dose dependent effects we designed a 
combined drug therapy of acute single dose administration of FK-506 plus chronic daily 
administration of AMH. The doses chosen for the combined therapy examination were below 
the maximal dose given in the dose response study in order to examine the combined 
therapeutic effect of the two drugs given together.  
 
There was a concern that employing the maximal drug doses would produce a ceiling effect on 
either DARPP-32 phosphorylation or behavior and limit the evaluation of single drug therapy 
versus combined drug therapy. A second concern was that high doses of FK-506 can have 
detrimental effects including seizure and immune suppression that may not be beneficial post 
TBI. Future examinations of this combination regimen will need to adjust drug dosages to 
determine maximal effectiveness.  
 
We showed that a combination therapy of a single acute administration of FK-506 post TBI (1.0 
mg/kg i.p.) combined with a daily chronic treatment with AMH (5 mg/kg i.p.) prevented the loss 
of DARPP-32-Thr34 phosphorylation at 3 weeks post injury compared to vehicle treated animals 
indicating that the combination therapy was able to effectively treat TBI induced DARPP-32 
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dysfunction (Figure 29). Furthermore, examination of ERK 1/2 phosphorylation with 
combination therapy demonstrated that the combined therapy was able to attenuate ERK 1/2 
phosphorylation decreases seen in the striatum post TBI at 3 weeks as well (Figure 30). This 
demonstrates that the combination therapy was able to effectively treat alterations in cell 
signaling pathways within the striatum associated with TBI. Interestingly as compared to our 
earlier results (Figure 17), there was no decrease in p-DARPP-32-Thr34 in contralateral 
striatum (Figure 29) at 3 weeks post injury. This discrepancy is most likely due to the behavioral 
analysis that the rats underwent for this experiment. DARPP-32 is extremely responsive and it is 
possible that the behavioral analysis induced some level of benefit in striatal signaling, which is 
intriguing when one considiers paradigms examining environmental enrichment.  
 
In addition to striatal effects the combination of FK-506 and AMH reduced the lesion volume in 
TBI animals compared to vehicle (Figure 32). The same effect in the reduction of lesion volume 
was seen with FK-506 alone, but not with AMH alone indicating that FK-506 at 1.0 mg/kg i.p. 
has some neuroprotective affects. This is particularly interesting when coupled with the 
behavioral data which demonstrates that there is no benefit to behavior with this dose of FK-
506. This strongly suggests that the synergistic benefit of FK-506 and AMH post injury is related 
to non-neuroprotective events. 
 
It is important to note that while studies have shown the neuroprotective effect of BDNF 
administration and ERK 1/2 activation, there is also research demonstrating an ERK 1/2 
signaling pathway that promotes caspase activation and neuronal death. In brain injury research 
it has been shown that oxidative stress can induce aberrant activation of ERK 1/2 and CREB 
which corresponds with mitochondrial dysfunction and cell death (Enomoto et al., 2005). 
Therefore it is possible that by activating the DARPP-32-Thr34 site and inducing an increase in 
ERK 1/2 activation we could have facilitated further cellular dysfunction. However, our research 
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would suggest that, at least chronically, ERK 1/2 activation plays a positive role in outcomes. 
Future evaluations will need to examine ERK 1/2 activation temporally within the striatum to 
better elucidate its role in striatal dysfunction. 
 
Combination drug therapies represent a promising new area in TBI research as does the 
targeting of subcortical brain structures. We demonstrate that the combination of FK-506 and 
AMH was able to attenuate striatal dysfunction post-TBI. Furthermore the combination therapy 
demonstrated no significant difference from sham for recovery of beam-balance performance 
(Figure 33) or in spatial learning (Figure 35). While singe drug treatment groups demonstrated 
significant differences in both spatial learning and on motor tasks compared to sham. The 
potential mechanisms of benefit for these two drugs are many. FK-506 improves cell survival, 
axonal protection, and decreases inflammatory signaling in TBI paradigms. AMH is known to 
improve outcomes in both experimental and clinical TBI.  
 
4.5 CONCLUSION 
 
We present here a common mechanism shared between both FK-506 and AMH within the 
striatum. The attenuation of striatal DARPP-32 dysfunction after TBI is a novel therapeutic 
target after TBI and we have demonstrated that it represents a viable synergistic target for 
combined treatment strategies. Furthermore, we have provided an initial lesion volume analysis 
indicating that neuroprotection does not play a key role in these synergistic benefits.    
 
  
153 
 
 
5. POTENTIAL UPSTREAM SIGNALING DEFICITS INVOLVED IN DARPP-32 MODULATION 
 
 
5.1 INTRODUCTION 
 
Alterations in DARPP-32 signaling post TBI could be caused by a number of upstream signaling 
events. Following the acute primary injury, which often consists of a focal contusion and more 
diffuse structural damage, there are a series of subsequent secondary responses, which 
include, but are not limited to, excitotoxicity, ischemia, oxidative stress, and ongoing structural 
and chemical alterations. Both glutamate and DA play key roles in modulating DARPP-32 
signaling, thus dysfunction in either signaling molecule could present a potential mechanism for 
ongoing DARPP-32 dysfunction. However, therapies targeting glutamatergic excitotoxicity have 
shown limited benefit and unfortunate toxicity. Given that we see DARPP-32 dysfunction 
chronically as well as acutely it is logical to assume that striatal alterations consist of both early 
and late or persistent events. DA, within the striatum, acts at both D1 and D2 receptors. Given 
that prior research has demonstrated that D2 antagonists can negatively affect recovery from a 
TBI (Kline et al., 2007; Hoffman et al., 2008) it may be that there is a dysfunction in D2 signaling 
that has not been elucidated post injury. 
 
One area in particular that has not been well studied in TBI and has just begun to be elucidated 
in other disease states including Parkinson’s disease (PD) is the role that non-DA receptors play 
in DA signaling. Of particular interest is the role of adenosine A2a receptors and the control they 
exert over DA D2 receptors. Changes in A2a signaling have been shown to be important to D2 
signaling within the striatum and play a crucial role in cell signaling events that affect learning 
and memory, including long term potentiation (LTP) and long term depression (LTD). 
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D2 receptors can act through inhibitory G-proteins that lead to an inhibition of AC and cAMP 
(Weiss et al., 1985; Onali et al., 1985) or independently of cAMP pathways (Memo et al., 1986).  
D2 receptors have also been shown to inhibit PI hydrolysis and subsequent Ca mobilization 
(Vallar et al., 1989; Picetti et al., 1997).  Furthermore activity at D2 receptors is coupled to 
alterations in DARPP-32 phosphorylation and function (Greengard et al., 1999). These signaling 
pathways have been shown to be important for striatal goal directed learning and memory. 
Changes in D2 receptor activation, protein, and second messenger signaling systems have 
been implicated in psychotic disorders and are a prime target for therapeutic drugs used to treat 
both PD and HD (Fuxe et al., 2005; Fuxe et al., 2007). 
 
An interesting caveat of D2 receptor activation is that in vitro studies utilizing co-
immunoprecipitation methods and in-vivo studies utilizing fluorescent and bioluminescent 
energy transfer (FRET and BRET) analyses have shown that many D2 receptor systems exist in 
heterodimerized pairs (Canals et al., 2003; Fuxe et al., 2005). D2 receptors have been shown to 
form heterodimers with adenosine A2a receptors and metabotropic glutamate-5 (Mglut-5) 
receptors (Ferre et al., 2008). A2a and Mglut-5 heterodimers are of particular interest for TBI 
research due to their role in striatal long term potentiation (LTP) and long term depression (LTD) 
and subsequent plasticity of striatal connections (Fuxe et al., 1998). The identification of 
heterodimer systems within the striatum indicate that D1 and D2 have control over CREB 
signaling within striatal neurons. Further, they modulate LTP and LTD dependent glutamatergic 
and adenosine transmitter systems (Centonze et al., 2003). Changes in the function of these 
heterodimers can drastically alter DAergic signaling through the D2 receptor and have been 
implicated in numerous disease states including schizophrenia, diseases of addiction, and 
Parkinson’s disease (PD). 
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In PD, the contribution of neurotransmitters beyond DA is important to therapeutic manipulation 
as utilization of these other receptor systems provides an alternative way to manipulate DAergic 
signaling. D2-A2a interactions proposed by Fuxe et al., (2005) allow for precise alterations in 
intracellular signaling pathways that have been associated with cognitive function and striatal 
output.  Furthermore, radioligand binding studies have identified a tight antagonistic relationship 
between A2a and D2 receptors that is acutely affected by DA concentration. 
.       
In patient populations, adenosine A2a antagonists combined with traditional PD therapies 
including levodopa have decreased the incidence of negative side effects, increased DA drug 
effectiveness, and reduced the dosage of DAergic medications necessary for therapeutic 
benefits (Antonelli et al., 2006). Natural antagonists of A2a receptors have also been associated 
with decreased incidence of PD and other neuroprotective effects. In A2a knockout mice models 
there is noticeably less neuronal death and dysfunction when animals are exposed to toxic 
compounds such as MPTP and rotenone typically used to induce PD in mice. 
 
Alterations in A2a receptors relevant to striatal DAergic D2 receptor signaling represent a 
possible mechanism of cognitive dysfunction after TBI.  A2a receptors can control D2 receptor 
signaling via two independent mechanisms; either through a direct heterodimeric system or 
through second messenger systems (Figure 37).  In either situation adenosine through action at 
the A2a receptor acts as an inhibitor of D2 signaling (Fuxe et al., 1998; Fuxe et al., 2005). 
Changes in the behavior of A2a and D2 receptors can have dramatic effects on DA effects in 
the striatum and represent a potential mechanism of DARPP-32 dysfunction following TBI.   
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Figure 37: A2a and D2 receptors interact in the striatum in two different ways. Either through a 
PKA independent heteroceptor system that induced intracellular alterations of calcium or 
through a PKA dependent second messenger system that affects MAPK and DARPP-32 
signaling pathways. 
 
5.2 METHODS AND MATERIALS 
 
5.2.1 Animals and Surgery 
 
CCI.  Sprague Dawley rats (300-325 g) were used for these experiments (n = 36). As described 
previously (Cernak, 2005; Dixon et al., 1991). A craniotomy is performed by one trained 
technician and a pneumatic cylinder with a 4 to 5 cm stroke, mounted on a cross bar to adjust 
position of impact, is adjusted to an impact velocity of .5 to 10 m/s, cortical deformation between 
1 and 3 mm, and duration of impact between 25 and 250 ms. Each animal was injured with an 
impact velocity of 4m/s and 2.7 mm cortical deformation over the right cerebral cortex.  The 
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animals were sacrificed at 1 day, 2 weeks, or 4 weeks following TBI.  The brain was taken from 
each animal and striatal tissue excised and placed into -70 Celsius until use.  
 
5.2.2 Western Blot Analysis 
 
After deeply anesthetized with pentobarbital (Nembutal, 80-100 mg/kg; Abbott Laboratories, 
North Chicago, IL), animals were decapitated and the brains quickly removed and chilled on ice.  
Tissue from the striatum was excised.  Tissues was homogenized in Lysis buffer (suspension 
buffer) which contains 0.1M NaCl, 0.01M Tris-Cl (pH 7.6), 0.001 M EDTA (pH 8.0), 1 µg/ml 
aprotinin, 100 µg/ml phenylmethylsulfonyl fluoride (PMSF), and protein concentrations were 
determined using a BCA protein Assay Kit (PIERCE, Rockford, IL).  Samples containing 20 g 
of protein were subjected to SDS-polyacrylamide gel electrophoresis through a 10% acrylamine 
gel, and after transferred to nitrocellulose membranes and immunolabeled with antibodies 
specific for adenosine A2a or DA D2 receptors (mouse monoclonal 1:500; Santa Cruz) followed 
by goat antimouse immunoglobulin G conjugated to peroxidase (1:10,000; PIERCE, Rockford, 
IL). Proteins were visualized with a chemiluminescence detection system (SuperSignal, 
PIERCE, Rockford, IL). To assure equal loading, the membrane were restriped and reblotted 
with rabbit anti-actin antibody (1:15,000, Sigma, St. Louis, MO). 
 
5.2.3 Co-Immunoprecipitation 
 
Following homogenization and protein determination as detailed above 100 g of protein was 
incubated with rabbit polyclonal adenosine A2a receptor antibody and 20 ml of strepavidin 
beads (PIERCE, Rockford, IL) diluted in ethanol.  Following overnight incubation the bead-
antibody-protein complexes were boiled and the supernatant subjected to the western blot 
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analysis as detailed above.  For co-immunoprecipitation all primary antibodies used following 
running and transfer were mouse monoclonal to reduce the detection of rabbit IGg attached to 
the strepavidin bead complex. 
 
5.2.4 Immunohistochemical Methods 
 
Tissue Preparation: Animals were be deeply anesthetized with pentobarbital (Nembutal, 80-100 
mg/kg; Abbott Laboratories, North Chicago, IL) at the appropriate interval after CCI and sham 
procedure. The rats were transcardially perfused with 100 ml 0.1 M phosphate buffered saline 
(PBS) with 5 U/ml heparin pH 7.4, followed by 500 ml 4% paraformaldehyde with 15% saturated 
picric acid in 0.1 M phosphate buffer pH 7.4.  After perfusion, the brain was removed and placed 
into the same fixative for 30 minutes, then immersed in 4% paraformaldehyde in 0.1 M 
phosphate buffer pH 7.4 at 4 C overnight. The brain was transferred to 15% sucrose in 0.1 M 
phosphate buffer pH 7.4 at 4oC for 24 hours, then to 30% sucrose in 0.1 M phosphate buffer pH 
7.4 at 4oC until the brain sunk.   
 
Section of Tissue: The cryoprotected rat brain was frozen and used for cryostat sectioning. 
Coronal sections were cut for the striatum in 35 µm thickness in a cryostat (Jung CM 1800; 
Brodersen Instrument, Valencia, PA) and collected in 24-well culture plates containing 0.1 M 
phosphate buffered saline (PBS). 
 
Confocal Fluorescent Immunohistochemistry: Immunohistochemistry for D2 and A2a was 
conducted in 24-well culture plates by free floating technique. Sections were pre-blocked with 
10% normal rabbit serum (NRS) and 0.1% Triton X-100 in 0.1 M PBS. Sections were incubated 
with primary antibodies (Chemicon, Inc.) with 5% NRS and 0.1% Triton X-100 in 0.1 M PBS at 
4°C for 16-24 hours, respectively.  Affinity-purified rabbit anti-rat IgG and rabbit anti-goat IgG 
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labeled with fluorescent tags (1:50; Jackson ImmunoResearch Laboratories, West Grove, PA) 
were incubated as secondary antibodies with 5% NRS and 0.1% Triton X-100 in 0.1 M PBS at 
4°C for 2 hours on a shaker. Tissue was rinsed between all steps with 0.1% Triton X-100 in 0.1 
M PBS three times for at least 10 min each time. Sections were rinsed several times in 0.1 M 
Tris-buffered saline (TBS), mounted on subbed slides, dehydrated in alcohols, defatted in 
xylenes, and coverslipped for confocal microscopic analysis. At least three sections of brain 
tissue through striatum were processed for each antibody immunoreactivity. Control 
experiments were run in parallel to confirm specificity. Primary antibodies were either omitted or 
preabsorbed with peptide at 4°C for 16 hours before the incubation. 
 
5.3 RESULTS 
 
5.3.1 Alterations in non-dimerized A2a-D2 receptor protein following TBI 
 
To investigate the levels of A2A receptor protein in rat striatum following CCI model of TBI we 
homogenized rat striatal sections excised from fresh rat brain and stored them at -70 degrees 
Celsius. Membranes with rat striatal protein were probed with a primary antibody to A2A 
receptors to determine protein amount at 1 day, 2 weeks, and 4 weeks following TBI.  B-actin 
was run on all membranes to verify equal protein loading in all samples.  Membranes were also 
probed with D2 receptor antibodies to compare D2 protein levels to A2A protein levels. 
 
Densitometry on A2A receptor western blots (Figure 38) comparing sham surgery on the 
ipsilateral side (sham right) to CCI ipsilateral side (injured right) showed no significant difference 
at 1 day or at 2 weeks.  Nor was there any significant difference in D2 receptor levels at 1 day or 
2 weeks. However analysis of 4 week western blots showed a significant difference for both A2A 
receptors (p=0.05) and D2 receptors (p<0.05). 
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Figure 38: A2A and D2 receptor protein levels as determined by western blot in 1 day, 1 week, 2 
week, and 4 week striatal sections.  Densitometry analysis performed using ImageJ on 1 day, 2 
week, and 4 week samples.  4 week striatal sections showed significantly reduced A2A and D2 
receptor protein levels in injured right side compared to sham right side.  S-L (sham left side); S-
R (sham right side); I-L (injured left side); I-R (injured right side).  *P≤0.05 
 
There is also a significant difference in the ratio of A2a-D2 receptor protein (p<0.05) in TBI 
compared to sham ipsilateral at 2 weeks post injury suggesting a possible alteration in A2a-D2 
tonic function (Figure 39).  
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Figure 39: Example western blots and densitometry analysis of A2a/D2 receptor levels in 
standard and co-ip preparations. Standard A2a/D2 receptor ratios demonstrate a significant 
increase in the number of A2a to D2 receptors in ipsilateral injured striatum compared to sham 
(p<0.05) while there is a trend for significance in a dimerized co-ip preparation (p=0.06). Data 
presented represents mean A2a/D2 ratio standardized to actin ± SD. 
 
5.3.2 Alterations in A2a-D2 receptor heterodimer protein following TBI 
 
To determine if there was a change in A2a and D2 receptor heterodimer expression post TBI in 
the striatum, we examined co-immunoprecipitation of A2a-D2 protein expression and confocal 
co-localization at 1 day and 2 wks post TBI.  Confocal co-localization demonstrates a decrease 
in the co-localization of A2a-D2 receptors in striatal neurons (Figure 40). Co-
immunoprecipitation analysis showed a trend towards alterations in A2a-D2 heterodimer levels 
following TBI (p=0.06) (Figure 39). 
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Figure 40: Confocal imaging shown co-localization of A2a and D2 receptors in (top) ipsilateral 
sham striatum and (bottom) ipsilateral CCI striatum. Confocal examination demonstrates a 
decrease in A2a/D2 co-localization due to an alteration in D2 receptor staining pattern in CCI 
striatum.  D2 receptors in injured striatum demonstrate an increase in punctate staining that may 
be related to receptor aggregation. 
 
5.4 DISCUSSION 
 
The striatum is composed of two separate but morphologically indistinguishable GABAergic 
medium spiny neuron populations. D1 predominant and D2 predominant cell populations have 
unique projection patterns that dictate different mechanism both within the striatal network and 
to other brain regions. Our analysis of DARPP-32 signaling deficits post TBI does not indicate a 
predominant effect on either cell population, though future studies need to fully characterize 
each cell population with respect to DARPP-32 and ERK 1/2 phosphorylation alterations. 
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However, prior research has demonstrated a significant level of behavioral dysfunction in D2 
antagonist treated animals with a TBI (Kline et al., 2007; Hoffman et al., 2008). Because of this 
we investigated the direct consequence of a TBI on D2 receptor expression and found that there 
was a significant alteration post TBI at chronic timepoints (Figure 38). We also found an 
alteration in both the level of D2/A2a receptor expression within the striatum and a trend 
towards a specific decrease in the level of D2/A2a heterodimer expression as determined using 
co-immunoprecipitation and confocal co-localization (Figures 39 and 40). This indirectly 
suggests that post TBI there is a significant alteration in D2 binding characteristics as prior 
studies have shown that A2a activity can directly affect DA binding to D2 receptors.  
 
A persistent decrease in the tonic inhibition that A2a receptors have on coupled D2 receptors 
would cause an ongoing increase in intracellular Ca2+ release associated with D2 action 
(Figure 41). This would have the effect of increasing calcineurin activity within the striatum and 
subsequently decreasing DARPP-32-Thr34 phosphorylation. The ability of FK-506 to block p-
DARPP-32-Thr34 loss after TBI (see prior chapter) is consistent with increases in calcineurin 
activity. This represents a potential cause of persistent DARPP-32 dysfunction in the striatum 
post TBI.  
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Figure 41: Schematic representation of the theoretical affects of A2a/D2 alterations in both 
heterodimer and non heterodimer interactions on intracellular signaling. 
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6. SUMMARY AND CONCLUSIONS:  PERSISTENT DYSFUNCTION FOLLOWING A TBI AND 
THE POTENTIAL ROLE OF DARPP-32 
 
 
6.1 HISTORICAL PERSPECTIVE 
 
Examination of neurologic function following an experimental TBI has been integral to TBI 
research since suppressed reflex testing first described by Denny-Brown and Russell (1940). 
Early paradigms limited themselves to the assessment of unconsciousness as a marker for 
neurologic function following injury (Ommaya et al., 1966; Ommaya and Gennarelli, 1974; 
Yarnell and Ommaya, 1969). Most criteria for establishing the level or severity of injury was 
based predominantly upon a calculation of the forces involved or a histologic analysis of 
traumatic damage (Brown et al., 1972; Saunders et al., 1979). While important to evaluating the 
neuronal, axonal, and vascular damage that occurred due to a TBI, the necessity of dissection 
made these assessments difficult to translate to clinical outcomes of surviving patients. In the 
early 1980’s more detailed cardiovascular monitoring (heart rate, respiratory rate, blood 
pressure, perfusion pressure) coupled with tests of neurologic deficit (consciousness, corneal 
reflex) were used in monkeys to enhance the clinical applicability of injury models (Brown et al., 
1980; Gennarelli et al., 1981). In 1974 Teasdale and Jennett introduced the Glasgow Coma 
Scale (GCS) to provide a reproducible, consistent scoring system for TBI. Based upon the GCS 
a battery, of acute neurological tests was developed to examine the immediate severity and 
scope of experimental TBI in felines (Hayes, et al., 1984) and rats (Dixon, et al., 1987). To 
evaluate gross neurological motor function over a period of recovery McIntosh and colleagues 
(1989) developed a composite neuroscore to evaluate the chronic neurobehavioral state of 
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animals following a TBI. The composite neuroscore utilizes a series of tests designed to 
evaluate motor and somatosensory components of rodent behavior.   
 
Both the acute examination of reflex suppression (Dixon et al., 1987) and the chronic evaluation 
of motor neurologic function (McIntosh et al., 1989) are utilized to evaluate and track the status 
of experimental TBI. This allows researchers to determine injury severity, recovery, and 
outcome without relying purely upon pathology and histology. Furthermore, reflex suppression 
and the composite neuroscore are more direct measures of neurologic damage than physiologic 
monitoring that involves cardiodynamic processes.  
 
TBI causes persistent dizziness and disturbances in motor function and balance (Rutherford, 
1977). Rutherford (1977) also noted disturbances in fine motor skills in even mild levels of TBI. 
The examination of complex motor tasks is an important part of the evaluation of experimental 
injury. The combination of beam-balance, to examine dizziness and balance, and beam-
walking, to examine components of fine motor coordination, have been used extensively in 
rodent models of TBI (Dixon et al., 1987; Dixon et al., 1991; Kline et al., 2002). 
 
The utilization of a beam-walking task in experimental brain injury was first described by Feeney 
and colleagues in 1982, while the beam balance task was described by Dixon et al., 1987. Both 
beam tasks (beam balance and beam walking) were used to characterize the FP (Dixon et al., 
1987) and cortical impact (Dixon et al., 1991) models of injury. In addition to the beam tasks, the 
rotarod task was modified by Hamm and colleagues to evaluate deficits following injury in 1994. 
The rotarod task was first developed by Dunham and Miya in (1957) to evaluate the 
neurological effects of drugs and is the equivalent of a forced walking task often employed in 
patient recovery. Vestibulomotor testing in rodent models of TBI shows excellent sensitivity and 
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reliability in predicting severity and monitoring outcomes (Hamm, 2001). The rotarod and beam 
tests are also valuable in the evaluation of therapeutic interventions.  
 
The combination of vestibular and motor examinations following experimental TBI in rodents is 
particularly useful given that the parietal cortex, the location of the primary motor and sensory 
cortices, is often the cortex of greatest impact. The examination of complex vestibulomotor 
testing following experimental brain injury allows for a clinically relevant paradigm of recovery, 
one which is both reliable and sensitive to therapeutic manipulation. 
 
TBI patients also report significant cognitive disorders that present immediately after the initial 
injury or evolve during the subsequent months to years. These include deficits in memory, 
learning, and executive function (Binder et al., 1986; Arciniegas et al., 2000). The evolution of 
experimental TBI towards rodent models has allowed a much more in depth characterization of 
cognitive deficits following a TBI. Examination of cognitive deficits post TBI has been integral to 
understanding TBI deficits in patients. One of the most commonly employed methods of 
cognitive assessment post TBI is the Morris water maze apparatus (Dixon et al., 1997; Adelson 
et al., 1997; Kline et al., 2008). As discussed in the introduction, while the Morris water maze 
has limitations, it allows for a much more in depth analysis of cognitive dysfunction after TBI 
then simple neurological scores or motor behavior. This is particularly important considering that 
cognitive processing generally involves a wider spectrum of brain regions and is potentially less 
likely to recover than motor deficits. Furthermore, treatment strategies aimed at attenuating cell 
loss within cortical regions may be effective in dealing with motor deficits without affecting 
cognition. 
 
The Morris water maze task is particularly useful for examining spatial learning and memory. 
This makes it an excellent tool for evaluating hippocampal dysfunction. Both FP and CCI 
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models of TBI have demonstrated significant cell loss in hippocampal CA1, CA3, and DG 
regions (Graybiel et al., 1990; Fox et al., 1998; Bye et al., 2007). There are well documented 
deficits in learning and memory associated with hippocampal lesions (Aggleton et al., 1999). 
This has made efforts to reduce cell death in the hippocampus of prime importance to TBI 
research. However, clinical and experimental failures of neuroprotective strategies to produce 
meaningful cognitive benefit necessitate a new direction for TBI research. 
  
6.2 MOVING BEYOND THE HIPPOCAMPUS 
 
TBI is a heterogenous and complex injury composed of acute, sub-acute, and chronic injuries 
(Kochanek, 1993; Park et al., 2008). Animal models including CCI (Lighthall, 1988; Dixon et al., 
1991) and FP injury (FP) (Dixon et al., 1987) have provided insight into the cellular and 
mechanical mechanisms of central nervous system (CNS) dysfunction and cell death in TBI, 
allowing for the examination of valuable treatment strategies (Kline et al., 2007) and a better 
understanding of persistent deficits (Fox et al., 1998; Wagner et al., 2002; Wagner et al., 2004). 
Unfortunately, many of the neuroprotective strategies employed in TBI research have not 
translated well into clinical settings (Gualtieri, 1988; Tolias & Bullock, 2004). Potential reasons 
for poor translation of animal results include, but are not limited to, 1) the complexities of multi-
system traumas typically seen in clinical settings (Ladanyi & Elliot, 2008; Capone-Neto & Rizoli, 
2009), 2) a compromised blood brain barrier (Whalen et al., 1998; Folkersma et al., 2009), 3) 
potential drug toxicities and side effects (Muir, 2006), and incomplete preclinical evaluations. 
Strategies that target glutamatergic excitotoxicity acutely to provide neuronal sparing have 
proven particularly difficult given the important function of glutamate signaling in learning, 
memory and cellular potentiation (Parsons et al., 2007; Christoffersen et al., 2008; Gil-Sanz et 
al., 2008). To address these issues, multiple studies have utilized paradigms designed to inhibit 
cell death pathways with the intent to reduce the level of acute neuronal loss following injury 
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(Faden et al., 1989; Jennings et al., 2008). This, however, has often met with varied success 
due to persistent cellular dysfunction even with significant cell sparing (Muir, 2006; Bye et al., 
2007). 
 
We examined the hippocampus at a moderate injury level in chapter 2 and found persistent 
dysfunction in calcineurin signaling at up to 2 weeks post injury. This included nearly two-fold 
increases in calcineurin activity and regional alterations in hippocampal expression of both the 
calcineurin regulatory and catalytic subunits. Of particular interest is the fact that the alterations 
in calcineurin subunit distribution within CA1 and CA3 hippocampal regions do not appear to be 
movement towards the nucleus which is associated with cell death signaling pathways. Rather 
the most significant events appear to be the loss of catalytic expression within dendritic fields 
and the impressive upregulation of both subunits within the dentate gyrus. This suggests that 
calcineurin pathology post TBI is not exclusively related to neuronal death and there may be 
more insidious deficits that we have yet to fully understand. 
 
At a more severe injury level as used in chapters 3 and 4 there remains little to no ipsilateral 
hippocampus in injured animals making the analysis of hippocampal pathology difficult at 
chronic timepoints. However what we can conclude from our studies is that even in the face of 
lesser cell death there remains significant alterations in key cell signaling molecules within the 
hippocampus post TBI. The dysfunction in calcineurin signaling has been well reported in FP 
injury (Kurz et al., 2005) and treatment with the calcineurin inhibitor FK-506 demonstrated a 
restoration of axonal conduction deficits seen post FPI (Reeves et al., 2007). Calcineurin is not 
limited to the hippocampus, however, and is widely expressed throughout the brain. For this 
reason FK-506 has the potential to play a significant role beyond hippocampal protection, which 
makes it a promising of choice for TBI induced deficits. There are some concerns over the use 
of FK-506 as it has significant toxicities associated with higher drug concentrations. 
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Ongoing, significant, hippocampal signaling pathologies not associated with widespread 
hippocampal loss, the benefits of FK-506, a drug that potentially acts on multiple brain regions, 
and the nature of a diffuse injury such as TBI all strongly indicate that it is critically important to 
begin looking beyond the hippocampus into other areas of potential dysfunction in experimental 
TBI. 
 
6.3 DIVING INTO THE STRIATUM 
 
6.3.1 Complexities 
 
The striatum is complex. It is an interconnected network of excitatory and inhibitory signaling 
with predominantly GABAergic inhibitory outputs. Figure 42 from Albin et al., 1989 
demonstrates a simplified schematic of the basal ganglia with the more realistic schematic 
determined from experimental preparations. 
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Figure 42: A) Simplified schematic of striatal signaling relevant to thalamic and cortical activity. 
B) The more realistic schematic demonstrated by electrophysiology and binding studies 
involving striatal outputs (From Albin et al.,1989).  
 
Compared to the relatively simple architecture of the hippocampus, the striatum is a nightmare 
of signaling events, all of which could potentially be altered in TBI. There are significant 
alterations in DAergic tone within striatal tissue following a TBI (Massuci et al., 2004). 
Alterations in either DA or glutamate have significant implications for striatal function. In general, 
when considering striatal function it is easiest to think of the striatum as a modulator. It 
essentially dictates the strength of signaling within both the thalamus and cortex through tonic 
involvement of medium spiny neuron outputs (Mega et al., 1994; Calabresi et al., 2007). In 
doing so striatal signaling essentially works to assist the other brain areas in appropriate 
functional control. 
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This is apparent with regards to movement disorders, especially Parkinson’s Disease, where 
striatal dysfunction essentially removes the control that patients have over the initiation of 
movements and maintenance of fine motor control. What is less clear is how this striatal 
function acts in cognition. The predominant theory involves a similar mechanism to that 
proposed in movement control. Essentially striatal output modulates cognitive processing 
allowing other brain regions to properly function. A dysfunction in striatal output therefore has 
the effect of making it difficult for the brain to properly choose the appropriate signal. Thus, 
reduced striatal output essentially leads to attention difficulties, and learning and memory 
deficits. Increased striatal output can have a similar effect where it overly dampens other 
neuronal systems leading to addictive behavior and psychosis (Goldman-Rakic, 1995; Wickens 
et al., 2007). In TBI this may actually be temporally related with an upswing in DA and striatal 
activity early followed by chronic dysfunction (Figure 43). 
 
Figure 43: Dopamine is a tightly regulated system that has potential negative consequences 
with increased or decreased dopaminergic tone. Currently studies indicate that immediately 
following TBI there is an increase in dopamine while chronically there is a decrease. 
Therapeutic strategies used in TBI should consider the implications of this bi-phasic response in 
dopamine systems following TBI. 
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Given these complexities, treatments aimed at striatal dysfunction are difficult to evaluate. Is cell 
death or axonal damage important in a system where in Parkinson’s Disease you require an 
80% loss of DAergic inputs to even see behavioral alterations? Probably not, but then how do 
you evaluate possible dysfunction if it exists? 
 
6.3.2 Benefit of Striatal Examination 
 
While examining the striatum may be difficult there remains one significantly important aspect of 
striatal function that makes it almost a perfect system to examine in the complex pathology of 
TBI. Striatal outflow signaling is almost exclusively done by the GABAergic medium spiny 
neurons. While other neuronal populations exist within the striatal architecture, they are 
internally modulatory and do not directly involve themselves in outflow signaling (Snyder et al., 
1998). This essentially creates a system with innumerable inputs, but only one output. Any 
alteration in upstream signaling events should be represented within the medium spiny neurons. 
Thus, to examine neuronal pathology within the striatum one need only examine one group of 
neurons. This sounds overly simple, and it does represent a simplification of the problem. There 
still exists glial elements and the potential for inflammatory processes which may cause 
pathology not directly linked to neuronal signaling, but one could argue that when determining 
the function of the striatum it is the neuronal population that is the most important to consider. 
 
Within the striatum the GABAergic medium spiny neurons comprise about 95% of the neuronal 
architecture making them an abundant neuronal type within striatal samples. They receive 
glutamatergic, DAergic, GABAergic, adenosine, noradrenergic, and serotonergic inputs from 
multiple brain regions including the cortex, substantia nigra, and ventral tegmental area (Snyder 
et al., 1998; Calabresi et al., 2000; Azdad et al., 2009). More importantly nearly all of the 
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function of the medium spiny neurons is dictated by the key regulatory molecule that we 
examined in chapters 3 and 4, DARPP-32. 
 
DARPP-32 is essentially the molecular equivalent of the striatal medium spiny neuron. It is 
expressed within more than 90% of the medium spiny neuron population, is only expressed 
within medium spiny neurons, and responds to nearly every signaling event within the neuronal 
body. It regulates nuclear transcription, synaptic plasticity, and upstream signaling. As explained 
in the introduction and further in chapter 3, DARPP-32’s effects are determined by the 
phosphorylation state of its Thr34 and Thr75 sites. By examining the phosphorylation sites of 
DARPP-32 you can essentially determine if your manipulation is having an effect on striatal 
signaling. This effectively turns DARPP-32 into a molecular screening tool for potential 
therapeutic effects on striatal pathology. Furthermore, since DARPP-32 is important to the 
essential function of striatal outflow neurons manipulating it is a powerful tool in altering striatal 
signaling and potentially providing neurologic benefit. So that is what we did. 
 
6.3.3 DARPP-32 in TBI 
 
TBI causes a significant, prolonged dysfunction in striatal DARPP-32 phosphorylation and 
downstream signaling events including PP-1 activity and ERK 1/2 phosphorylation (Figures 
17,20,22). DARPP-32 dephosphorylation occurs acutely at Thr34 following a TBI and persists 
up to 4 weeks after injury (Figure 17). An increase in PP-1 activity is seen at both 1 day and 2 
weeks post injury (Figure 20) consistent with the loss of phosphorylation at DARPP-32-Thr34. 
ERK 1/2 phosphorylation in nuclear extracts is decreased at 3 weeks post injury relative to 
sham levels (Figure 22). Each of these events demonstrates individual dysfunction at points 
within the cell signaling pathway of striatal medium spiny neurons, taken together they indicate 
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a breakdown of striatal cellular signaling (Figure 43) that has significant implications for the 
function of the frontal cortex, amygdala, limbic cortices, and a number of other brain regions.   
 
Figure 44: A) Early alterations (up to 1 day post injury) seen in DARPP-32 signaling post TBI. 
B) Chronic alterations (past 2 weeks) in DARPP-32 signaling post TBI. The only system that 
appears to correct itself overtime is PKA activity, however as is evident from the figure even the 
increase in PKA activity seen at later timepoints is not enough to overcome DARPP-32 
dephosphorylation effects. A persistent increase in PP-1 activity and decrease in ERK 1/2 
phosphorylation can alter neuronal plasticity, nuclear transcription, and cell survival signaling.  
  
This chronic alteration in DARPP-32 signaling is consistent with data demonstrating decreases 
in DA within the striatum overtime (Massuci et al., 2004). Furthermore the change in DARPP-32 
signaling confirms that there is a dysfunction in striatal neurons following a TBI regardless of the 
upstream mechanism. This is critically important because it indicates that the striatum is not 
only a viable target for post TBI deficits, but is potentially a necessary one in addition to the 
hippocampus and cortex. 
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6.4 DEVELOPING NEW THERAPIES FOR TBI 
 
There are two approaches to the development of new therapeutic strategies for TBI and both 
have seen success. First, there is the examination of new molecular targets in multiple brain 
regions or within other systems that may affect brain function, including inflammation. The 
majority of these examinations remain focused on neuronal survival, however they are 
beginning to address cellular pathology in addition to neuroprotection. Recent studies involving 
steroids have shown promise theoretically because in addition to neuroprotection they also 
involve the inhibition of inflammation and the potentiation of beneficial neuronal cell signaling 
(Gibson et al., 2008). In addition multiple drugs which target mitochondrial oxidative stress 
signaling have shown experimental promise, again predominantly through a cell death 
mechanism, but oxidative stress is also important in synaptic plasticity (Friberg et al., 1998; 
Mbye et al., 2009). 
 
The second approach to new therapeutic interventions post TBI is to combine two current 
therapies with the hope that they will provide a synergistic or complimentary benefit in post TBI 
pathology. Again the focus of many of these manipulations is on targeting multiple aspects of 
neuroprotection, however it is generally recognized that by targeting a number of different 
cellular pathologies benefits are more likely to appear in behavioral measures (Kline et al., 
2007; Griesbach et al., 2008). Unfortunately there is an inherent difficulty in combining existing 
TBI therapies in experimental trials. Many treatments developed for use in TBI rely upon the 
inhibition of one negative event with the caveat that they may potentially cause another. This is 
true in studies involving hypothermia where the inhibition of cell death is the positive event 
which needs to be weighed against the potential for hemodynamic consequences that could 
lead to worsened outcomes (Yan et al., 2000; Kline et al., 2002). This is also true of NMDA 
antagonists designed to inhibit glutamatergic toxicity, but at the potential consequence of 
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limiting normal neuronal plasticity (McIntosh et al., 1989; Izquierdo et al., 1997). Thus by 
combining a number of therapies with different mechanisms of action it becomes difficult to 
manage appropriate levels when the combined therapies may potentially cause the negative 
events associated with a single therapy to be compounded. 
 
We chose to take both approaches with the hope that we would be able to design a combination 
therapy that provided a synergistic benefit and limited adverse outcomes by targeting a specific 
molecular event, DARPP-32 phosphorylation alterations after TBI. 
 
6.5 CONCLUSION 
 
Striatal DARPP-32 pathology post TBI represents a very promising therapeutic target that 
responds to multiple signaling events, is an excellent readout of striatal cellular dysfunction, and 
has the potential to affect function in multiple other brain regions.  
 
In chapter 4 we discussed how we proceeded to target DARPP-32 phosphorylation deficits post 
TBI. Figure 24 outlines the theoretical model of combining FK-506 and Amantadine in post-TBI 
treatment. However, the benefits of utilizing FK-506 and AMH extend beyond a synergistic role 
in DARPP-32 function. FK-506 has shown benefit in both hippocampal pathology and on white 
matter damage post TBI (Reeves et al., 2007). AMH has known clinical benefits on cognitive 
and behavioral processing post TBI (Table 2). Our hope was that by using DARPP-32 as a 
synergistic target we could gain the benefits associated with both of these drugs without 
enhancing any negative side-effects and in addition provide significant improvements in striatal 
function. 
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We showed that by using dosages of both drugs that did not provide benefits in rodent 
behavioral examinations (Figures 33-35) and combining them into a single treatment strategy 
we were able to modestly improve behavioral outcomes post TBI (Figures 33 and 35). By 
utilizing DARPP-32 as our molecular target we effectively developed a synergistic drug therapy 
that demonstrated benefits in striatal molecular signaling (Figures 29 and 30) and outcomes. 
 
Furthermore, our benefits were not directly related to neuroprotection as our lesion volume 
analysis shows that there is no added benefit to lesion volume (Figure 32) with the addition of 
chronic AMH administration over a single dose of FK-506. A significant reduction in lesion 
volume suggests that neuroprotection was not important for the combination therapy. Behavior 
itself may also play an important role in recovery post TBI. We saw an attenuation of DARPP-32 
phosphorylation loss in the contralateral striatum of rats undergoing behavioral analysis in 
Figure 29 compared to what was previously seen in Figure 17. Given DARPP-32’s important 
role in motor and memory functions of the striatum this may indicate that a relatively intact 
contralateral striatum was able to respond to simple behavioral interventions. 
  
It remains to be seen if the reversal of DARPP-32 pathology played a significant role in 
behavioral outcomes or if it was simply a read-out of the benefits provided by the combination 
therapy. We believe it represents both, and future studies utilizing DARPP-32 knockout mice will 
likely demonstrate that this combined drug therapy is less able to provide functional benefits in 
the absence of DARPP-32 signaling. 
 
6.6 LIMITATIONS AND FUTURE DIRECTIONS 
 
We recognize that there are limitations in the analysis of this system. While DARPP-32 is 
specific to the striatal medium spiny neurons in our cell homogenates, PKA, ERK, CREB, and 
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PP-1 are not. Thus, while the trend in PKA and PP-1 activity is potentially within the neuronal 
population there is also the possibility of influences from other interneurons, glia, and infiltrating 
inflammatory cells. What is interesting, however, is that even with these considerations our 
drugs have an effect on the system of interest. Future examinations of flourescent co-locazation 
studies will help to elucidate the striatal compartment where we are getting the majority of our 
effects. 
 
There are also limitations in the analysis of the immunohistochemitry data for both the 
calcineurin subunit analysis and p-DARPP-32 cell expression. We chose to use semi-
quantitative methods in both instances over the more quantitative stereologic methods for a 
number of reasons. One was due to the technical challenge of performing unbiased stereology 
in each of these studies. The second was dependent upon how we approached the examination 
of our DAB staining. We were interested in the expression patterns of the DAB stain not only 
within cell bodies or dendritic branches, but also within the neuropil. A stereologic approach 
does not allow us to comment on the level of neuropil staining since there is nothing to count. 
We chose to use a blinded scoring method to analyze the calcineurin data in the hopes that we 
could capture multiple aspects of any alterations and were thus limited to the utilization of non-
parametric analyses to determine statistical significance. With regards to the p-DARPP-32 semi-
quantitative cell count method, this method was utilized because it was not felt that an unbiased 
approach could be employed to identify “positive” neuronal bodies. We wanted to determine if 
there was a reduction in cell body expression of p-DARPP-32-Thr34 and setting a threshold for 
what was considered a positive neuron (based solely on its level of p-DARPP-32-Thr34 
staining) seemed to be a logical way to approach the question. Another potential approach 
would be to use densitometry on cell bodies to determine overall decreases in cell staining, 
however the difficulty with a densitometry approach is that differences in background staining 
can affect the outcome. Future studies utilizing flourescent staining may be able to overcome 
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these limitations by employing a measure of the level of flourescence of cell bodies in injury 
versus sham. 
 
For these studies we utilized the classic spatial learning version of the morris water maze, which 
has been well published in TBI literature. However, there are modifications which are better able 
to examine working memory which may be more relevant to a striatal injury. There are also a 
number of other potential behavioral tasks that should be examined that have stronger striatal 
components including novelty seeking, reward learning, motor learning, and executive function 
tasks. By developing a more widespread analysis of behavioral deficits we would be able to 
potentially tease out individual brain region dysfunctions in a TBI paradigm. 
 
Future studies will also need to employ a variety of injury severities and locations which may 
cause variations in striatal damage that would help elucidate the responsiveness of DARPP-32 
to injury. Also a more rostral injury could cause more significant striatal dysfunction given that it 
would have a greater affect on cortical neurons that send projections into the striatal 
compartment than the more caudal injury utilized for these studies. 
 
Finally there remains a significant concern over the specificity of our drug treatments. While we 
observed alterations in our system of interest, this does not mean that these drugs mechanisms 
of actions are limited to DARPP-32. In fact both FK-506 and Amantadine have multiple potential 
targets within the brain including other brain regions, inflammatory response, and a number of 
potential neurotransmitter targets. This makes detailing the exact effect of drug therapy difficult 
to determine, but may actually provide a more consistent benefit in the complex injury caused 
by a TBI. The future utilization of a DARPP-32 knockout model will help elucidate the particular 
role of DARPP-32 in this combination therapy and other potential therapeutics in a TBI. 
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APPENDIX A: SUPPLEMENTAL MATERIAL FOR CHAPTERS 3 AND 4 
 
 
 
Supplemental Figure 1: 
182 
 
 
Supplemental Figure 2: 
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Supplemental Figure 4: Sample images of lesion post controlled cortical impact.  
Supplemental Figure 3: 
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